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Abstract 
Neutral amino acids are essential for protein synthesis, energy homeostasis, and many vital 
biochemical pathways. As several neutral amino acids are essential and cannot be synthesised 
by humans in vivo, their uptake and reuptake by the body’s absorbing epithelial layers is of 
major importance for systemic amino acid homeostasis and human health. Two of the major 
pathways for the absorption of neutral amino acids in the small intestine and kidney are the 
Broad Neutral Amino acid Transporters 1 and 3 (B
0
AT1 and B
0
AT3).  
B
0
AT1 is of medical interest as an indirect regulator of blood glycemia via cellular amino 
acid starvation response pathways. Absence of B
0
AT1 results in improved glycemic control 
and other metabolic effects, revealing it as a potential pharmacological target to treat type II 
diabetes.  
Essential to understanding the role of B
0
AT1 as a global metabolic regulator is its 
requirement for plasma membrane expression with heteromeric protein partners: collectrin in 
the kidney and Angiotensin Converting Enzyme 2 (ACE2) in the small intestine.  Both 
proteins are membrane-anchored by a single trans-membrane domain and are homologous. 
B
0
AT3 also requires collectrin or ACE2 for membrane expression. Beyond this requirement 
for plasma membrane expression, however, little is known about the underlying mechanisms 
of the interaction.  
This thesis demonstrates additional protein partners of B
0
AT1, namely Aminopeptidase N 
(APN), syntaxin 1A, and syntaxin 3. These proteins facilitate changes in the kinetic 
parameters of neutral amino acid transport, in addition to regulating membrane expression. 
Moreover, I demonstrate that collectrin is required for catalytic activation of both B
0
AT1 and 
B
0
AT3, while both APN and ACE2 increase B
0
AT1 and B
0
AT3 substrate affinity, 
respectively. ACE2 and APN also form large complexes with B
0
AT1 at the small intestine 
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brush border membrane. A binding site in both transporters for collectrin is identified as lying 
in the hydrophobic pocket between TM 5 and 7 of the transporters. Using a mixture of 
experimental and bioinformatics tools, I was able to map the interacting domains of collectrin, 
which involve multiple regions of the protein, including the TM domain and large regions of 
the N-terminus. The ability of collectrin and B
0
AT1 orthologs to cross-react with each other 
and the homologous region of ACE2, suggests a highly conserved structure-function 
relationship between them. 
In conclusion, B
0
AT1 and B
0
AT3 form large, stable protein complexes with collectrin, ACE2 
and other proteins, the binding site and function of which are highly conserved. The necessity 
of these interactions mean these complexes should be thought of as heteromultimeric 
transporter metabolons – multimeric protein units facilitating efficient neutral amino acid 
transport in epithelial cells. There is increasing evidence that the formation of stable 
heteromeric membrane transport complexes is a common theme underlying the function of 
many transporters initially studied in isolation. Understanding the physiology and structure-
function relationships of transporters in their native multimeric states is fundamental to 
understanding relevant biological roles. Especially as membrane transporters are heavily 
over-represented as causative agents of human disease and as therapeutic drug targets. 
Targeting stable, intrinsic protein-protein interactions presents a still unexplored field of drug 
treatment in biomedical science. 
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Chapter 1: Introduction 
 
1.1 Neutral Amino Acid Transport in the Physiological Context 
1.1.1 The importance of neutral amino acids to metabolism and homeostasis 
Proteins constitute one of the four major biochemical building blocks required for sustainable 
life along with carbohydrates, lipids, and nucleic acids. They form the majority of functional 
and structural components of cells, and are a major source of metabolic energy, contributing up 
to 5 % and 15 % of energy requirements under resting and starvation conditions, respectively 
[1]. Of the 20 canonical amino acids many are essential as they cannot be synthesised by 
humans. These are the neutral amino acids leucine, phenylalanine, valine, isoleucine, 
methionine, tryptophan, threonine, and the basic amino acids lysine and histidine [2, 3]. 
Essential neutral amino acids are precursors for a wide range of vital metabolites: TCA cycle 
intermediates, neurotransmitters, nitrogen carriers, and ketone bodies – to name a few. Dietary 
intake of proteins in the small intestine and their reabsorption from the glomerular filtrate in 
the kidney are important elements of neutral amino acid homeostasis. 
 
1.1.2 Physiological adaptions of the intestinal and renal epithelium  
The main sites of protein digestion, absorption and retention are the epithelia of the small 
intestine and renal proximal tubules [4]. The epithelium is a single-celled layer enclosing the 
lumen of the small intestine and proximal tubules of the kidney nephrons (Fig. 1.1). The small 
intestine lumen represents the site of protein hydrolysis into amino acids and peptides and their 
exposure to the apical portion of epithelial cells, known as the brush border membrane. In 
humans full protein digestion and absorption requires approximately 6 hours to passage 
through the 6.9-7.1 meters of small intestine, driven by the enteric muscular movements of 
peristalsis [5]. Peristalsis is not required in the kidney because the filtration pressure in 
 
2 
 
 
  
3 
 
 
 
 
 
Figure 1.1 Morphology and structure of the intestinal and renal epithelium 
The basic functional unit of the small intestine is the luminal cavity along which stomach 
content passes during the processes of nutrient absorption. In the kidney the basic functional 
unit is the nephron, which absorbs nutrients from the glomerular blood filtrate. The gross 
morphology and structure of the two organs are quite different (top left). Moving to greater 
magnification common features become apparent: a convoluted lumen enclosed by the 
epithelial cells (kidney nephron and small intestine), villus (intestine only), the single-celled 
epithelium layer, and microvilli in a hexagonal packing array. The epithelium is separated by 
tight junctions into an upper part or brush border membrane and a lower part or basolateral 
membrane. The brush border membrane is the site of amino acid absorption, and its surface 
area is significantly increased by microvilli packing (electron micrograph, bottom left [6]) 
showing the hexagonal packing array from a single enterocyte. The white scale bar indicates a 
length of 200 nm. Blood supply at the epithelium lies below the basolateral membrane and is 
the pathway for the absorbed amino acids to the rest of the body. The physiological properties 
of the epithelial cells, including major pathways for neutral amino acids, are detailed in Figures 
1.2 and 1.3.  
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Bowman’s capsule, where blood is initially filtered into the kidney, is continuous with arterial 
blood pressure and enough to push the glomerular filtrate along the nephrons [7]. Both the 
small intestine and proximal tubules have further longitudinal sub-divisions. Moving from the 
stomach, the small intestine consists of the duodenum followed by the jejunum and ileum. The 
proximal tubules are divided into S1, S2, and S3 sections moving from the glomeruli towards 
the loop of Henle (see Fig. 1.1).  
 
The small intestine and proximal tubule brush borders are among the most convoluted 
membranes in the human body [8]. In the intestine, surface area is increased by morphological 
adaptions emanating from the mucosal tissue, from which the epithelium is formed. These 
include ridges called plicae circulares and protrusions or villi, which cover the plicae circulares. 
Individual villi are covered by numerous types of functionally distinct epithelial cells, of which 
the enterocytes are responsible for nutrient absorption. The greatest density of enterocytes is 
towards the tip of the villi, while the crypts contain stem cells that produce future enterocytes 
and other epithelial cells. The enterocyte brush border membrane itself forms microvilli, 
heavily folded structures which maximise the available surface area through a hexagonal 
packing array (Fig 1.1) [6]. Proximal tubules have no villi, instead the brush border enterocytes 
form a flat epithelial layer from which the hexagonally-packed microvilli protrude [9]. Absence 
of villi in the kidney is compensated by the division of the absorption pathway into many  
individual nephrons, each ~3 cm long [10]. 
 
In humans the length, circular folds, villi, and microvilli packing combine to give a total small 
intestine brush border surface area of ~30 m2  [8]. The cumulative cross sections of 200,000 to 
1.8 million nephrons in an adult kidney [9, 11] allow for a glomerulus filtration rate (GFR) of 
80-140 ml/min – as a result the total blood volume of an adult human can be filtered in less 
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than an hour [7]. The capacity for the reabsorption of essential nutrients is also large. For 
example, the glomerulus filters 300 𝜇moles of amino acids from renal arterial blood per minute, 
of which ~80-98% is reabsorbed in healthy humans [12, 13]. 
 
Another adaption of absorptive epithelia is their asymmetric structure, exemplified by 
polarisation of the enterocyte. The enterocyte plasma membrane is divided into two regions: 
the brush border (apical) and basolateral membranes (Fig. 1.1). The asymmetry arises through 
differential distribution of proteins to the apical and basolateral membranes. The integrity of 
separation between these membrane regions is maintained by tight junctions, continuous 
contact points between epithelial cells [14]. Proteins trafficked to one membrane cannot pass 
through tight junction complexes to the other. For example, trafficking of the Na
+
/K
+
 ATPase, 
occurs exclusively, in both the proximal tubules and small intestine, to the basolateral 
membrane [12, 15]. The compartmentalised membrane creates a thermodynamic environment 
optimised for the absorption and reabsorption of neutral amino acids across brush border 
membranes.  
 
1.1.3 Brush border membrane conditions are optimised for active transport  
Brush border membranes, like all lipid bilayers, are largely impenetrable to neutral amino acids 
[16]. The resulting rate of flux across the brush border is calculated by Fick’s first law of 
diffusion corrected for water-lipid-water phase transitions (Appendix A1, eq.1.1, p.225) [16]. 
As a consequence the diffusion rate of, for example, L-leucine across the brush border is very 
slow (Fig. 1.2A, red tracing). In order to increase the rate of L-leucine transport, either 
energetically passive (Fig. 1.2A, yellow tracing) or active (Fig. 1.2A, blue tracings) facilitated 
transport is used. Energetically passive diffusion through either the membrane or facilitated 
transporters cannot move substrate beyond the equilibrium point of the L-leucine concentration  
6 
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Figure 1.2 Principles of L-leucine flux across the brush border membrane  
A) The thermodynamic endpoint (equilibrium) in each transport scenario α, β, γ, and relative 
time (t) to reach this endpoint in the distribution graph. B) The potential transport mechanisms 
underlying these thermodynamic profiles for L-leucine brush border absorption. α) With no 
other diffusion pathway except directly through the brush border membrane, the rate of L-
leucine flux is governed by its diffusion constant (D) and partition coefficient into the lipid 
bilayer (see Appendix 1A, eq. 1). β) Introduction of a leucine transporter circumvents the need 
for membrane partitioning as L-leucine transport is now catalysed through a more favourable 
chemical environment. However, the eventual equilibrium point is still unchanged in the 
absence of sodium, or another co-transported ion. The equilibrium point is independent of the 
flux rate, being set by the free potential energy (µleu) of the leucine concentration gradient 
across the brush border (see Appendix 1A, eqs. 1.2 & 1.3). This scenario is most favourable for 
downhill flux of L-leucine at the epithelial basolateral membrane. γ) The introduction of a 2nd 
solute (Na
+
) with a greater potential energy than leucine (µNa >> µleu) allows for the 
accumulation of leucine far in excess of its equilibrium point. The potential energy available 
from sodium (Appendix 1A, eq. 1.8) is the combined electrical and chemical potential energies 
(Appendix 1A, eqs. 1.5 & 1.2). 
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gradient. At which point the potential energy (𝜇𝑠
′°) and free energy (𝐺𝑠
′°) available approaches 
zero (Appendix 1A, eqs. 1.2 and 1.3, p.225). Moreover, as the L-leucine gradient dissipates the 
net inward flux rate also steadily decreases. Therefore, facilitated diffusion is inefficient under 
conditions requiring maximal absorption of L-leucine, such as a protein poor diet. To optimise 
L-leucine absorption, the brush border membrane uses the potential energy stored in the 
concentration gradient of inorganic ions. The membrane proteins mediating these processes are 
secondary active transporters. Such transporters are ‘secondary’ as the potential energy source 
is the electro-chemical gradient of the water soluble ions, usually sodium, protons or potassium. 
In contrast, a ‘primary’ active transporter drives its substrate against a potential energy gradient 
directly by utilising the free energy released by chemical hydrolysis of phosphate bonds from 
energy-rich ATP.  
 
In most cells the primary active Na
+
/K
+
 ATPase transporter maintains a continuous potential 
energy source for other secondary active transporters by establishing the unequal distribution 
of sodium and potassium across the plasma membrane (Fig 1.2B and Appendix A1, eq. 1.4, 
p.226). However, the Na
+
/K
+
 ATPase is present only at basolateral membranes of renal and 
intestinal enterocytes, maintaining a cytosolic sodium concentration of 10-20 mM [17-19]. In 
the small intestine a sodium gradient for active uptake of L-leucine across the apical membrane 
is achieved by NaHCO3  secretion from Brunner’s gland. These secretions simultaneously 
establish a large lumen Na
+
 concentration (~145 mM) and neutralise the highly acidic stomach 
chyme entering the duodenum [20]. In the proximal tubule brush border the luminal sodium 
concentration is similar to that of blood plasma, as sodium passes freely from afferent 
arterioles into the glomerular filtrate and nephrons [12]. 
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The positive elemental charge (𝑞) of sodium means the sodium electrochemical gradient has an 
electrical potential energy component, calculated using the Nernst equation (Appendix A1, eq. 
1.5, p.226). In addition to sodium and potassium gradients, established by the Na
+
/K
+
 ATPase, 
brush border membranes have significant chloride permeability [12]. The electrical potentials 
for all 3 permeate ions combine in the Goldman-Hodgkin-Katz (GHK) equation (Appendix A1, 
eq. 1.6, p.227) to calculate the brush border electrical (membrane) potential (𝑉𝑚). In healthy 
individuals and animals, the intestine brush border membrane potential has been recorded at 
−35 mV to −48 mV [21-24]. During L-leucine transport, the electrical potential for sodium is 
the difference between the membrane potential and sodium’s equilibrium (or Nernst) potential 
(Appendix A1, eq. 1.7, p.227). This provides enough electro-chemical potential energy 
(Appendix A1, eq. 1.8, p.227) for a large concentration of L-leucine in the enterocytic cytosol 
(Fig. 1.2B and section 1.3.2).  
 
Because of the presence of tight junctions between enterocytes, three physiological 
compartments exist across absorptive epithelia, creating three distinct electro-chemical 
potentials for sodium. However, as the small intestine and proximal tubule tight junctions are 
more permeable than the cell membranes, especially to ions, water and small solutes, a 
relatively small trans-epithelial voltage ( 𝑉𝑇𝐸)  is observed. The absorbing epithelia are 
classified as ‘leaky’ with low resistance and  𝑉𝑇𝐸  close to zero [25-27] (Fig. 1.2B). 
Consequently, only the electrical potentials across the brush border and basolateral membranes 
have a significant effect on sodium flux. 
 
An inside negative membrane potential exists between the cytosol of enterocytes and both the 
lumen and interstitial compartments. As a result, facilitated diffusion through passive 
transporters is utilised for the release of neutral amino acids across the basolateral membrane 
10 
 
(Fig. 1.2B) [4]. The physiological parameters at the small intestine and renal brush border are 
given in Tables 1.1 and 1.2. 
 
1.1.4 Protein digestion and absorption mechanisms at the brush border membrane 
The chemical variety of amino acids requires a variety of sodium- and other ion-driven 
transporters for efficient absorption at brush border membranes (Fig. 1.3A). Absorption is 
preceded by digestion of dietary protein in the small intestine. In the proximal tubule amino 
acids are absorbed directly, but blood circulated peptides must be degraded before absorption. 
Therefore, a number of proteases and peptidases are found in both organs. 
 
Protein digestion in the small intestine begins with the hydrolysis of proteins by gastric and 
pancreatic proteases [15, 28]. The resulting products are oligopeptides 2 to 10 amino acid 
residues long [28]. These are further hydrolysed by peptidase enzymes anchored in the brush 
border membrane. Eleven mammalian brush border peptidases are known to hydrolyse 
oligopeptides into single amino acids and di- or tripeptides [17, 28-30].   
 
In the kidney proximal tubules reabsorption of intact proteins is still required as proteins and 
peptides smaller than ~22 kDa can pass through the glomerulus [7, 31, 32]. The main 
mechanism for renal protein reabsorption is endocytosis at the brush border, with protein 
internalisation being modulated by the protein receptors megalin and cubilin [33]. Brush border 
peptidases are thought to play a relatively minor role in hydrolysing intact proteins and 
peptides for reabsorption. 
 
The peptide hydrolysis products or individual amino acids are then transported across the brush 
border membrane. The main brush border amino acid transport systems were characterised 
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before discovery of the responsible proteins (reviewed in [4, 34, 35]). Competition experiments 
revealed a single system for long side-chain neutral amino acid uptake in both small intestine 
and kidney termed system B
0
, or NBB [34, 36]. Molecular cloning and heterologous expression 
subsequently identified Broad Neutral Amino Acid Transporter 1 (B
0
AT1) as the molecular 
correlate of system B
0
 [37-40]. B
0
AT1 is the main pathway for absorption of neutral amino 
acids across both, the proximal tubule and small intestine brush border membranes. Its 
widespread expression in the small intestine is maximised in enterocytes at villi tips [41] (Fig. 
1.3B). 
 
Other transporters in mammals contributing to the brush border absorption of neutral amino 
acids are the small neutral amino acid transporter Broad Neutral Amino Acid Transporter 3 
(B
0
AT3, kidney), di- and tri-peptide transporters PepT1 (intestine) and PepT2 (kidney), the L-
proline, L-alanine, glycine transporters PAT1 (intestine) and PAT2 (kidney), and the proline 
transporter IMINO (kidney and intestine) [4, 34, 42, 43] (Fig. 1.3A). Several other brush 
border exchangers also play a role in net uptake of some neutral amino acids, including 
rBAT/b
0,+
AT (SLC3A1/SLC7A9) and ASCT2 (SLC1A5) [4, 43-48]. Despite reports that 
peptide transport via PepT1 mediates uptake of up to 80% of a protein load [15, 17], the 
proportion of protein absorption absorbed as peptide vs amino acids is debated by recent 
evidence from PepT1-deficent mice, which showed significant contribution to protein 
absorption by PepT1 only under high protein diet conditions [49]. Similarly, B
0
AT1 knockout 
mice are healthy, although smaller than wildtype mice, suggesting some functional 
compensation between B
0
AT1 and peptide transporters [50]. 
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Table 1.1: Physiological parameters of the mammalian small intestine epithelium  
 
Parameter Value References 
Brush border Rm
* 
127 Ω ∙ cm2 to 3 KΩ ∙ cm2 [51] 
Trans-epithelial Rm 50−90 Ω ∙ cm2 [51-54] 
Intra-cellular Vm −35 to −48 mV [17, 21-24] 
Trans-epithelial Vm −3 mV [15] 
Parameter Fasting 
(mmol∙ L−1) 
Post-feeding 
(mmol∙ L−1) 
References 
[Na
+
] luminal/ cytosolic  140−145/10−20 101−139/10−20 [17, 55, 56] 
[K
+
] luminal /cytosolic  4.5−20/120 [55, 57-59] 
[Cl
-
] luminal/cytosolic  125-135/8-21 [55, 59] 
[HCO3
-
] luminal  2.7-75 10 [60, 61] 
luminal pH 4−7a, 4.4−8.1b 4.2−6.7a, 5.2−8b [59, 61, 62] 
Osmotic pressure (luminal) 124−266 mOsm/kg 250−367 mOsm/kg [61] 
 [L-leucine] luminal/cytosolic  0.32/1.09 mM 3.02-14/1.32 mM [17, 63-65] 
 [L-glutamine] luminal/cytosolic 0.15/1.10 mM 1.21/1.31 mM 
[L-asparagine] luminal/cytosolic 0.15/1.10 mM 1.21/1.31 mM 
 [L-methionine] luminal/cytosolic 0.05/0.20 mM 0.60/0.12 mM 
 [L-valine] luminal/cytosolic 0.23/1.02 mM 1.69/0.92 mM 
 [L-alanine] luminal/cytosolic 0.17/1.68 mM 1.88/3.17 mM 
 [L-glycine] luminal/cytosolic 0.21/1.85 mM 0.74/2.17 mM 
 [L-isoleucine] luminal/cytosolic 0.08/0.38 mM 0.89/0.43 mM 
 [L-phenylalanine] 
luminal/cytosolic 
0.23/0.34 mM 1.76/0.56 mM 
[Total amino acids] 
luminal/cytosolic 
3.21/18.94 mM 29.29/22.7 mM 
a = duodenum, b = jejunum/ileum 
* Widely discrepant values are a result of different experimental approaches (see [51])  
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Table 1.2: Physiological parameters of the mammalian proximal tubule epithelium 
 
Parameter Value References 
[Na
+
] luminal/ cytosolic  145/10−20 mM [66] 
[K
+
] luminal /cytosolic  4 mM/140−150 mM [67, 68] 
[Cl
-
] luminal/cytosolic  115-135/8−21 mM [69-73] 
[HCO3
-
] luminal/cytosolic  21−24 mM/13.4 mM [25, 74, 75] 
luminal pH/cytosolic pH 6.75-6.9/7.1-7.3 [75-77] 
Brush border Rm 260 Ω ∙ cm2 [25] 
Trans-epithelial Rm 5 Ω ∙ cm2 [25] 
Intra-cellular Vm −50 to −70mV [25, 26] 
Trans-epithelial Vm −3 to +2 mV [25, 26] 
Osmotic pressure (luminal) 280−290 mOsm/kg [78] 
Selected Neutral Amino Acids (μmol∙ L-1)*  
 [L-leucine] luminal 98−205 [43, 79-81] 
 [L-glutamine] luminal 233−798 
[L-asparagine] luminal 26−106 
 [L-methionine] luminal 13−40 
 [L-valine] luminal 127−335 
 [L-alanine] luminal 120−494 
 [L-glycine] luminal 100−384 
 [L-isoleucine] luminal 39−90 
 [L-phenylalanine] luminal 42−74 
 [L-tryptophan] luminal 23−65 
[Total amino acids] luminal 1690−3685 
* Values are given for blood plasma concentrations, which will be the same for the  
   glomerular filtrate at the start of the proximal tubules before significant absorption occurs.   
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Figure 1.3 Protein digestion and neutral amino acid absorption at the brush border 
membrane 
A) Diagram of the small intestinal or renal epithelial layers containing individual epithelial 
(brush border) cells and the position of tight junction, creating brush border (BBM) and 
basolateral (BM) divisions. The major transport pathways for neutral amino acid absorption 
at the brush border membrane and their tissue specificity (kidney (K) or small intestine (I)) 
are also shown. Transporter ion dependence and substrates are shown as chemical structures 
or symbols in the lumen. Also shown at the brush border membrane, are the B
0
AT1 and 
B
0
AT3 heteromeric subunits ACE2 and collectrin. B) Cross-section from the small intestine 
of an adult mouse showing villi protruding from the mucosal layer [41]. B
0
AT1 protein 
expression was detected by immunofluorescence.  
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1.2 Secondary Active Membrane Transporters 
 1.2.1 Mechanisms, diversity, classification 
Approximately 400 loci in the human genome encode for identified or putative secondary 
active transporters [82-87]. They contain transporters for every major class of biogenic 
molecules including monosaccharides, disaccharides, amino acids, peptides, water, fatty acids, 
sterol lipids, inorganic ions, trace metals, nucleosides, sugar nucleotides, and other metabolic 
intermediates [18, 87, 88]. 
 
An accepted method for classifying secondary active transporters is the Transporter 
Classification Database (TCDB) recognised by the IUBMB as the approved classification 
system [89-93]. In addition, the Human Genome Nomenclature Committee (HGNC) 
authorises the Solute Carrier (SLC) system for classifying the human loci encoding secondary 
active transporter proteins in humans [83]. These transporter classification systems are based 
on sequence similarity. The recent elucidation of phylogenetically diverse secondary active 
transporter structures supports an alternative classification based on a fewer number of 
structural folds or motifs. Four of the main structural folds are: the Major Facilitator 
Superfamily (MFS) fold, the GltPh or elevator-mechanism fold, the Mitochondrial Carrier 
Fold (MCF), and, pertaining to transporters studied in this thesis, the LeuT fold (section 1.3.4) 
(for reviews see [94-96]). 
 
Secondary active transporters are subdivided further, depending on the ‘coupling’ of their 
substrates. Two modes of action are defined: symporters, which move all substrates and co-
transport ions along the same vector; and anti-porters (or exchangers), which translocate one 
or more substrates/co-substrates bi-vectorially across the cell membrane. Uniporters, which 
utilise only the diffusion gradient of a substrate, are cited as a 3
rd
 mode; however, technically 
17 
 
uniport is not active as it does not drive the uphill transport of substrate unless that substrate 
is charged. The stoichiometry of a transport cycle is open to large variability within these two 
modes of transport. In the proximal tubule and small intestine the major brush border neutral 
amino acid and peptide transporters are either sodium- or proton-driven symporters (see Fig. 
1.3A).  
 
Secondary active transporters have a generic mechanism useful for understanding how 
electrochemical gradients are coupled to translocation of substrate across a membrane. The 
‘alternate access’ model [97] proposes at least two, protein-wide conformational changes to 
‘alternately’ expose the substrate to both sides of a biological membrane. As seen (section 
1.3.3) the favourable driving force (−∆𝐺𝑜′) for uphill solute transport is dependent on the 
combined electro-chemical potential energy of transported substrate(s) and is not intrinsic to 
any transporter conformational events. Which individual conformational event in the 
transport cycle represents the greatest impact on the overall favourable energy balance is still 
debated, with charge ion movement through the membrane or increased entropy on solute 
(usually ion) release being two commonly identified steps [95, 98, 99].    
 
1.2.2 The Solute Carrier 6 family of secondary active transporters 
B
0
AT1 and B
0
AT3 are members of the Solute Carrier Family 6 (SLC6) of secondary active 
transporters (Fig. 1.4). The SLC6 family contains 20 members and is responsible for the 
transport of amino acids and their metabolites including neurotransmitters, osmolytes, and 
creatine [100-102]. The family comprises four branches: GABA transporters, monoamine 
transporters, and amino acid transporters I and II. The amino acid II branch was named with 
the characterisation of B
0
AT1 [103] and all members, except SLC6A16 (NTT5), are now 
identified brush border membrane or brain amino acid transporters [39, 40, 104-108].  
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Figure 1.4 Sequence similarity tree of human SLC6 transporters and their transport 
mechanisms 
The sequence alignment input was generated using PROMALs3D from human sequences 
drawn from the UniProt database. The phylogenetic tree was created using MEGA (v7.0.14) 
using a maximum likelihood method (section 2.7.5). The tree with the highest log10 likelihood 
(-15471.9704) is shown. In the analysis showing 19 SLC6 transporters, SLC6A10 was not 
included as it is a non-functional pseudogene [100]. Transporter protein names are written at 
the end of the branches with the Solute Carrier (SLC) gene nomenclature in brackets. 
Transporters are grouped by colour into their SLC6 subfamilies. Legend: S = substrate, ions 
are referred by their chemical symbol, the mode of transport for co-substrates is indicated in 
brackets. Scale bar = 0.2 amino acid substitutions per site. 
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SLC6 transporters are involved in a wide range of physiological processes: neurotransmitter 
re-uptake [109-124], synaptic vesicle loading and uptake [108, 125], glycemic regulation 
[126, 127], mouse oocyte development [128], kidney [37-39, 105-107, 129-133], intestinal 
[38, 40, 104, 105, 107, 129] and lung [134, 135] epithelial amino acid clearance, cell volume 
regulation [121, 136-139], ATP replenishment [140-142], DNA synthesis [143], apoptosis 
[144], and placental trophoblast transport [136, 145]. They play a diverse role in many human 
diseases, including: Hartnup disorder (section 1.3.5), immunoglycinuria, clinical depression, 
addiction, anxiety, ADHD, Parkinson’s disease, autism, schizophrenia, suicide, OCD,  
alcoholism (reviewed in [146, 147]), platelet aggregation and dysfunction [148, 149], muscle 
wasting [140], and irritable bowel syndrome [150]. While transport specificity of most SLC6 
members is known, the physiological role of brain amino acid transporters PROT, NTT4, 
NTT5, and B
0
AT2 remains elusive [108, 151, 152]. The monoamine, GABA and glycine 
transporters are functionally modulated by numerous psychostimulants, neuropsychiatric, and 
analgesic drugs, including amphetamine, methamphetamine, cocaine, 
methylenedioxyamphetamine (MDMA, ecstasy), Tricyclic Antidepressants (TCAs), Selective 
Serotonin Reuptake Inhibitors (SSRIs), and tiagabine (reviewed in [100, 153-158]). In 
contrast, exploratory pharmacology of B
0
AT1 has only recently begun [131, 159-162] due to 
realisation of its importance to glycemic control (section 1.3.5). 
 
SLC6 transporters were initially characterised as Na
+
/Cl
-
/AA symporters, with the most 
common transport stoichiometry being  2Na
+
: 1Cl
-
 : 1 AA (for early reviews see [163, 164]). 
The variety of stoichiometries has now expanded with B
0
AT1, B
0
AT2 and NTT4 requiring 
only a single Na
+
 as a co-substrate [39, 40, 104, 108]. The number of co-transported sodium 
ions varies from 1 to 3 in chloride-dependent members (see [100]), while the serotonin 
transporter SERT (SLC6A4) also counter-transports a potassium ion [165, 166]. Several 
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recent reviews of the SLC6 family cover their tissue distribution, localisation, physiology, 
pharmacology, disease associations and biophysical properties [100-102, 155, 167]. 
 
1.3 Broad Neutral Amino Acid Transporters B0AT1 and B0AT3 
1.3.1 Overview 
B
0
AT1 (SLC6A19) is the molecular correlate of intestinal and renal system B
0
, catalysing the 
secondary active transport of neutral amino acids across the brush border membrane [39, 40, 
168]. B
0
AT1 protein and mRNA is abundantly expressed in the kidney and small intestine 
epithelium [41, 107], small amounts of mRNA are also expressed in epidermal cells and the 
pancreas [167]. Immunohistochemistry shows kidney distribution is predominately in 
segments S1 and S2 of the proximal tubule [107, 132, 169]. In the small intestine, B
0
AT1 
expression is greatest in the enterocytes at the villus-tips (see Fig 1.3B), being 
transcriptionally activated by Hepatic Nuclear Factors 1α (HNF1α), and 4 (HNF4) [41]. The 
B
0
AT1 knock-out mouse displays large increases in urine levels of all neutral amino acids 
(neutral aminoaciduria), confirming its role as the major brush border neutral amino acid 
transporter [34, 127, 167, 170]. 
 
B
0
AT1 is a Na
+
- dependent symporter, with a Na
+
 /AA
0
 transport stoichiometry of 1:1. The 
free energy provided by the movement of one Na
+
 ion down its electro-chemical gradient 
allows for the uphill translocation of one neutral amino acid into the cell. Interestingly, 
intracellular potassium also regulates transport by B
0
AT1 without being transported itself 
[171].  B
0
AT1 favours the longer aliphatic, branched neutral amino acids as substrates, with 
affinity in the order of Leu ≈ Met ≈ Val ≈ Ile > Gln ≈ Asn > Phe ≈ Cys ≈ Ala > Gly ≈ Ser 
≈ Thr ≈ Tyr ≈ His ≈ Pro > Trp [39, 40]. Changes in specificity are driven by changes in the 
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apparent 𝐾𝑚  of these substrates rather than changes in transporter capacity ( 𝑉𝑚𝑎𝑥 ) (see 
section 1.3.3). 
 
B
0
AT3
1
 is expressed in the mouse renal brush border membrane but not in humans [107, 167], 
preferring smaller neutral amino acids, primarily glycine and L-alanine, over longer branched 
ones. A mouse B
0
AT3 knockout displays significant glycinuria in addition to urine excretion 
of glutamine and methionine (section 1.3.5) [106, 132]. The strongest expression of B
0
AT3 is 
observed in the S3 segment of the proximal tubules [107, 132]. The transporter was originally 
cloned in 6 alternatively spliced isoforms from mouse kidney, many truncated and probably 
non-functional [172]. Functional cloning reported sodium- and chloride-dependence of the 
B
0
AT3 [106] but no electrogenic transport: presumably due to concurrent cotransport of a 
single sodium and chloride. This report was contradicted by reporting of inward currents 
induced by the presence of all B
0
AT3 substrates [132]. An electrogenic, but chloride-
dependent B
0
AT3 is consistent with the more common SLC6/NSS symport stoichiometry of 
1AA
0
: 2 Na
+
: 1Cl
-
, leading to a greater concentrative capacity than B
0
AT1 with no greater 
charge flux per transport cycle (section 1.3.2). Human B
0
AT3 is non-functional [173], only 
murine B
0
AT3 has been used for functional characterisation to date [106, 132]. 
Glycine/alanine transport at the human renal brush-border is mediated instead by the proton-
dependent transporter PAT2 (SLC36A2) [132, 174]. The genes encoding B
0
AT1 and B
0
AT3 
are located adjacent to each other on human chromosome 5p15 and are suspected of having 
arisen by gene duplication [103] – a hypothesis supported by the 50%  protein sequence 
identity they share.  
 
                                                          
1
 B
0
AT3 was previously known as XT2. 
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B
0
AT1 and B
0
AT3 require either of the single TM domain-containing ancillary proteins 
collectrin or angiotensin converting enzyme 2 (ACE2) as essential subunits for plasma 
membrane trafficking [106, 132, 169, 175-178] (section 1.5.1). B
0
AT1, however, retains a 
small amount of activity and plasma membrane expression when expressed alone in Xenopus 
laevis oocytes – explaining its initial characterisation without collectrin or ACE2  [37, 39, 40, 
169]. B
0
AT1 also mediates collectrin-independent neutral amino acid uptake when purified 
from kidney [131, 171]. Early functional characterisation of B
0
AT3 failed [172], probably 
due to the absence of collectrin or ACE2 [106, 132]. However, this may only explain mouse 
B
0
AT3 membrane expression as human B
0
AT3 is non-functional.  
 
In addition to collectrin and ACE2, B
0
AT1 is regulated in vitro by various kinases, including 
Protein Kinase B (PKB) [179], serum and glucocorticoid inducible kinases 1-3 (GSK1-3) 
[180] and Janus Kinase 2 [181]. All of these kinases stimulate or stabilise surface expression 
with modest effects, which are not essential to B
0
AT1 surface expression or function. 
 
1.3.2 B0AT1 and B0AT3 thermodynamics at the brush border membrane 
Across the epithelium brush border membrane, a large sodium inward electro-chemical 
potential gradient exists for B
0
-like transporters (section 1.1.3). Both B
0
AT1 and B
0
AT3 
utilise this electro-chemical gradient for the inward flux of neutral amino acids.  
 
A simple combining and re-arrangement of the membrane equilibrium equation (Appendix 
A1, eq. 1.8, p.227) for both B
0
AT1 substrates L-leucine and sodium (incorporating a 
physiologically relevant sodium gradient) shows that B
0
AT1 can concentrate L-leucine at a 
100:1 cytosol to extracellular concentration (Appendix A2, eq. 1.9, p.228). For B
0
AT3, with a 
2 Na
+
: 1 Cl
-
: 1 AA
0
 stoichiometry, the concentration ratio for accumulation of L-alanine 
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increases to 1000:1. Combined with large surface area of the brush border membrane, this 
demonstrates both B
0
AT1 and B
0
AT3 are capable of maximising the acquisition of neutral 
amino acids from dietary protein and blood filtrate. 
1.3.3 Michaelis-Menten kinetics and it assumptions for B0AT1 and B0AT1  
The most common treatment of transporter kinetics is the Michaelis-Menten (MM) model. 
Michaelis-Menten kinetics are measured under conditions where depletion of substrates is 
minimal and a single substrate concentration is varied while all others are at saturation 
concentrations. This experimental scenario allows for rate determination based on single 
substrate variation and are known as initial rate conditions [182]. Following on logically, if 
substrate concentrations are effectively constant, the concentrations of all transporter-
substrate intermediates during the transport cycle will also be at steady state after the first 
turnover of the transport. This first assumption of Michaelis-Menten kinetics is known as the 
steady-state assumption [183-185].  
The steady-state assumption applies to physiological conditions for sodium and chloride in 
the intestinal and proximal tubule lumens, where a large excess concentration is maintained. 
However, it does not apply to the significant changes in neutral amino acid concentrations 
experienced by B
0
AT1 and B
0
AT3 before and after meals (see Tables 1.1 and 1.2). Other 
important assumptions are at time zero, i.e. the beginning of experimental measurement, 
trans-substrate concentration is zero and no reverse transport occurs. 
Michaelis-Menten kinetics are a useful model because its assumptions allow a transporter (T) 
catalysing substrate (S) translocation to be described by a simplified chemical equation: 
 
                      (eq.1.10) 
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and the resulting steady-state transport rate or velocity (𝑣) described by: 
 
𝑣 =
𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑚 + [𝑆]
 
                          (eq. 1.11) 
 
the Michaelis-Menten equation, which is derived from the differential rate laws of equation 
1.9 (p. 228) incorporating the steady-state assumption (see e.g. [183]). It is the saturation 
curve for the variation of one substrate’s concentration ([𝑆]) under initial rate conditions. The 
parameter 𝑉𝑚𝑎𝑥  refers to the maximal (saturation) transport rate. The parameter 𝐾𝑚  (the 
Michaelis constant) has the experimental meaning: 
 
𝐾𝑚 = [𝑆]  →  𝑣 ≡
1
2
𝑉𝑚𝑎𝑥  
           (eq. 1.12) 
 
in units of concentration, which is invariant given initial rate conditions and steady-state 
assumptions. However, it is also a macroscopic rate constant, whose meaning varies 
depending on whether the second Michaelis and Menten assumption is accepted or not. They 
assumed substrate binding and dissociation to be much faster than any subsequent step (i.e. 
𝑘−1 ≫ 𝑘2)  and to form a rapid equilibrium. Under this simplified condition, 𝐾𝑚 
approximates the dissociation constant ( 𝐾𝑚 ≈ 𝑘−1 𝑘1⁄ )  for the reaction and 𝑘2  is rate-
limiting, i.e. 𝑉𝑚𝑎𝑥 ≈  𝑘2. Chemically, the lower the Michaelis constant the ‘tighter’ substrate 
binding to the transporter, i.e. the greater the non-covalent bond formation energy. This 
assumption is not necessarily correct [186], in which case  𝐾𝑚 has the canonical definition : 
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𝐾𝑚 =
𝑘2 + 𝑘−1
𝑘1
 
           (eq. 1.13) 
 
Where 𝑘2 is not the sole rate-limiting step in the transporter cycle and instead, binding and 
subsequent turnover have reached steady-state. The meaning of the Michaelis constant can 
change based on the relative rates of discrete chemical steps occurring after initial substrate 
binding. If we assume the Michaelis constant equals the dissociation constant, then 𝐾𝑚 is 
equal to the ‘affinity’ of the substrate. However, unless this can be demonstrated, 𝐾𝑚 is best 
described as representing ‘apparent’ affinity. The assumption the 𝐾𝑚 equals 𝐾𝑑  is justified 
for most transporters as turnover (𝑘𝑐𝑎𝑡) is typically of the range of 10
−2 to 10−3seconds, 
whereas binding is measured in sub-millisecond ranges.   
 
The possible meanings of the Michaelis constant is not just an empty academic exercise as it 
gives important information what steps in the transport cycle are rate-limiting. For example, 
the substrate specificity of B
0
AT1 and B
0
AT3 is determined largely by changes in apparent 
𝐾𝑚 rather than 𝑉𝑚𝑎𝑥, suggesting changes are due to substrate binding. Mouse B
0
AT1 has the 
highest apparent affinity for L-leucine (0.63-1.16 mM), followed by glutamine (0.52-3.2 
mM), alanine (4.1 mM), phenylalanine (0.59-4.7 mM) and glycine (11.7 mM) [39, 40, 168]. 
B
0AT3’s apparent 𝐾𝑚 for its two main substrates alanine and glycine is 0.9 mM and 2.3 mM, 
respectively [106, 132]. What is notable about B
0
AT1 and B
0
AT3 is their high 𝐾𝑚 values 
compared with most other SLC6 transporters (see [100]). If the rapid equilibrium assumption 
is made ( 𝐾𝑚 ≈ 𝑘−1 𝑘1⁄ ), this suggests much weaker substrate binding than the 
neurotransmitter SLC6 transporters (e.g. DAT 𝐾𝑚 = 2.5 μM [100, 187, 188]). The low 
affinity of B
0
AT1 for many substrates for which it is the only brush border transporter, e.g. 
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tryptophan, is probably compensated for by absorption time along the intestinal tract and the 
high number of kidney nephrons [189] (section 1.1.2). Furthermore, the relatively high 𝐾𝑚 of 
B
0
AT1 is reflective of its physiological role in the brush border membrane, where combined 
neutral amino concentration after a meal is several mM (Tables 1.1. and 1.2). 
 
For B
0
AT1 a four-step kinetic model has been proposed [39]. The isolated chemical steps 
proposed in this model are consistent with subsequent x-ray crystal structures from isolated 
B
0
AT1 and B
0
AT3 homologues (section 6.2.3) and several steady-state kinetic features of 
B
0
AT1. For example, the apparent 𝐾𝑚  of sodium and AA
0
 are highly dependent on each 
other’s steady-state concentration [39, 131]. Given the rapid equilibrium assumption (i.e. 
𝑘−1 ≫ 𝑘2) this indicates binding of both substrates is co-dependent and simultaneous [190], 
and is explained by coordination of sodium by the substrate carboxylate group (see section 
1.3.4).  
 
The ancillary partners of B
0
AT1 and B
0
AT3, collectrin and ACE2, are involved in trafficking 
the transporters to the plasma membrane (section 1.5.2). As a function of increased plasma 
membrane expression, the kinetic property affected by ancillary protein co-expression is 𝑉𝑚𝑎𝑥. 
However, steady-state kinetics measurements of isolated B
0
AT1 and B
0
AT3 were initially 
measured in the absence of either ancillary (e.g. [39, 40, 131, 168, 171]). 
 
Little is known about B
0
AT1 or B
0
AT3 microscopic rate constants, making it difficult to 
derive any comprehensive rate equations other than simplified Michaelis-Menten models. 
However, based on crystal structures of B
0
AT1 and B
0
AT3 ancestors, a general SLC6 
structure, transport cycle and binding mechanism has been proposed [95, 191].  
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1.3.4 B0AT1 and B0AT3 structure and substrate binding sites  
The publication of the first high-resolution structure of the SLC6 family ancestor LeuT 
caused a revolution in understanding the structure and substrate binding of B
0
AT1 and 
B
0
AT3 [192]. Subsequent crystal structures of LeuT [193-196], MhsT from B.halodurans 
[197], the D. melanogaster dopamine (DAT) [198], and human serotonin (SERT) [199] 
SLC6 transporters in various confirmations, has allowed for a full transport cycle to be 
proposed [200]. A homology model based on LeuT showed B
0
AT1 was composed of 12 TM 
α-helices [201]. Sequence homology and structural conservation shows B0AT1 and B0AT3 
contain the pseudo two-fold inverted axis of symmetry common to all known SLC6 
transporters (Fig 1.5). The axis of symmetry demonstrates that helices 1-5 and 6-10 represent 
a repeated fold, which can be superimposed by inverting and overlaying them (Fig. 1.6). The 
two-fold inverted-repeat fold is a structural architecture shared by several other transporter 
families [202-205]. The remaining two helices, TM11 and 12, are less conserved across the 
SLC6 family but retained in all human members, including B
0
AT1 and B
0
AT3 [201].  
 
Based on this structural conservation, B
0
AT1 and B
0
AT3 consist of two subdomains (Fig. 1.7, 
central panel). The first two helices of each repeat motif form the ‘bundle’ subdomain 
(helices 1/6 and 2/7). A second ‘hash’ subdomain formed by the 3rd and 4th helices in each 
inverted repeat (helices 3/8 and 4/9) constitutes a relatively rigid scaffold around the bundle. 
During the outward to inward transition of the transport cycle, the bundle is hypothesised to 
bend at unwound regions in the middle of TM1 and 6 [194]. The unwinding is caused by 3 
consecutive conserved glycine residues and makes available the functional groups of several 
nearby residues for substrate binding as they are not required for α-helix hydrogen bonding 
[206]. This results in a ‘rocking’ or hinge-bending movement of TM1 and 6 outwards into the 
bilayer between a gap formed between TM helices 5 and 7 [95, 194, 207]. The proposed 
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SLC6 transporter mechanism will be elaborated on in the context of B
0
AT1 and B
0
AT3 
interactions with ancillary proteins in the discussion (section 6.2.3). 
 
Bundle symmetry is also reflected in the conservation of SLC6 substrate and ion binding sites 
in B
0
AT1 and B
0
AT3. Amino acid carboxyl- and amino-group, first sodium binding (Na1), 
and chloride binding sites are formed by residues in bundle helix pairs 1/6 and 2/7 (Fig. 1.7A 
and 1.7B). Amino acid side-chain and second sodium site (Na2) binding residues are located 
predominately in the hash domain helices TMs 3/8 and 1/8, respectively (Fig. 1.7C). All 
substrate carboxylate and amine co-ordinating atoms (≤  3.5 Å) are conserved in LeuT, 
Drosophila DAT, human SERT and B
0
-like transporters. Where residue identity is not 
conserved, the actual co-ordinating atom is unchanged. For example, A22 and T254 in LeuT 
are C49 and S278 in B
0
AT1, co-ordinating substrate in all cases by the main chain carbonyl 
(Cα=O).  
 
A pattern emerges in B
0
AT1 and B
0
AT3 binding sites, where differences in substrate-ion 
stoichiometry and substrate specificity cannot be easily explained because of the high level of 
residue conservation. For example, B
0
AT1 has conserved Na1, Na2, and substrate binding 
sites like other SLC6 transporters, but a transport stoichiometry of 1 Na
+
:1 substrate. In 
contrast, B
0AT3’s conserved Na1, Na2, substrate, and chloride binding sites are consistent 
with its 2 Na
+
: 1Cl−: 1 substrate stoichiometry. Likewise, as substrate specificity from B0AT1 
to B
0
AT3 changes, involving shortening of the amino acid side chain length, no differences 
are observed in the side-chain binding pocket residues. Two substrate side-chain stabilising 
residues in mouse B
0
AT3, N420 and V110, differ in functional mouse B
0
AT3 and non- 
functional human B
0
AT3 (T421 and I111) – possibly contributing to the non-functionality of 
the human transporter.   
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Figure 1.5 Sequence alignment and conservation in SLC6 Broad Neutral Amino 
Acid Transporters 
Sequence alignment of human B
0
AT1 (UniProt ID Q695T7), human B
0
AT3 (Q96N87), 
mouse B
0
AT1 (Q9D687), mouse B
0
AT3 (O88576), and SLC6 homologues, the Drosophila 
melanogaster dopamine transporter DAT (Q7K4Y6) and LeuT from Aquifex aeolicus 
(O67854). The alignment was created and verified using PROMALs3D [208], with structural 
alignment filtering using the x-ray crystal structures of LeuT (PDB 2A65) and DAT (4M48) 
[209]. Substrate and ion binding residues are coloured as indicated in the figure legend. TM 
helices are numbered and sit above the MSA corresponding to the amino acids which form 
them. Note: although conservation of substrate and multiple ion binding sites is shown, this 
does not necessarily reflect the observed transport stoichiometry of the individual transporters, 
only the potential conservation of such binding sites.  
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Figure 1.6 Membrane topology of B
0
AT1 and B
0
AT3 and repeat motif symmetry  
Top: membrane topology and orientation of B
0
AT1 and B
0
AT3. The two repeated 5 x 5 
halves of the transporter are separated by a dashed line. Symmetric helices are paired by 
colour: 1and 6 (blue), 2 and 7 (grey), 3 and 8 (green), 4 and 9 (pink), 5 and 10 (maroon). 
Helices 11 and 12 do not form part of the pseudo two-fold inverted repeat motif, but are 
present in both B
0
AT1 and B
0
AT3. Helices 1 and 6 are separated into two halves by short 
unwound regions in the middle of the membrane. Bottom: The 2nd repeat motif (faded) is 
inverted, rotated 180° about the axis of symmetry (top) and overlaid on the first repeat motif 
to demonstrate the pseudo two-fold axis of asymmetry. The α-helices of all SLC6 
transporters with elucidated structures have the same conserved repeat motif [191, 193]. 
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Figure  1.7 B
0
AT1 and B
0
AT3 conserved substrate and ion binding sites  
Central Figure: The homology model of human B
0
AT1 is based on the outward open 
(competitive inhibitor bound) conformation of the Drosophila melanogaster dopamine 
transporter DAT (PDB ID 4m48). The bundle (cyan) and hash (magenta) sub-domains, along 
with TM5 (yellow) and part of IL4 (blue) are coloured. TM helices are numbered 1-12. 
Sodium ions (purple) and chloride (red) are represented as ionic radii spheres.  L-leucine 
(green) is represented as a stick structure. Close up panels: Binding sites are constructed 
from homology models of human B
0
AT1, mouse B
0
AT3, and x-ray crystal structures for 
DAT or LeuT (PDB ID 2A65). Binding residues involved in A) chloride binding, B) Na1 
plus L-leucine amine and carboxylate binding, and C) Na2 plus L-leucine side chain binding. 
The three panels for each binding site show details from the B
0
AT1, B
0
AT3 and DAT or 
LeuT outward occluded binding sites. Binding residues are coloured to reflect their bundle 
(cyan) or hash (magenta) origin and labelled with residue identity, number and intermolecular 
bond length (Å). All oxygen (red) and nitrogen (blue) atoms involved in intermolecular 
hydrogen bonding or dipole-ionic interactions are represented by dashed lines (- - - - -), in C) 
all labelled residues without a dashed line are involved in L-leucine side chain Van der Waal 
interactions. Hydrogen atoms have been removed for clarity of viewing. ? denotes the 
possibility the Na2 site in B
0
AT1 is occupied by a sodium ion. 
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The translocation of only one sodium ion in B
0
AT1 is mysterious given the high conservation 
in LeuT, DAT, B
0
AT1, and B
0
AT3 sodium binding sites. Even where conservation is not 
absolute, for example B
0
AT1 residues C49 (Na1) and S431 (Na2), neither C49 nor S430 
change the sodium co-ordinating atom. Interestingly, when SLC6 transporters are chloride-
independent, such as B
0
AT1, only one sodium ion is translocated [100] (see Fig. 1.4). In 
addition, a close functional association between chloride binding and the Na2 site has been 
observed for the dopamine transporter DAT (SLC6A3) [210].  
 
B
0
AT1-mediates chloride-independent transport [39, 40], with F74 representing the only 
change in the conserved SLC6 chloride binding site. A polar side-chain equivalent to 
B
0
AT1C49, generally replacing an alanine, is also exclusive to chloride-independent SLC6 
members, NTT4, B
0
AT2, and B
0
AT1, and PROT (SLC6A7), whose ion stoichiometry is not 
known [100]. These differences perhaps represent an alternative binding mode and transport 
mechanism to chloride-dependent SLC6 transporters. Brӧer [167] has hypothesised the pH-
sensitive B
0
AT1 [39, 171] has a hydroxyl binding site in place of chloride, to aid 
isomerisation from inward facing to extracellular facing during the transport cycle. Recent 
structural and molecular dynamics evidence suggests protonation of Glu290 in LeuT is a key 
event for inward to outward facing transition in the space that later evolved into a chloride 
binding site in SLC6 members [200, 211]. Forming part of the B
0
AT1 Na1 binding site, the 
cysteine sulfhydryl proton from C49 could act to stabilise a hydroxyl anion. In contrast 
B
0
AT3, which is chloride-dependent, has the conserved alanine (A34) in this position, and is 
pH-insensitive [106].  What exact role, however, chloride plays in the general SLC6 transport 
mechanism is still unclear [212-215].  
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An ordered substrate-first [40] and random binding order [39] were proposed for B
0
AT1 
based on the Michaelis-Menten assumption that the maximal transport rate (𝑉𝑚𝑎𝑥) for any 
single steady-state substrate concentration can be modulated by changing the concentration of 
the substrate that binds last [190]. However, the appearance of a random binding order from 
kinetic transport data could also represent the interdependence of amino acid and sodium 
binding, as has been shown for other SLC6 homologues where sodium at Na1 forms a co-
ordination ligand for the substrate (see Fig. 1.7B, [192, 194, 216]).  Evidence from SLC6 and 
other secondary active transporters indicates that binding of the driving substrate(s), always 
ions, proceeds uphill substrate binding [195, 214, 215, 217-219]. Furthermore, no outward 
open SLC6 transporter crystal structures have been found bound with substrate alone, while 
several have been solved binding only sodium [193, 194, 198]. Based on this evidence it is 
likely B
0
AT1 and B
0
AT3 exhibit ordered binding, with sodium ions binding prior to, or as a 
co-ordinated pair with,  amino acids.  
 
1.3.5 Clinical relevance of Broad Neutral Amino Acid Transporters 
Mutations in the gene encoding B
0
AT1 are the monogenetic cause of Hartnup disorder: a 
disease characterised by the wasting of neutral amino acids (aminoaciduria) in urine and 
faeces [220-222]. The first indication that B
0
AT1 malfunction caused Hartnup disorder was 
made when familial mutations in Hartnup individuals was mapped to human chromosome 
5p15 – the location of the SLC6A19 gene [223]. Subsequent molecular cloning, 
characterisation, and sequencing of Hartnup patients has located all known disease-causing 
mutations to the B
0
AT1 gene [37, 38, 168, 224-227].  
 
Although renal/intestinal aminoaciduria is the defining symptom of the disease, various 
heterogeneous secondary symptoms have been reported in Hartnup cases [220, 222, 225, 228, 
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229]. These symptoms include a photosensitive pellagra-like skin rash (as observed in niacin 
deficient patients) [220, 225, 229-235], cerebellar ataxia and motor reflex impairment [220, 
225, 229, 230], dystonia [232, 236], acrodermatitis enteropathica [228], papilloedema with 
peripapillary haemorrhage [230, 236], hypoalbuminemia and edema [230, 235, 237], smaller 
body mass and size [236, 238], seizures [224], a variety of neuropsychiatric symptoms 
ranging from mild depression and mood swings to violent outbursts, full psychosis, mental 
retardation [220, 225, 229, 230, 236, 239, 240], and even death [241]. Associated symptoms, 
excepting aminoaciduria, are absent from recent cases in developed nations (e.g. [37, 38, 226, 
227, 242]) and may represent ascertainment bias. This has led to the idea that more severe 
Hartnup disorder symptoms are overcome by supplementation of dietary protein and the 
compensatory uptake of peptides via the intestinal peptide transporter PepT1 [170, 243]. This 
speculation is supported by symptom alleviation, but continued aminoaciduria, in Hartnup 
patients treated with oral amino acid or amino acid supplements [231, 243]. 
 
Of the 23 known B
0
AT1 amino acid mutations resulting in Hartnup disorder, all follow a 
recessive Mendelian pattern of inheritance [170, 224]. Of these, 16 are caused by single 
amino acid changes,  two by nonsense mutations,  3 by amino acid deletions, and 2 by 
aberrant splicing events [37, 38, 170, 176, 224-227] (Fig. 1.8). Another B
0
AT1 mutation 
(F360S) co-segregates with a decreased risk of Chronic Kidney Disease (CKD) and 
decreased serum creatinine levels [244]. Another 2 single amino acid mutations (V252I, 
G284W) and another splice variant (c.1016+1G>A) were also reported for B
0
AT1 but 
without any adverse health associations [244]. However, as G284R represents a Hartnup 
disorder mutation in European populations, G284W is likely to be Hartnup causing. 
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Anomalous cases of Hartnup disorder have also been reported, including cases where purely 
renal aminoaciduria [238, 245] or intestinal malabsorption [170] were observed. With the 
exception of G284, there is a lack of Hartnup mutations in residues near the highly conserved 
B
0
AT1 binding sites (compare Figs. 1.7 and 1.8). For example, the mutation B
0
AT1R240Q 
lies at the extracellular-membrane interface of TM7/EL3, too distal to be implicated in direct 
substrate/ion binding. Subsequently, R240Q became instrumental in uncovering the 
interaction of B
0
AT1 with its ancillary protein ACE2 (section 1.5.2) [169]. 
  
In addition to its role in Hartnup disorder, B
0
AT1 plays a significant role in global metabolic 
control via amino acid signalling [50, 126]. B
0
AT1 knockout mice demonstrate an anti-type 2 
diabetes metabolic phenotype, largely as a result of increased (approx. 40-fold) serum levels  
of the endocrinal hormone FGF21, most likely secreted from the liver [126]. This phenotype 
includes: reduced plasma insulin levels, efficient plasma glucose clearance, conversion of 
white (storage) adipose tissue into beige (metabolising) adipose, and stimulation of ketone 
body production (simulating carbohydrate starvation conditions) [50, 126].  
 
The cellular response to increased concentrations of amino acids is activation of the mTOR 
pathway [246, 247], which, as expected, was downregulated in the B
0
AT1 knockout mouse 
small intestine and other organs [50].  Conversely, the Amino Acid Starvation Response 
(AASR) or GCN2/ATF4 pathway, which responds to amino acid depletion in cells, was 
upregulated in intestinal tissue of B
0
AT1 knockout mice and  in liver [50].  
 
B
0
AT3 has been implicated in the benign renal malabsorption disorders iminoglycinuria and 
hyperglycinuria [174], including the transient developmental form of iminoglycinuria, known 
as developmental iminoglycinuria [132]. Iminoglycinuria is characterised by increased renal  
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Figure 1.8 Hartnup disorder and other associated mutations in B
0
AT1 
The homology model of human B
0
AT1 was built from the Drosophila melanogaster 
dopamine transporter DAT (PDB ID 4m48). Hartnup disorder and other, non-disease causing, 
mutations are indicated by mutation type in the figure legend. Selected residues of interest are 
labelled (see text). R240 has been reported as both a missense (R240Q) and nonsense 
(R240X) Hartnup causing mutant [37, 169]. G284 has been reported as both a Hartnup 
causing missense mutation (G284R) and missense of unknown effect (G284W) [226, 244]. 
Several splice variant mutations which cannot be shown are: IVS8 + 2G, IVS11 + 1A (both 
Hartnup causing) and 1016+1G>A (unknown association). Sodium ions from the proposed 
Na1 binding site (B
0
AT1 and B
0
AT3), Na2 binding site (B
0
AT3), and chloride binding site 
(B
0
AT3) are shown in violet (sodiums) and red (chloride).   
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excretion of imino acids proline and hydroxyproline, as well as glycine. Usually benign, 
iminoglycinuria has been associated with nephrolithiasis [248, 249], mental retardation [250], 
gyrate atrophy [251], deafness [252], blindness and hypertension [253]. Human subjects 
homozygous or heterzygous for one of 4 mutations present in B
0
AT3: G79S, Y319X, L478P, 
G496R – displayed  iminoglycinuria only when co-segregated with further mutations in the 
alternative renal glycine transporter PAT2 (SLC36A2) [174]. This pattern suggests 
redundancy among imino acid and glycine uptake pathways and possibly little contribution 
towards the disease phenotypes by B
0
AT3 in humans [167]. Notably B
0
AT3(Y319X) 
homozygotes do not have iminoglycinuria [167]. 
 
Evidence linking hypertension to dysfunction of the broad neutral amino acid transporter in 
the kidney has been inconclusive [167, 254]. B
0
AT3 has been implicated in hypertension in 
mice, but subsequent studies,  reported no association in humans [255, 256] and hypertension 
in mice only under stress-inducing conditions [106]. Likewise, research linking human 
SLC6A19 (B
0
AT1) DNA microsatellites with hypertension was inconclusive [257]. There is 
however, evidence of up- and downregulation of rat B
0
AT3 in the proximal tubules and 
kidney outer medulla under high salt (hypernatremia) [258] and ischemic [259] conditions, 
respectively.  
 
1.4 Heteromeric Partners of Secondary Active Transporters 
1.4.1 What do heteromeric partners of the secondary active transporters do? 
As B
0
AT1 and B
0
AT3 require collectrin and ACE2 as obligatory heteromeric partners for 
plasma membrane expression (section 1.5.2), it is worth first surveying what is known more 
generally about the under-researched field of heteromeric secondary active transporters.  
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Most membrane proteins perform their biological functions in the context of stable and 
isolatable proteins complexes. In a recent example the stable interactome of membrane 
proteins from Saccharomyces cerevisiae was surveyed, and each membrane protein 
(including transporters) had, on average, 1.1 interactions with other membrane proteins [260]. 
Nearly two-thirds of these interactions reflected proteins with no previously known 
functional association [260]. Fully understanding the biological function of secondary active 
transporters such as B
0
AT1 and B
0
AT3 requires the study of these intact heteromeric protein-
protein complexes. 
 
Interactions of secondary active transporters with other proteins can have two functional 
outcomes: changes in expression/localisation or changes to catalytic function (Fig. 1.9). As 
most  transporters are expressed at the plasma membrane [100-102, 155] changes in 
localisation or expression via protein-protein interactions necessarily involves either 
trafficking to the cell surface, away from it, or stabilisation in the membrane [261]. 
Alterations in steady-state plasma membrane expression will manifest as an alteration in 
maximal rate (Vmax) of transporter activity as the two are directly proportional. The second 
possible functional effect of protein-protein interactions in transporters is modulation of the 
catalytic mechanism. Modulation can manifest itself in kinetic parameters of substrate 
affinity or turnover number (𝐾𝑚 or 𝑘𝑐𝑎𝑡) and, as a consequence, substrate specificity.  
 
Given the potential ubiquitous nature of stable protein-protein interactions among secondary 
active transporters, it is interesting so few heteromeric interactions have been identified, or 
researched in depth. A survey of some of the better characterised examples provides a 
snapshot into the potential range and diversity of these interactions.  
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Figure 1.9  Heterodimeric secondary active transporters in humans 
Obligatory secondary active transporter heterodimers are necessary for either trafficking from 
secretory pathway membranes to the plasma membrane, for catalytic activation of transport, 
or for both. A) For the SLC3/SLC7 amino acid exchangers, the SLC3 (rBAT/4F2hc) 
ancillary subunit requires a SLC7 substrate-translocating heteromer partner for both stability 
and trafficking from the ER, otherwise it is degraded by the proteasome [262, 263]. B) In 
contrast SLC16 transporter subunits require embigin and/or basigin for Golgi exit as well as 
ER exit [264-267]. The 7 TM containing transporter SLC51A (Ost α) requires its ancillary 
SLC51B (Ost β) for both trafficking to the plasma membrane (C) and for substrate 
translocation (taurocholic acid is shown) at the plasma membrane (D). The point at which 
SLC51B controls trafficking is unknown (?).  
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1.4.2 Heteromeric amino acid transporters of the SLC3 and SLC7 families 
The most well characterised heteromeric secondary active transporters are the amino acid 
transporters of the SLC3 and SLC7 families (see reviews in [254, 268, 269]. Each 
heteromeric transporter consists of one SLC7 ‘light’ substrate translocating subunit, and a 
second SLC3 ‘heavy’ ancillary subunit. There are two heavy subunits, namely rBAT 
(SLC3A1) and 4F2hc (SLC3A2). The rBAT subunit heterodimerises with SLC7 light 
subunits b
0,+
AT (SLC7A9), and AGT1 (SLC7A13) [44, 270]. The 4F2hc subunit 
heterodimerises with one of 6 SLC7 subunits: LAT1 (SLC7A5), LAT2 (SLC7A8), y
+
LAT1 
(SLC7A7), y
+
LAT2 (SLC7A6), asc1 (SLC7A10), and xCT (SLC7A11) [271-280]. 
Functionally, all SLC3/SLC7 heteromeric amino acid transporters are amino acid exchangers, 
although they vary in their ion dependence and relative affinity for the different classes of 
amino acids at extracellular and intracellular faces [269]. In amino acid absorption, rBAT 
heteromers are localised to the brush border membrane of renal and small intestinal epithelial 
cells, whereas 4F2hc heteromers are localised exclusively to the basolateral membrane 
(reviewed in [254]). The rBAT/ b
0,+
AT heteromer is a brush border sodium-independent 
transporter for cationic amino acids and cystine (section 1.1.4), which it exchanges for 
cytosolic neutral amino acids [46, 263, 281]. rBAT/AGT1 is a brush border anion transporter 
that is involved in cystine uptake in the S3 segment of the renal proximal tubule [44]. The 
4F2hc-associated transporters have a wider tissue expression and are vital amino acid uptake 
systems in almost all major human tissues [269]. Numerous mutations in rBAT/ b
0,+
AT 
underlie renal aminoaciduria cystinuria [282]. For 4F2hc-associated transporters, especially 
LAT1 and xCT, over-expression is a hallmark of many cancer cells and activated 
lymphocytes [254]. The structure of the 12 TM containing SLC7 translocating subunits and 
their bacterial ancestors share the LeuT fold with SLC6 secondary active transporters  
(section 1.3.4).  
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The SLC3/SLC7 heterodimer is unique in being the only known solute transporter subunits 
whose interaction is dependent on a single disulphide linkage. Both rBAT and 4F2hc heavy 
subunits are type II, N-glycoproteins with M.W.s of ~94 and ~85 kDa, respectively. Both 
contain a small intracellular N-terminal, a single α-helix TM domain and a large extracellular 
domain [283].  The disulphide bridge is mediated by a cysteine located 4-5 amino acids to the 
extracellular side of the single TM domain, pairing with a cysteine in the extracellular loop 
between TM3 and TM4 of the light subunits [269]. The extracellular domains of rBAT and 
4F2hc have ~20% homology to bacterial α-amylases, with a crystal structure of human 4f2hc 
extracellular domain (PDB ID 2DH2) confirming they retain the same TIM barrel and anti-
parallel β-barrel domains [283, 284]. No enzymatic activity has been demonstrated for either 
rBAT or 4F2hc extracellular domains [283]. For all holotransporters, rBAT and 4F2hc are 
essential for trafficking to the plasma membrane (reviewed in [285]), and thus can be viewed 
as affecting Vmax of the translocating light subunits. b
0,+
AT, reconstituted alone from the ER 
is fully functional, suggesting rBAT has no effect on catalytic mechanism or specificity of 
transport [263]. Although rBAT/b
0,+
AT and 4F2hc-associated transporters are fully functional 
as heterodimer, rBAT/b
0,+
AT also forms heterotetramers of two disulphide-linked 
heterodimers held together by non-covalent associations in vivo [286].  
 
Despite the necessity of the disulphide bond in all SLC3/SLC7 heterodimers, it is not 
sufficient for correct complex formation and plasma membrane trafficking [269]. The large, 
extracellular domains for both ancillary subunits rBAT and 4F2hc appear essential for ER 
exit and trafficking [268]. For example, the folding and stability of b
0,+
AT in the ER is rBAT-
independent, whereas unassociated rBAT is degraded by the ER proteasome due to the role 
of b
0,+AT in the correct ER folding of rBAT’s extracellular domain [262, 263]. Once correct 
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b
0,+
AT-mediated folding occurs membrane trafficking is rapid and the degradation of rBAT 
prevented [262]. N-linked glycosylation of human rBAT also appears to be essential for 
stability and trafficking of the heterodimer [287]. For most of the 4F2hc-associated 
transporters, the extracellular domain appears essential for interaction and trafficking [288]. 
However, deletion of the 4F2hc extracellular domain with LAT1 seems to either simply slow 
light subunit trafficking, without effecting final membrane expression, or be totally 
replaceable and unnecessary [288, 289]. Recent structural evidence indicating a large surface 
area of interaction between human LAT2 and extracellular 4F2hc supports the importance of 
the heavy chain C-terminal domain [290-292]. Where they have been studied, the N-terminal 
and TM domains of 4F2hc and rBAT are also essential for interaction and functioning of the 
transporting subunits [288, 292]. 
 
1.4.3 Embigin and basigin: monocarboxylate (SLC16) transporter ancillaries 
The monocarboxylate transporter (MCT) family comprises 14 members in humans and has 
been identified in all eukaryotic species sequenced [293]. All members consist of 12 TM α-
helical domains and are part of the large MFS superfamily which, based on other solved MFS 
structures, suggests that MCTs also contain the MFS fold and repeated two-fold pseudo-
symmetry [94, 294] (section 1.2.1). Eight human members have verified physiological 
transport substrates and mechanism identified: SLC16A1 (MCT1), SLC16A7 (MCT2), 
SLC16A8 (MCT3), SLC16A3 (MCT4), SLC16A2 (MCT8), SLC16A10 (TAT1), SLC16A12 
(MCT12) and, recently, SLC16A11 (MCT11) [295-298]. MCTs 1-4 are all proton-dependent 
monocarboxylate symporters with a H
+
: substrate stoichiometry of 1:1, although direct proton 
co-transport in MCT3 and MCT11 [297]has not been verified experimentally (for reviews see 
[293, 295, 296, 299]). SLC16A2 is a high affinity thyroid hormone uniporter, mutations in 
which cause Allan-Herndon-Dudley syndrome and other clinically diverse mental retardation 
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conditions [300, 301]. TAT1 is a kidney and small intestine basolateral uniporter for aromatic 
amino acids [302]. MCT12 is as a kidney basolateral membrane and retinal creatine uniporter, 
non-synonymous mutations in which cause juvenile cataract with microcornea (or cataract 47)  
[303, 304] and age-related cataract [305]. In addition, MCT7 (SLC16A6) has been implicated 
as a ketone body transporter in Zebra fish [306], and MCT9 (SLC16A9) as a carnitine 
transporter based on serum level changes in a genetic polymorphism of the encoding gene 
[307]. 
 
Monocarboxylate transporters 1-4, 11 and 12 require either the immunoglobulins embigin or 
basigin (CD147) as ancillary proteins for correct plasma membrane expression [295, 297, 298, 
303]. However, unlike the SLC3/SLC7 heterodimers, MCT trafficking is not always 
dependent on embigin or basigin. For example, MCT3 and MCT4 are both expressed 
independently of ancillary proteins in retinal pigment cells [308]. Embigin and basigin are 
type I single pass membrane proteins containing a short intracellular C-terminal, a single TM 
α-helix, and a large extracellular glycosylated domain with 2 or 3 immunoglobulin folds 
depending on the splice variant [293, 299, 309]. Heavy N-glycosylation of embigin is 
illustrated by the difference between the predicted molecular weight of 36 kDa and the 
observed molecular weight of ~70 kDa [293]. Basigin is less heavily glycosylated [309]. 
Embigin and basigin are essential for correct trafficking to the plasma membrane, but not for 
stability as holotransporter are stable without ancillary association [266, 310]. In contrast to 
SLC3/SLC7 heterodimers, embigin and basigin control trafficking from both the Golgi body 
and ER [266, 310]. A combination of exogenous expression, co-localisation, co-
immunoprecipitation, FRET, and mouse basigin knockout experiments confirm physiological 
partner of MCT1, MCT3, and MCT4 is basigin, while MCT2 shows specificity for embigin 
[264-267]. However, cross-reactivity between heteromers was observed within species and 
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physiological pairing are also species specific, for example, rat MCT1 prefers embigin 
association to basigin [264, 310, 311]. Basigin partially rescues several age-related cataract-
associated mutations in MCT12 by enhancing their membrane expression in vitro [312]. The 
number of orphan human SLC16 transporters suggests the possibility they may also require 
an essential subunit for plasma membrane expression. 
 
 Replacement of the basigin’s immunoglobulin domains with those of the Ig surface receptor 
CD2 demonstrated the TM domain and intracellular N-terminus mediate trafficking of MCT1 
and 4 to the membrane [266].  Association of ancillary TM domains has been mapped to a 
putative binding site adjacent to TMs 3 and 6 of MCTs [294, 310]. Charge-swap mutagenesis 
in particular, implicated a conserved glutamate at position 218 in human basigin as mediating 
electrostatic or ionic-hydrogen bonding interactions with Arg86 in TM3 of MCT1 [294]. The 
role of other transporter domains in ancillary-specific association was shown by the removal 
of MCT2’s intracellular C-terminus, which ablated the transporter’s ability to be trafficked by 
basigin, making the transporter entirely embigin-dependent [264]. 
 
Although the choice of heteromer partner does not modulate the substrate kinetic properties 
of MCTs per se, they do seem to influence the sensitivity of MCTs to the inhibitor pCMBS 
[264]. For example, inhibition by pCMBS only occurs when MCT1 is co-expressed with 
basigin, but not with embigin. Similarly, the sensitivity of MCT2 to the inhibitor AR-
C155858 is greatly reduced when the transporter is co-expressed with embigin but not with 
basigin [264]. 
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1.4.4 The sterol transporter family SLC51 heteromer Ost α-Ost β 
The SLC51 family heterodimer Ost α-Ost β, is an unusual example of an essential secondary 
active transport heterodimer where both subunits were cloned and functionally identified 
simultaneously [313]. Using a cDNA library from little skate (Raja erinacea), and functional 
screening in oocytes, both Ost α (SLC51A) and Ost β subunits (SLC51B) were identified as 
essential components of a taurocholate transport system [313]. Human and mouse Ost α-Ost 
β was found to be a facilitative diffuser for taurine- and glycine-conjugated bile acids and 
other sterols, with taurocholate being the main physiologically relevant substrate [314]. Co-
localisation and expression levels of the two subunits is well correlated in the basolateral 
membrane of small intestine epithelial cells where they mediate the epithelial efflux of bile 
acids and sterols into circulation [315, 316]. An Ost α knockout mouse displayed strong 
disruption to small intestine bile acid and steroid reabsorption, decreased gall bladder bile 
acid pool, sterol serum levels, and other altered indicators of significantly disrupted sterol and 
cholesterol homeostasis [317, 318].  
 
Human Ost α is an N-glycosylated, 486 residue α-helical membrane protein containing 7 TM 
domains, and is thought to constitute the substrate translocation subunit of the Ost α-Ost β 
heterodimer [319]. Human Ost β is predicted to be a 128 residue 14.3 kD, single-pass type I 
integral membrane protein. Heterodimerisation of the two proteins is essential for delivery of 
both subunits to the plasma membrane and the functional uptake of sterol substrates [313, 
314, 320]. In addition, there is evidence suggesting the 2 subunits are interdependent for 
protein stability and that their complex exists as heteromultimers [320]. The N-glycosylation 
of Ost α is also dependent on the stable interaction with Ost β [315, 320, 321]. Truncation 
mutants of Ost β established the TM domain as vital for complex formation, although not 
sufficient for trafficking [322]. Mutation of a conserved tryptophan and asparagine residue 
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pair at the predicted extracellular-TM domain interface of Ost β also disrupts Ost α 
transporter activity but not plasma membrane expression [322]. While a di-arginine pair 
adjacent to the cytosol-TM domain interface prevents incorrect orientation of the protein into 
the membrane [322].  In summary, Ost α-Ost β is an example of a heteromeric transporter 
where the ancillary subunit is necessary for biogenesis, trafficking and catalytic activation of 
the translocating subunit. 
 
1.5 Heteromeric Partners of Broad Neutral Amino Acid Transporters 
1.5.1 Collectrin and Angiotensin Converting Enzyme 2 (ACE2) 
B
0
AT1 and B
0
AT3 are unique among SLC6 members in having heteromeric interactions with 
ancillary proteins collectrin and ACE2 that are necessary and sufficient for full plasma 
membrane expression [106, 132, 169, 175, 178]. Human collectrin has high sequence 
homology with mammalian orthologs (>80%) and to human ACE2 (47.8%) over the 
sequence coverage region [323] (Fig. 1.10A). It is speculated that ACE2 is a chimera, arising 
from a gene fusion of collectrin and its paralog Angiotensin Converting Enzyme I (ACE) 
[323-326]. A hypothesis supported by the proximity of collectrin and ACE2 within ~64 
kilobases of each other on the X chromosome [324].  
 
Collectrin and ACE2 are type I single TM domain-containing proteins (Fig. 1.10B). 
Collectrin is predicted to consist of a signal peptide (residues 1-14) an N-terminal 
extracellular domain (15-141) the TM domain (142-164) and intracellular C-terminus (165-
222). ACE2 is a 805 residue protein consisting of 2 structural domains:  the N-terminal 
extracellular peptidase domain, containing a classic zinc coordinating metallopeptidase motif 
HEXXH [327], and linker-TM domain. The ACE2 linker-TM domain from residues 592-805 
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is homologous to collectrin, while the catalytic domain is homologous to the catalytic domain 
of ACE [323, 328].  
 
Collectrin research has focused on distinct physiological roles: amino acid transport in kidney 
proximal tubules [175, 178], epithelial cell polarity and growth [323, 329-334], the 
development of hypertension [335-339], or insulin secretion [340-344]. Originally 
characterised as upregulated following partial kidney nephrectomy [323, 333, 334], 
subsequent mouse knock-outs of collectrin demonstrated the collectrin-dependence of B
0
AT1, 
B
0
AT3, and, to a lesser extent, IMINO (SLC6A20) in the proximal tubules [175, 178]. 
Collectrin has also been associated with indirect upregulation of other, unrelated, renal brush 
border transporters in salt-sensitive hypertensive mice [175, 338]. Early reports localised 
collectrin mRNA to the kidney [323] but lower expression levels of collectrin mRNA and 
protein has been found in pancreatic β-islet cells, β-islet clonal cells lines [342, 343], vascular 
endothelium [337] and rat retinal pigment epithelium [345]. Expression of collectrin is 
extensive throughout the proximal tubule S1, S2, and S3 sections [175, 178], while protein 
but not mRNA levels are much lower in pancreatic tissue [343]. A report of collectrin mRNA 
expression in the liver, heart, stomach and jejunum of the small intestine should be treated 
with caution as mRNA levels were normalised to ≤ 1/1000 of housekeeping transcripts and 
protein expression was not verified [175]. 
 
No structural information beyond membrane topology predictions is available for collectrin 
due to a lack of homologous proteins with known structures. Collectrin’s calculated  M.W. of 
just over 25 kDa is at odds with its commonly observed M.W. of ~40-48 kDa on western 
blots, [175, 178, 342, 343]. Part of this increased observed M.W. is explained by O- and N-
linked glycosylation, occurring in both β-islet cells and the proximal tubule [329, 342, 343]. 
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Figure 1.10 Structure and homology of collectrin and ACE2 
A) Sequence alignment of human collectrin (UniPROT ID Q9HBJ8) and ACE2 (Q9BYF1). 
Conserved residues in overlapping region are indicated (*) below the alignment. Residue 
numbers are indicated at the start of each row. The predicted TM domain is coloured green. 
The alignment was made using the AlignMe program [346]. The overlapping region of ACE2 
with collectrin begins at F592 and covers the C-terminal part of the protein, but it excludes 
the large N-terminal zinc metallopeptidase catalytic domain shown in B) as topology and 
secondary/tertiary structure in the case of ACE2. Collectrin is shown as a topology cartoon. 
ACE2 (left) is divided into 2 main domains: the catalytic domain with four subdomains I 
(cyan) II (yellow) III (green) IV (purple) and the linker-TM domain (592 to C-terminus). The 
linker-TM domain is the homologous region to collectrin (right), which consists of an N-
terminal extracellular part (1-141), TM-helix (142-164) and a cytosolic (165-222) domain. 
The ACE2 catalytic domain is the crystal structure of human ACE2 (PDB ID 1R42), with 
zinc (violet) indicating the approximate location of the catalytic site. A chloride ion (red) 
involved in hydrolysis of some substrates is also shown.  
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ACE2 was originally identified simultaneously from an EST database [347] and human heart 
failure 5’ cDNA library [348]. Initially, mRNA and protein expression was noted only in 
human heart, kidney and testis [347, 348], but subsequent protein expression was also 
observed in human lung [349-352], liver [353], small intestine [169, 351, 352], venous 
endothelium [352], arterial smooth muscle [352], and brain [354]. Like collectrin, ACE2 is 
preferentially localised to the brush border membrane, but is found in epithelial cells of both 
the proximal tubule and small intestine [355]. ACE2 has been the subject of intense research 
interest due to its multiple physiological roles in blood pressure regulation, heart disease, 
glycemic control, foetal growth, diabetic nephropathy, ischemia-reperfusion injury in 
lung/kidney, intestinal inflammation [356] and as the SARS-associated corona virus receptor 
(for reviews see [325, 357-369]). 
 
ACE2 hydrolyses C-terminal amino acids from peptides with proline in the penultimate 
position and a hydrophobic residue at the C-terminal (Pro-X) [370, 371]. The elucidation of 
the ACE2 structure [372] with comparative modelling and mutagenesis studies, revealed  
arginine 273 forms an electro-static bond with the C-terminal carboxylate oxygen of peptide 
substrates in the active site [370, 373, 374]. Peptide binding initiates a ‘hinge-bend’ 
movement of catalytic subdomains I and II to close the binding pocket [372] (see Fig. 10B). 
Divalent zinc is essential for substrate coordination at the active site and protein stability [371, 
372]. ACE2’s main biologically relevant catalysis is the hydrolysis of angiotensin II (1-8) to 
angiotensin 1-7 [347, 348, 371] with a 𝐾𝑚 of 2 μM [371]. Angiotensin II peptide binds to the 
G-protein-coupled angiotensin receptors to increase aldosterone production, which in turn 
increases blood pressure by retention of Na
+
 ions [375-378]. ACE2 also hydrolyses numerous 
other vaso-regulatory peptides [371, 379, 380] and also converts angiotensin I to angiotensin 
1-9, a peptide of unknown function [348]. As a result of its role in the degradation of 
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angiotensin II and biogenesis of numerous vasodilatory peptides (particularly angiotensin 1-
7), ACE2 has been the subject of research as a potential treatment for hypertension and 
prevention of heart failure through direct application of the protein or activation using 
chemical agonists [357-360]. 
 
ACE2 is highly expressed at the small intestine brush border and its unique carboxy-Pro-X 
specificity amongst brush border peptidases suggests it also plays a significant role in protein 
digestion. ACE2’s specificity for C-terminal neutral amino acid matches the specificity of the 
broad neutral amino acid transporters [39, 40, 370, 371, 374]. In the kidney, ACE2’s N-
terminal catalytic domain is cleaved by the metalloproteases ADAM-17 [381, 382] and type 
II serine protease TMPRSS2 [383]. However, the ADAM-17 hydrolysis site, which lies 
between Arg708-Ser709 in human ACE2, is likely to be determined by the 3 dimensional 
conformation of the recognition site rather than a simple linear motif [384, 385]. 
 
1.5.2 The interactions of B0AT1 and B0AT3 with collectrin and ACE2  
Initial indications that collectrin was involved in kidney nutrient uptake came from collectrin 
null mice
2
, whose extensive renal neutral aminoaciduria replicate the Hartnup disorder 
phenotype [175, 178]. Expression of B
0
AT1 and B
0
AT3 was significantly reduced in these 
mice and direct interaction between collectrin and B
0
AT1 in the kidney was confirmed by co-
immunoprecipitation using wild-type tissue [175]. Dependence of B
0
AT1 activity on ACE2 
co-expression was subsequently demonstrated, along with intestinal and kidney co-
localisation [169]. Direct interaction between ACE2 and B
0
AT1 was confirmed by co-
immunoprecipitation and reduction of isoleucine uptake in ACE2 null mice intestine ex vivo 
[176, 189]. Functional interaction between both collectrin and ACE2 with murine B
0
AT3 has 
                                                          
2
 As collectrin and ACE2 are located on the X chromosome, the male collectrin/ACE2 null mouse is a (−/𝑦) 
genotype while the female is a collectrin/ACE2 mouse (−/−). 
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also been established [106, 132]. Moreover, ACE2 modestly increased surface expression and 
proline uptake by the IMINO transporter (SLC6A20) in vitro, while a ACE2 knock-out 
mouse increased levels of faecal proline [189, 386]. However, IMINO surface expression in 
Xenopus laevis oocytes and activity are reasonably robust without ACE2 co-expression 
([386], unpublished observation).  
Knock-out mice for B
0
AT1, collectrin and ACE2 display some phenotype similarities. For 
example, all three knock-outs demonstrate significantly lowered serum insulin levels [50, 126, 
341, 387, 388]. However, different tissue expression and multiple physiological roles mean 
direct comparisons of collectrin and ACE2 knock-outs should be treated cautiously. 
Illustrating the difficulties with direct phenotype comparison, ACE2 seems to play a 
significant role in diabetic neuropathy, whereas collectrin knockout mice display no gross 
kidney defects beyond loss of brush border transporter expression (see Fig. 1C [175] and Fig. 
3 [178]). Furthermore, while B
0
AT1, collectrin and ACE2 all play a role in global response to 
blood insulin levels, collectrin and ACE2 roles in glycemic regulation are controversial and 
appear to be mediated by their expression in pancreatic β-islet cells [340-343, 387-390], 
where B
0
AT1 is minimally expressed [107]. 
 
The exact nature, stoichiometry, initiation, and composition of B
0
AT1 and B
0
AT3 
interactions with ACE2 and collectrin are unknown. Initial analysis showed the B
0
AT1-
collectrin interaction was not mediated by a Cys-Cys disulphide bond [175]. Mutations in 
B
0
AT1 associated with Hartnup disorder subsequently demonstrated an ancillary protein-
specific dependence of B
0
AT1 transport activity [169, 176]. For example, B
0
AT1R240Q and 
A69T are both ACE2 and collectrin dependent, while another two Hartnup mutations 
B
0
AT1D173N and B
0
AT1P265L show very slight discrimination between collectrin and 
ACE2 [169, 176]. B
0
AT1R240Q also had little effect on the small residual activity of B
0
AT1 
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observed when the transporter is expressed without collectrin or ACE2 in Xenopus oocytes, 
indicating this residue is involved in specific interactions with the transporter rather than 
effecting its intrinsic activity [169]. These residues are all distally located on homology 
models of human B
0
AT1 from the putative substrate and ion binding sites (see Fig. 1.8). No 
additional research has been conducted to discover the role of these mutations in B
0
AT1 or 
B
0
AT3-ancillary protein complex formation or function, nor the location of a collectrin or 
ACE2 binding site(s).  
 
 
1.5.3 Syntaxins 
Syntaxin 1A is a 288 residue type II T-SNARE membrane protein regulating synaptic 
vesicular fusion via formation of coiled-coil bundles with other SNARE proteins [391, 392]. 
The full SNARE complex requires four SNARE domains, two located on incoming vesicle 
(V-SNARES) and two on the cytosolic face of a membrane (T-SNARES). The post-vesicular 
fusion SNARE complex forms a parallel four-helix coiled-coil bundle, which facilitates 
fusion of the two membranes together [393]. In the neuronal SNARE complex two helices 
are provided by the vesicular SNAP-25, and one each by the membrane-embedded 
synaptobrevin and syntaxin 1A [394, 395]. Syntaxin 1A has been shown to interact with 
SLC6 transporters NET, DAT, SERT, GAT1 and GLYT2 [396-404]. In particular, the 
relationship between the NSS γ-aminobutyric acid (GABA) transporter GAT1 and syntaxin-
1A has been well characterised [398]. Syntaxin 1A modulates GAT1-mediated GABA 
uptake, efflux, exchange, in addition to expression of GAT1 in a substrate-dependent manner 
via sub-cellular redistribution [405-410]. The net result of these molecular interactions is an 
approximately 75% reduction in the turn-over rate of GAT1, while surface expression is 
increased at the same time [398, 409].  
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Systematic domain deletion of syntaxin-1A demonstrated inhibition of GAT1 GABA 
transport is mediated via the membrane-adjacent coiled coil H3 and TM domains [409]. This 
inhibition required both domains to be present and therefore, appeared to be synergistic. 
Binding to GAT1 occurred through direct interaction with cytoplasmic N-terminal aspartate 
residues of GAT1 [409]. The syntaxin 1A-H3-TM domain inhibition of GABA transport is 
overcome by counter-interactions between GAT1’s N-terminal aspartates with a cluster of 
arginine residues in IL4 [405]. Subsequently, the cytosolic N-terminus of both the 
norepinephrine transporter (NET, SLC6A2) and the dopamine transporter (DAT, SLC6A3) 
have been shown to directly interact with syntaxin 1A [400, 411, 412]. Various kinases have 
also been implicated in facilitating the syntaxin 1A-neurotransmitter transporter interactions 
[404, 411, 413, 414]. Direct serine phosphorylation of syntaxin 1A N-terminal by casein 
kinase 2 initiates the DAT-syntaxin 1A interaction and consequent dopamine efflux [415], a 
reaction further dependent on membrane lipid composition [416]. In contrast to syntaxin 1A-
GAT1 interactions, both NET and DAT immunoprecipitation with syntaxin 1A did not 
require syntaxin’s C-terminal TM domain [400, 411].  
 
Syntaxin 1A paralogs syntaxin 3 and 4 are involved in vesicular fusion and membrane protein 
regulation in epithelial cells [328, 329], localising in a manner which suggests a potential role 
in brush border and basolateral membrane polarity [330-333]. Collectrin has been 
immunoprecipitated with the SNARE protein-associated protein snapin in pancreatic β-islet 
cells [342, 343]. These results suggest the possible involvement of syntaxin proteins, B
0
-like 
transporters and their ancillaries in larger brush border protein complexes. However, no direct 
cross-reactivity between collectrin or syntaxin proteins has yet been reported, either with 
each other or with different transporters.  
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1.5.4 Other potential heteromeric partners 
Several other proteins present as potential interaction partners with B
0
AT1 and/or B
0
AT3, 
based previous biochemical and proteomics research from renal and intestinal brush border 
tissue. Aminopeptidase N (APN) is, like ACE2, one of the 11 mammalian membrane–
anchored intestinal peptidases [28-30], and is abundantly expressed in both the small intestine 
and renal brush borders [417]. The tissue distribution of APN and B
0
AT1 overlap in the small 
intestine and S1/S2 segments of the proximal tubules. 
 
APN is a zinc metalloprotease which homodimerises in vivo and hydrolyses N-terminal 
amino acids at the brush-border membrane except when a proline lies adjacent to the N-
terminal amino acid [31, 418, 419]. APN belongs to the gluzincin metalloprotease family 
with two consensus zinc-binding sequences, HEXXH and BXLXE (zinc-binding residues in 
bold, B = bulky side-chain, X = any residue) [420]. A third consensus site GXMEN is an 
exopeptidase substrate-binding sequence also common to all aminopeptidases [327]. Human 
APN is a type II signal-anchored TM protein with a 2 domain topology [419], reminiscent of 
ACE2 (section 1.5.1). However, the membrane orientations of APN and ACE2 are reversed 
and they are not homologous. The first 3 subdomains form the short cytosolic N-terminal, a 
TM α-helix, and an extracellular anchoring domain, which links to the extracellular peptidase 
domain (4 subdomains) [419-421]. APN has a broad specificity for neutral amino acids in the 
order Ala > Phe > Tyr > Leu, overlapping with the substrate preference of B
0
AT1 (Leu > 
Gln > Ala > Phe) [39, 40, 418].  
 
The removal of APN from bovine brush border membrane vesicles (BBMV) by papain 
treatment, was shown to reduce Na+ dependent alanine transport in the same vesicles, 
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suggesting a direct link between APN and the functioning of a neutral amino acid transport 
system [422]. The kinetic characterisation of these vesicles suggested both the Vmax and Km 
were affected by APN removal.  
 
 
1.6 Project Aims 
The interactions of broad neutral amino acid transporters B
0
AT1 and B
0
AT3 with single TM 
domain-containing ancillary proteins are still largely unexplored. The main questions for my 
thesis were: 
1. Are there other ancillary partners of B0AT1 and/or B0AT3 that modulate either 
transporter expression or function?  What is the composition of any protein complexes 
and how do they mediate functional modulation? 
2. What are the molecular determinants of B0AT1 and/or B0AT3 interaction with 
collectrin and ACE2? And where is the interaction site(s) on the transporters? 
3. How does collectrin interact with B0AT1 and B0AT3 in protein complex formation 
and function? 
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Chapter 2: Methods   
This methods chapter is the original work of S.J. Fairweather. 
 
2.1 Xenopus laevis Oocytes 
2.1.1 Xenopus laevis oocytes – overview  
Pioneered by Gurdon et. al. [423-425] Xenopus laevis oocytes have been used extensively for 
the characterisation of heterologous membrane proteins. They afford several advantages for 
the physiological characterisation of membrane transporters. The most important for 
functional elucidation are an oocyte’s large size, allowing for easy physical manipulation, and 
robust translation of heterologous mRNA into correctly folded and functional protein [426]. 
Moreover, as an unfertilised gamete cell  Xenopus oocytes contain relatively few endogenous 
membrane flux systems, resulting in low background signal relative to over-expressed 
heterologs in most cases [427, 428]. These features result in large signal amplitudes and good 
signal to noise ratios. An overview of the preparation, morphology and various utilisations of 
Xenopus laevis oocytes is given in Figure 2.1. 
 
2.1.2 Basic electrical and biochemical parameters of Xenopus laevis membranes 
Xenopus laevis oocytes have been well-characterised as efficient and viable expression 
systems for membrane proteins in general [429-433] including secondary amino acid 
transporters [426, 428, 434]. Stage V or VI oocytes [435] express heterologous membrane 
proteins with the greatest efficiency [426, 429]. Theoretically, the micro-injection of a 
saturating amount of in vitro synthesised GTP-capped RNA (cRNA) can lead to the 
translation and expression of  1010 − 1011 individual membrane transporters [434, 436]. This 
equates to a saturable expression rate ~300,000 transporters/second. Expected surface area 
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of a stage V-VI oocytes with a diameter of 1 to 1.3 mm is to 12.6 to 21.2 mm
2(3)
, and this has 
been verified with reported surface areas up to 10
6
-10
7 
µm
2 
[437]. This helps to explain why 
large numbers of transporters can be expressed in oocytes, in turn allowing for measurements 
of transporters with very low turnover rates [426, 438]. 
 
A healthy mature oocyte has a characteristic bi-hemispheric appearance; the animal 
hemisphere being various shades of brown and the vegetal hemisphere a creamy white (Fig. 
2.1). The poles should be uniform in colour with a pronounced demarcation between them 
and no blemishes or marks that break the uniformity of the colouring. Microbe-infected or 
otherwise apoptotic oocytes have an opaque interior, easily observed through the animal 
hemisphere. Oocytes over-expressing the membrane transport of interest, display regions of 
over-expression that appear ‘burnt’ or clear, making the oocyte highly porous and unsuitable 
for experimentation. 
 
Membrane electrical parameters of membrane resistance (Rm), potential (Vm), and current 
(Im), are important indicators of both oocyte viability (health) and reliability in 
electrophysiological experiments [427] (Table 2.1). Membrane resistance is high relative to 
many other living cells [439] but has also been quoted as varying widely from 100 kΩ to 2 
MΩ [427]. Resistance and capacitance are the main factors affecting the rate of change of 
membrane potential according to the 1st order exponential equation: 
 
𝑉𝑚 = 𝑉0𝑒
(− 
𝑡
𝐶𝑚𝑅𝑚 
)
                                         (eq. 2.1) 
 
                                                          
3
 Approximated based on the surface area of a perfect sphere, 𝑆𝐴𝑠𝑝ℎ𝑒𝑟𝑒 = 4𝜋𝑟
2  
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Where 𝑡 is time, 𝑉0 is 𝑉𝑚 at 𝑡 = 0, and 𝐶𝑚 and 𝑅𝑚 are membrane capacitance and resistance, 
respectively. As membrane capacitance (Cm) is usually constant at 1 𝜇𝐹/𝑐𝑚2 across most 
biological membranes [439], changes of resistance can be recorded with high fidelity. 
Endogenous fluctuations in membrane resistance will distort any experiment involving 
membrane potential changes e.g. voltage-step experiments. Using oocytes with relatively 
consistent Rm values is therefore advisable. Reporting of membrane potential gives widely 
variant values ranging from −27 mV to −90 mV in oocyte Ringer solution [426, 434, 440-
444]. The author has typically observed Vm ranging from −20 mV to −60 mV, and healthy 
oocytes (i.e. based on appearance and Im) displaying a Vm between −25 mV and −45 mV in 
oocyte ringer buffer ( OR2+ , pH 7.8) (Appendix B). The membrane potential is highly 
dependent on preparation techniques, extracellular potassium concentration, oocyte 
dimensions, heterologous protein expression levels, and the correct microelectrode handling – 
factors which help explain the variety of observed Vm values. Membrane potential also varies 
following cRNA injection, with more negative resting potentials measured up to days 3 and 4 
post-cRNA injection before oocytes start to depolarise. 
 
Following the recovery from impaling, the resting steady-state ionic current (Im) of a healthy 
oocyte should lie between +10 nA and −20 nA when clamped at −50 mV, an Im exceeding 
−70 nA indicates a poor oocyte or an ion leak generated by heterologous expression. 
 
2.1.3 Limitations of Xenopus laevis oocytes as an experimental system 
The electrical properties of the oocyte membrane are established by the permeability of the 
membrane to electrogenic ions K
+
, Cl
-
, Na
+
 (section 1.1.3). Oocytes are most permeable to 
potassium, as a consequence Vm, as calculated by the GHK, approaches reversal potential for 
this ion. There is also a significant contribution to the membrane potential by the Xenopus  
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Figure 2.1 Preparation and utilisation of Xenopus laevis oocytes for the functional 
characterisation of membrane transporters 
Moving clockwise from top left: Oocytes are removed from the ovary of adult female 
Xenopus laevis frogs and digested with a collagenase solution until defolliculated (section 
2.1.4). Only developmental stages V and VI oocytes will express membrane proteins in large 
quantities from in vitro synthesised cRNA (section 2.1.5). Oocytes are selected with care and 
can be utilised for many different downstream applications, such as: radiolabelled uptake 
physiology (section 2.6.1) to study transporter function, electrophysiology to study the 
transport and electrical properties (section 2.6.2), and protein biochemistry applications to 
study protein folding and trafficking (sections 2.1.6 and 2.1.7).  
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Table 2.1 Physical properties of Xenopus laevis oocytes (modified from [434]) 
 
Property Value Reference 
Membrane potential (𝑉𝑚) −27 mV to −90 mV [440-444] 
Membrane resistance (𝑅𝑚) 100 kΩ−2 MΩ [427, 445] 
Resting (unclamped) membrane 
current (𝐼𝑚)
 
0 nA to −40 nA* [427] 
Membrane Capacitance  (𝐶𝑚) 1 𝜇𝐹/𝑐𝑚
2 [439] 
Diameter 1-1.3 mm [446] 
Total volume ~1 μl [446, 447] 
Water accessible volume 368 ± 21 nl [444] 
Surface area 18−30 mm2 [444] 
Internal pH 7.4 ± 0.1 [448] 
[Na
+
] 4−20 mM [441, 444] 
[K
+
] 76−120 mM [444] 
[Cl−] 24−60 mM [441, 444] 
[Ca
2+
] < 0.3 μM [444] 
Buffering capacity (pH = 7.0) 20 mM/pH unit [448] 
* In the presence of Ca
2+
, the absence of which induces a large chloride-mediate inward  
   current and depolarisation of the oocyte.
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Na
+
/K
+
-ATPase [449], with minor contributions from sodium and chloride leak channels 
[444, 450]. The variety of endogenous ion channels, passive and active transporters in 
oocytes has been extensively reviewed [427, 444, 450, 451]. Several endogenous ion 
channels and transport systems can potentially interfere with the recording of B
0
AT1 and 
B
0
AT3-mediated inward sodium currents and amino acid fluxes [427, 428, 450]. Endogenous 
transporters include sodium-dependent symporters for alanine [452-454], glutamine [455], 
glutamate [456, 457], arginine [458, 459] and leucine [455]. None of these endogenous 
amino acid transporters generated more than 1-2 nA currents even at saturating 
concentrations of substrate. Voltage-gated channels included: a delayed rectifier K
+ 
conductance activated at > 30 𝑚𝑉  [460, 461]; a Cl- conductance activated by 
hyperpolarisations at > −100 𝑚𝑉 [462, 463]; and an unspecified Na+ conductance producing 
currents of 10-30 nA in, approximately, every third oocyte [464]. While uniform endogenous 
signals were subtracted from experimental oocytes, non-uniform Na
+
 conductance can only 
be averaged out over replicate recordings. These currents are also small enough that when 
present they did not contribute greatly to the experimental samples measured for B
0
-like 
transporters co-expressed with heteromeric partners, which are typically greater than 100 nA. 
 
2.1.4 Surgery and preparation of oocytes 
Isolation and preparation of X. laevis oocytes for injection of cRNA and expression of 
plasma-membrane proteins has been described previously [465]. It is, however, worth re-
examining the process of preparation and the specifications which are vital for viable 
expression of heterologous membrane proteins.  
Female Xenopus laevis frogs were anesthetised by submersion for 30 min in 3-Aminobenzoic 
acid ethylester (1.5g/L) (Sigma-Aldrich, St Louis, MO, U.S.A.). Anesthetised frogs were 
placed on ice to slow blood flow; the skin surface not required for surgery was covered by 
70 
 
wet tissues to keep it moist. A small (~1 cm) incision using a sterile scalpel blade is made 
into the peritoneal cavity midway between the midline and lateral edge of the frog. The 
incision penetrates outer epidermis and inner (thicker) muscle layers to access the ovary. 
Pieces of ovary are transferred into OR2−  (pH 7.8) buffer in a fresh Petrie dish and examined 
and discarded if any signs of damage, abnormal growth, infection, or disease are found. Once 
the required amount of ovarium has been removed, the muscle and epidermis layer were 
closed with suture stitches (one dissolvable for muscle, 2 non-dissolvable for epidermis) 
(B.Braun, Bell Vista, N.S.W., Australia). The wound was cleaned with ethanol and the frog 
placed in a holding tank for recovery from anaesthesia. Tap water is used at all times when 
handling live Xenopus laevis frogs. 
 
The Ovarium was cut into small clumps of ~15 to 30 oocytes and digested in 1.5 mg/ml 
collagenase D and 0.1 mg/ml collagenase A (Sigma-Aldrich) dissolved in OR2− (pH 7.8) 
buffer for 2−4hrs at 28 °C. The digestion is used to remove the four connective tissue layers 
surrounding the oocytes [447]. Following digestion, oocytes are washed and examined for the 
extent of defolliculation and individual separation. If oocytes are not fully digested they can 
be digested for further periods of time under the same conditions or, alternatively, digested at 
16−18 °C for 12 hrs until defolliculation is complete. Following complete digestion, oocytes 
were washed with 2 L of  OR2− (pH 7.8) buffer, followed by 2 L of  OR2+ (pH 7.8) until the 
solution is clear. Oocytes are stored o/n at 16-18 °C for recovery before injection. 
Defolliculated oocytes were maintained in OR
2+
 (pH 7.8, + 50 μg/ml gentamycin) buffer at 
16 − 18 °C. Maintenance of animals and preparation of oocytes was approved by the 
Australian National University animal ethics review board (ANU Protocol A2014/20). 
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2.1.5 In vitro transcription, microinjection and expression of proteins in Xenopus laevis 
oocytes 
Protein constructs cloned into pGem-He-Juel (section 2.4.1 and Appendix D) were linearized 
using  SalI or NotI (NEB, Ipswich, MA, U.S.A.) and in vitro transcribed using the T7 
mMessage mMachine Kit (Ambion, Austin, TX, U.S.A.). After purification using phenol-
chloroform extraction and precipitation, cRNA concentration was quantified using a 
Nanodrop spectrophotometer (Thermo Fisher Scientific, Scoresby, VIC, Australia) 
(OD260/OD280) and diluted to approx. 1mg/ml before use [169, 465]. Micro-electrodes for the 
injection of cRNA were pulled from boron silicate glass capillaries (World Precision 
Instruments, Sarasota, FLA, U.S.A.) using a P-97 Flaming/Brown micropipette puller (Sutter 
Instruments, Novato, CA, U.S.A.). Micro-injection of cRNA into oocytes was performed 
using a Micro4
TM
 micro-syringe pump controller and A203XVY nanoliter injector (World 
Precision Instruments, Sarasota, FLA, U.S.A.). The injection amount of all cRNAs was either 
optimised previously [39, 169], or optimised as described in the relevant figure legends 
throughout the thesis. Oocytes were used 3-6 days post-injection unless otherwise indicated. 
The incubating OR
2+
 (pH 7.8) buffer was changed daily and dead or damaged oocytes 
discarded. 
  
2.1.6 Surface biotinylation of proteins expressed in Xenopus laevis oocytes 
Surface biotinylation of Xenopus laevis oocytes was performed as described previously [426, 
465]. Briefly, following incubation at 18 °C for 3-6 days post-injection of cRNA, 15 oocytes 
were selected and washed thrice in ice-cold PBS buffer (pH 8.0). Oocytes were incubated for 
45 mins at room temperature in 0.5 mg/ml of EZ-Link™ Sulfo-NHS-LC-Biotin (Thermo 
Fisher Scientific) dissolved in PBS (pH 8.0), and then washed thrice in ice-cold PBS buffer. 
Subsequently, the plasma membranes were solubilised in oocyte lysis buffer (pH 7.6) for 2 
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hrs on ice with occasional, gentle inversion. Samples were centrifuged at 16,000 g, and the 
supernatant was mixed with 50 µl of streptavidin-coated agarose beads (Thermo Fisher 
Scientific). The mixture was incubated at 4 °C on slow rotation overnight. Beads were then 
washed 4 times with oocyte lysis buffer with a 10 min centrifugation at 16,000 g following 
each wash. The samples can be subjected to SDS-PAGE after addition of sample buffer and 
boiling for 5 min. 
 
2.1.7 Whole membrane isolation of Xenopus laevis oocytes 
Whole membrane preparation from Xenopus oocytes is a general membrane isolation 
technique which does not separate ER and plasma membranes, and thereby can be used to 
isolate the total folded protein synthesised in an oocyte [426]. Following incubation at 18 °C 
for 3-6 days post-injection of cRNA, 10-25 oocytes were homogenised by trituration in 
homogenisation buffer (pH 7.4). Homogenised oocytes were centrifuged at 2000 g for 10 min 
at 4 °C and the resulting supernatant carefully extracted to avoid the transfer of any floating 
lipids into ultracentrifugation tubes (Beckman Coulter, Brea, California, U.S.A.). Samples 
were centrifuged for 30 min at 140,000 g at 4°C using an Optima MAX-XP ultracentrifuge 
fitted with a XLA-100 rotor (Beckman Coulter). After centrifugation the supernatant with 
any remaining floating lipids was removed. The resulting pellet was washed with 
homogenisation buffer. Membrane pellets were dissolved at RT with homogenisation buffer 
plus 4 % (w/v) SDS until fully dissolved. The samples can be subjected to SDS-PAGE after 
addition of sample buffer and  heating to 60ᵒC for 5 min. 
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2.2 Murine Brush-Border Membrane Vesicles 
2.2.1 Brush-Border membrane vesicle isolation principles and properties 
Characterising the transport physiology of mammalian epithelial cells (section 1.2.4) was 
greatly facilitated by the development of techniques to isolate the brush border (see [17] for 
an overview). Whilst several methods for preferential isolation have been developed [466-
471], the most widespread remains the use of divalent cation precipitation (either Ca
2+
 or 
Mg
2+
) combined with density centrifugation [469, 472, 473]. The technique was based on an 
earlier observation that Ca
2+
 ions caused aggregation of liver microsomes [474]. 
Subsequently, the method was modified to prepare small intestinal brush-border vesicles [475] 
and renal brush-border vesicles [476].  
 
Divalent cation precipitation of epithelial BBMV works as a negative selection technique. 
Internal and basolateral membranes aggregate more easily in the presence of divalent cations 
because they are not densely covered by a glycocalyx like the brush-border plasma 
membrane [470, 472] [477, 478]. The greater aggregation of subcellular and basolateral 
membranes causes increased size of the membranes particles. The Svedberg equation can be 
rearranged to relate the mass of a particle to its sedimentation velocity: 
 
𝑠 =
𝑀𝐷(1 − ?̅?𝑝)
𝑅𝑇
 
          (eq. 2.2) 
 
Where 𝑠 is the sedimentation coefficient containing the velocity term, 𝑅 is the universal gas 
constant, 𝐷  the diffusion coefficient, T temperature, M is the molecular weight, D the 
diffusion coefficient and ?̅? the partial specific volume of the solute, and 𝑝 its density. This 
rearrangement shows as particle weight increases the sedimentation velocity will also 
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increase. During divalent cation precipitation, the intracellular and basolateral membranes 
aggregate into large complexes precipitating faster during centrifugation than brush border 
membranes.  Magnesium precipitation is preferred to calcium as Ca
2+ 
can activate epithelial 
phospholipases, leading to significant changes in the phospholipid composition of the 
resulting vesicles [479]. Extensive analysis was conducted on fractions isolated during the 
precipitation process to determine purity and enrichment by the presence/absence of specific 
membrane enzymes, lipid analysis, and freeze-fractured electron micrographs [475, 476, 479-
483]. Despite high yields and enrichment of brush border enzymes, analysis showed BBMVs 
are still heterogeneous thorough several purification rounds [466, 480, 484, 485].  
 
2.2.2 Preparation and characterisation of mouse intestinal BBMVs 
Because the initial requirement for BBMVs was primarily for physiological studies of plasma 
membrane transport processes and clinical relevance, earlier preparations tended to focus on 
isolation from humans and larger animals e.g. rabbit, pig, dog [475, 476, 479, 482, 486]. The 
move towards rodents as model animals for BBMV purification has been driven by the 
increasing use of mice as genetically modified research tools [472]. As a result the following 
procedure has been derived and modified from murine intestinal and renal BBMV protocols 
[472].  
 
Male or female C57BL/6J mice 12–24 weeks old were euthanized and the small intestine 
removed and placed in BBMV preparation buffer A + 1 mM glutamine (pH 7.1) and protease 
inhibitor (Roche). Small intestines were inverted, the mucosa scraped off and homogenised 
using an Omni mixer homogenizer (Omni, Hobart, Australia) under ice cold conditions. 
Homogenate samples were removed for later protein quantification. The homogenate was 
diluted with dH2O and MgCl2 to a final concentration of 12 mM, followed by incubation on 
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ice for 15 min and centrifugation for 15 min at 4 ºC at 5000 rpm. The supernatant was 
removed and centrifuged at 16000 rpm at 4 ºC for 30 minutes. The pellet was resuspended in 
20 ml of BBMV preparation buffer B (pH 7.1) containing 12 mM MgCl2 (final 
concentration?). The mixture was incubated on ice for another 15 minutes and centrifuged at 
5000 rpm at 4 ºC for 15 minutes. The supernatant was removed and re-centrifuged at 16000 
rpm at 4 ºC for 30 minutes. The pellet was resuspended in 500 μl of BBMV preparation 
buffer C (pH 7.4) with 30 syringe strokes and made up to 20 ml. Following a final 
centrifugation step at 20000 rpm for 30 minutes at 4 °C, the pellet containing purified apical 
membrane vesicles was resuspended in BBMV preparation buffer C (pH 7.4) and vesicles 
stored at -80 ºC for up to 6 months. BBMV from intestine are not transport competent, but 
were used for biochemical assays. All animal handling was approved by the Animal 
Experimental Ethics Committee and performed in accordance with the institutional guidelines 
at the Australian National University (Protocol A2013/39).  
 
To determine the enrichment of apical membrane proteins in BBMVs compared to 
homogenate, an alkaline phosphatase assay was conducted. Alkaline phosphatase is an 
abundant enzyme in the brush border membrane of the intestinal epithelium, which 
hydrolyses phosphate moieties from organophosphate compounds. The enrichment of brush-
border proteins from homogenate to vesicles was inferred from the increase in alkaline 
phosphatase activity measured at an absorption maximum of OD405. To perform the assay, 
1:10, 1:30, and 1:100 dilutions of both homogenate and vesicles were prepared. Samples (20 
μl) were added to 1 ml of alkaline phosphatase assay buffer in a polypropylene tube 
(PerkinElmer, Waltham, MA, U.S.A.) and pre-incubated for 2 to 5 minutes at 37 ºC. The 
activity of alkaline phosphatase was measured by mixing vesicle and homogenate samples 
with 100 μl of pyrophosphate (concentration?) to, and incubating the mixture for 1 minute at 
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37 ºC. The reaction was stopped by adding 1 ml of 1 M NaOH and the absorption measured 
at OD405 using a Cary Bio 50 spectrophotometer (GMI, U.S.A). The enrichment of BBMV 
proteins is calculated by normalising the rate of pyrophosphate hydrolysis at each dilution to 
the total protein amount calculated by Bradford assay and then dividing the normalised rate in 
vesicles by that obtained from mucosal homogenate.  
 
Preparations gave a total protein concentration of 4-15 mg/ml for intestinal BBMV with a 
typical enrichment of between 10 to 15-fold for brush-border-specific proteins over intestinal 
homogenates (sections 2.5.1 and 2.5.2). 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
2.3 Cell Cultures  
2.3.1 Human embryonic kidney 293 cell line culturing  
HEK 293 cells were cultured in RPMI1640 cell growth media (Sigma-Aldrich) containing 10% 
v/v FCS and 2 mM glutamine. Incubation occurred at 37 °C in a 95% air, 5% CO2 incubator. 
Cells were passaged at 75-80% confluency by treatment with 0.25% w/v trypsin/EDTA 
(Invitrogen) until the solution became opaque, indicating detachment of the cells from the 
flask surface. Trypsin activity was quenched by the addition of media containing FCS. To 
seed a fresh culture flask, cells were centrifuged at 1500 g for 5 min at RT, the media was 
aspirated and the cells re-suspended in RPMI1640 (10% v/v FCS, 2 mM glutamine)at the 
desired cell density. HEK 293 cells were used for the transient transfection and expression of 
Venus fly trap constructs (section 2.5.7). 
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2.3.2 Transport experiments with Chinese hamster ovary K1 cells expressing SLC6A19 
and collectrin  
CHO-SLC6A19-Collectrin clone #1 was provided by Sanofi-Aventis (Frankfurt am Main, 
Germany). Parental CHO cells were cultured and maintained in Ham’s F-12 GlutaMAX 
media (Life Technologies) supplemented with 10% FBS and 100µg/ml Zeocin (Life 
Technologies). CHO-SLC6A19-Collectrin stably transfected cells were cultured and 
maintained in Ham’s F-12 GlutaMAX supplemented with FBS (10 % v/v and the antibiotics 
hygromycin (0.33 µg/ml) (Life Technologies) and G418 (0.275 µg/ml) (Life Technologies). 
Cells were passaged over 7 day intervals with media replaced every 72 hrs. Experiments were 
conducted on cells with passage numbers from 3 – 10. For radiolabelled uptake assays, cells 
were seeded out in 35 mm culture dishes (Nunc, ThermoFisher Scientific, Waltham, MA, 
U.S.A.) and grown for ~48 hrs until > 80 % confluent.  Before uptake, cells were washed 
three times with Hank’s Buffered Salts Solution (HBSS, pH 7.4). Subsequently, uptake of 
radiolabelled compounds was measured at 37 °C for 6 min in HBSS (pH 7.4). When Na
+
-
independent uptake was measured, NaCl in HBSS was replaced by NMDG-Cl. To terminate 
transport, cells were washed three times with ice cold HBSS (pH 7.4). After aspiration, cells 
were lysed with 0.1 M HCl, scraped together and homogenised by trituration. Aliquots were 
used for scintillation counting and protein quantification.  
 
For transient expression of pcDNA3.1(+)-syntaxin constructs (Appendix D), CHO-SLC6A19-
Collectrin or CHO WT adherent cells were seeded into 35 mm dishes and grown until ~70 % 
confluent. Plasmid DNA (2.5 μg/dish) and lipofectamine LTX® reagent (Life Technologies) 
were diluted into Opti-MEM
®
 transfection media (Life Technologies) separately and then 
combined in a 1:1 ratio and incubated at RT for 5 mins. The diluted DNA-lipid complex was 
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then added to cells in 35 mm dishes. After incubation for ~48 hrs, cells were used for 
radiolabelled uptake assays. 
 
2.4 Molecular Genetics 
2.4.1 Molecular cloning  
All 5’ cloning and sub-cloning primers included a CCACC Kozak recognition site before the 
start codon; they also include restriction enzyme recognition sites as required by the vector. 
The first cDNA strand was synthesised using an Oligo dT primer (Sigma-Aldrich) and 
SuperScript
TM
 II or Superscript
TM
 III (Life Technologies) as RNA-dependent DNA 
polymerase. Gene-specific DNA was PCR amplified using mRNA-specific primers of 
interest through 35 cycles with either Taq polymerase (Qiagen, Hilden, Germany) (mRNA < 
800 b.p.) or Pfu polymerase (Agilent, Santa Clara, CA, U.S.A., or Promega, Madison, WI, 
U.S.A.). DNA was then purified (Wizard® SV, Promega or PCR purification kit, Macherey-
Nagel) and digested with the appropriate restriction enzymes (Promega or NEB). Digested 
DNA fragments were run on an agarose gel (1% w/v) and gel eluted (Wizard® SV, Promega). 
Target vectors and inserts were cut with compatible restriction enzyme sites and purified. The 
vectors were 5’-dephosphorylated using Antarctic phosphatase (NEB). Ligation was 
conducted on all insert-vector pairs using a 1:3 to 1:5 insert:vector ratio (Quick ligase, NEB). 
A list of all primer sequences and specifications used for molecular cloning can be found in 
Appendix C. All expression vector maps are shown in Appendix D. The gel-eluted DNA was 
precipitated with the help of yeast tRNA and dissolved in MilliQ H2O.  
 
Molecular cloning of murine transporters B
0
AT1 and B
0
AT3, ancillary proteins collectrin, 
and ACE2 has been previously reported [37, 169, 177]. . Mouse small intestinal total RNA 
was isolated as a PCR template to amplify mouse APN cDNA (RNeasy plus, Qiagen or 
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Nucleospin® RNA II, Macherey-Nagel, Düren, Germany). EcoRI endonuclease restriction 
sites were added to both the sense and anti-sense cloning primers to facilitate sub-cloning. 
Following amplification of APN, the PCR product was purified from an agarose gel (1% w/v) 
(Wizard® SV, Promega) and inserted into pZero Blunt (Life Technologies), using the same 
procedure as described below for all direct cloning. The insert was then excised using EcoRI 
and ligated into pGem-He-Juel (Appendix D, abbreviated pGHJ from here on) for in vitro 
transcription.  
 
Molecular cloning of murine syntaxin 1A or syntaxin 3 and 7 was conducted using total RNA 
isolated from mouse brain or mouse kidney as a template, respectively (RNeasy plus, Qiagen). 
For syntaxin 1A and 7, HindIII restriction endonuclease sites were incorporated in both the 5’ 
and 3’ cloning primers. For syntaxin 3, EcoRI restriction endonuclease sites were added to 
the 5’ and 3’ ends of the cloning primers.  Syntaxin 1A was first inserted by blunt-end 
ligation into the pCR
TM
-TOPO XL
®
 vector using Vaccinia virus topoisomerase I (Life 
Technologies) and the same procedure as described below for all direct cloning. The insert 
was then excised using HindIII or EcoRI and sub-cloned into pGHJ. 
 
Human ACE2 and mouse collectrin truncation primers were designed based on multiple 
pairwise alignments of ACE2 and collectrin. ACE2 ∆18-580 retains the collectrin homology 
consensus sequence, beginning just upstream of the consensus start site (ACE2-591). ACE2 
∆18-500 was designed to retain an in silico identified tyrosine-based ER sorting signal (ELM 
Accession ELME000120) annotated at ACE2-510-513, which may be important for 
trafficking to the plasma membrane. The predicted N-terminal signal peptide (ACE2 residues 
2-18, collectrin residues 2-14) was retained in all constructs. All collectrin truncation 
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boundaries were determined using information garnered from the collectrin sequence analysis 
and bioinformatics (section 2.7.4).  
 
For CHO cell experiments, syntaxin 1A and syntaxin 3 were sub-cloned from pGHJ vectors 
into pcDNA3.1+ mammalian expression vector using the same HindIII (syntaxin 1A) and 
EcoRI (syntaxin 3) endonuclease sites that were used for the original cloning. Sub-cloning 
was verified by restriction digests and sequencing. All pcDNA3.1+ syntaxin constructs were 
isolated using an endotoxin-free midi DNA preparation (NucleoBond
®
 Xtra EF Plus, 
Macherey-Nagel) before transfection into mammalian cell cultures.  
 
Ligated constructs were introduced into E.coli XL-1 cells by electroporation or by chemical 
transformation into E.coli DH5α or DH10β strains (NEB). After transformation bacteria were 
incubated in SOC media for 1.5 hrs at 37°C. Following recovery, serial dilutions of cells 
were spread onto LB-agar plates (Greiner Bio-One, Kremsmünster, Austria) containing either 
ampicillin (100 μg/ml) or kanamycin (50 μg/ml) (Sigma-Aldrich) depending on the antibiotic 
resistance gene used as a selection marker. The plasmid size of transformed over-night 
colonies was verified using rapid colony screening. To this end, individual colonies were 
streaked onto fresh antibiotic selection plates and picked following 12-18 hrs incubation. 
Bacteria were lysed using colony cracking buffer, resolved in resuspension buffer and the 
extract run on a 1% (w/v) agarose gel together with a supercoiled DNA marker (NEB or 
Takara, Shiga, Japan).  Correctly transformed colonies were propagated using the same 
selection antibiotics and concentrations in Luria-Bertani Broth (AMRESCO, Solon, OH, 
U.S.A.), followed by plasmid isolation using mini-, midi-, or maxi-preparations (Macherey-
Nagel, or Promega).  
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Monocarboxylate-transporter fusion constructs rMCT1-B
0
AT1 and rMCT1-B
0
AT3 were 
generated using overlap extension PCR on cDNA templates. The rMCT1 sense primer was 
designed to incorporate a XbaI cutting site before the start codon. The B
0
AT1 antisense 
primer comprised a XbaI site, while the B
0
AT3 antisense primer comprised an EcoRI site. 
The overlap primers contained 21bp from each cDNA in either sense or antisense orientation 
excluding stop and start codons. 
 
The final integrity and orientation of the cloned cDNA was verified by sequencing 
(Australian National University, Biomolecular Resource Facility). All genes, cRNA and 
proteins in this thesis are of homo sapiens or mus musculus origin unless indicated otherwise. 
 
2.4.2 Site-directed mutagenesis  
Single point mutations were introduced into B
0
AT1, B
0
AT3, APN and collectrin cDNA using 
the QuickChange® II or QuickChange® Lightning Site-Directed Mutagenesis Kits 
(Stratagene, La Jolla, CA, U.S.A.). Complementary primers containing the desired mutation 
flanked by 15-20 nucleotides corresponding to the cDNA sequences of target proteins were 
used to amplify the complete cDNA-containing pGHJ vector. Following 16 rounds (single 
b.p. change) or 18 rounds (multiple b.p. changes) of PCR amplification, reactions were 
treated with DpnI, which only recognises methylated DNA, thereby digesting the template 
DNA but not the amplified, mutated PCR product. Mutant plasmids were introduced via 
electrical transformation into E.coli XL-1 cells or chemical transformation of E.coli 5Hα or 
10Hβ strains (NEB). Transformed colonies were grown on LB-agar plates (Greiner) 
containing ampicillin (100 μg/ml) over night. Plasmid DNA was isolated from single 
colonies grown in LB-media (AMRESCO) overnight using mini-preparations (Macherey-
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Nagel, or Promega). All mutations were verified by DNA sequencing (Australian National 
University, Biomolecular Resource Facility). 
 
2.4.3 RNAi  knockdown and reverse transcription PCR 
Small interfering RNAs for CHO syntaxin 1A and 3 were selected from mouse MISSION 
predesigned siRNA (Sigma-Aldrich) binding to sequence regions that were 100 % identical 
to the corresponding Chinese hamster sequences. CHO-SLC6A19-Collectrin cells were 
transfected with the RNAi pairs when 30-50 % confluent using with 50 pmol of 
RNAi/condition (lipofectamine
®
 RNAiMAX, Life Technologies) and incubated at 37 °C for 
a further 48 hrs before experimental use. To verify silencing, total RNA was extracted from 
transfected cells (Macherey-Nagel, NucleoSpin
®
 RNA) and 1 µg was reverse transcribed into 
cDNA (Superscript
®
 II, Life Technologies). For semi-quantitative analysis, transcripts were 
amplified for 25 cycles. Following RT-PCR, samples were loaded onto a 1 % (w/v) agarose 
gel, and quantified using U.V. densitometry after running and staining (SYBR
®
 safe, Life 
Technologies). 
  
2.5 Protein Biochemistry 
2.5.1 Enzymatic assays 
Quantification and functional activity of APN (EC 3.4.11.14) were measured using 
colorimetric assays at 25 °C with either 6.5 mM L-alanine-4-nitroanilide or L-leucine-p-
nitroanilide as substrates in the assay buffer. The OD405 of the liberated 4-nitroaniline was 
quantified spectrophotometrically, with a ε405 = 9951 M−1cm−1 [487, 488]. Specific activity 
was converted to μmol min-1·μg-1 protein, and the quantity of APN as a % of total BBMV 
protein calculated using the relative activity of purified APN type IV-S from porcine kidney 
microsomes (Sigma-Aldrich).  
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2.5.2 Bradford assay 
The Bradford assay is a standard colorimetric total protein quantification assay based on the 
dye Serva Blue G (aka coomassie® brillant blue G-250), useful in the high ng to μg total 
protein range with a λmaxat 580 − 590 nm [489]. Although the dye interacts differently with 
different proteins, this noise will be averaged out over whole tissue samples as long as protein 
content is ≤ 1 μg/ml [490]. The modified protocol of Bollag et al. [490] was used. BSA 
standards dissolved in 30 μl milliQ H2O: 10, 25, 50, 75, 100, 200, 300, 400, 500 μg/ml, were 
made up to 300 μl samples/well in a 96-well format plate using 270 μl Bradford’s reagent 
(Sigma). Biological samples were used over a range of at least 3 dilutions in replicates of 3 
samples/dilution and also made up to 30 μl with milliQ H2O before Bradford’s reagent was 
added to make a final volume of 300 μl/replicate. Samples and BSA standards were 
incubated for 2 mins before absorbance at  λmax = 595 was measured on a Infinite® M1000 
PRO 96-well plate spectrophotometer (Tecan, Männedorf, Switzerland). Standard curves 
were used to program automatic calculation of total protein sample concentrations.   
 
2.5.3 SDS PAGE and western blotting 
Both in-house and pre-cast gel and buffer systems were utilised for the running of SDS-
PAGE denaturing protein gels throughout this thesis. Pre-cast gels used 4-12% w/v 
acylamide/bis-acrylamide Bis-Tris continuous gels with either MOPS or MES running 
buffers (NuPAGE, Life Technologies, Carlsbad, U.S.A or laboratory made). In house 10 % 
w/v acylamide/bis-acrylamide Tris-HCl gels with Tris-glycine running buffer were run on 
Mini-PROTEAN gel chambers (Bio-Rad, Gladesville, N.S.W., Australia). Samples were 
prepared for SDS–PAGE using 1 × Laemmli sample buffer containing DTT (Life 
Technologies) and some were heated according to the individual protocol. Gels were run at 
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150 V until the smallest protein ladder marker (SeeBlue2
®
 or Novex
®
 Sharp, Life 
Technologies) had migrated to the end of the gel, with a running time between 60 and 90 
mins. Where required, gels were stained to visualise total protein using a colloidal coomassie 
G-250 stain. SDS-PAGE transfer to nitrocellulose membranes was conducted using 
PROTEAN-3™ transfer chambers (Bio-Rad) for fully wet transfer in Tris-glycine buffer, or 
the semi-dry iBlot automated system (Life Technologies).  
 
After transfer, nitrocellulose and PVDF membranes were blocked overnight in 5% w/v skim 
milk powder/PBS-Tween 20 (pH 7.4) solution at room temperature. On the next day, blots 
were incubated in 2% w/v blocking solution for 2 hrs with primary antibodies at dilutions 
listed in Table 2.2. For detection, horseradish peroxidase- (HRP) conjugated sheep anti-
mouse (GE Healthcare), Goat anti-rabbit (Jackson ImmunoResearch, West grove, PA, 
U.S.A.), donkey anti-rabbit or anti-sheep IgG was used at the same dilution as the primary 
antibody, except for anti-rabbit IgG against mouse B
0
AT3 (1:1000). Blots were washed 3 × 5 
mins in PBS Tween 20 buffer between application of primary and secondary antibodies. 
Where indicated, western blots were quantified based on pixel density using ImageJ software 
v1.43u (National Institute of Health, Bethesda, ML, U.S.A.). For re-probing, nitrocellulose 
and PVDF membranes were stripped of antibodies and milk powder by incubation in a 
stripping buffer and heated at 65 °C for 30 mins. To remove β- mercaptoethanol, membranes 
were then washed thrice for 10 mins in sufficient volumes of PBS-Tween 20. 
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Table 2.2: Primary antibodies used for protein detection 
 
1° Antibody Epitope Concentration 
(mg/ml) 
Dilution Raised in Source 
anti-mouse B
0
AT1 6-32 Not 
determined 
1:3000 rabbit Pineda custom antibody 
anti-mouse B
0
AT3 593-614 Not 
determined 
1:200 rabbit Pineda custom antibody 
anti-human APN Not supplied 0.05 1:2000 rabbit Epitomics 
anti-mouse ACE2 788-805 1 1:4000 rabbit Abcam, Cambridge, U.K 
anti-mouse 
collectrin 
15-144 0.2  1:2000 sheep R & D Systems, Minneapolis, 
MN, U.S.A 
anti-mouse 
collectrin 
29-46 0.048 1:2000 mouse Enzo Life Science, Plymouth 
Meeting, PA, U.S.A. 
anti-human 
syntaxin-1A 
Val237
4
 Not 
determined 
1:1000 rabbit Cell Signalling Technology 
anti-human β-actin  1-100 0.6 1:2000 rabbit Abcam 
anti-human Na
+
/K
+
 
ATPase  
N-terminus Not 
determined 
1:25000 rabbit Abcam 
anti-human 
caveolin-1 
1-17 1 1:2000 rabbit Abcam 
 
  
                                                          
4
 Specified by manufacturer as residues around Val237 
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2.5.4 Blue-native PAGE 
Blue-native gel electrophoresis experiments were adapted from Schagger and Von Jagow 
[491]. Briefly, 40 µg of BBMV (1 µg/µl) were solubilised for 30 min in detergent buffer  
containing either digitonin or Triton X-100 at 0.5 or 1% w/v. Samples were centrifuged at 16, 
000 g and 4 °C for 5 min and the supernatant was transferred into a new Eppendorf tube. 
Non-solubilised pellets were retained to determine the efficiency of the solubilisation process 
by measuring the remaining protein concentration at λ = 280 nm and /or by western blotting. 
Blue-native loading dye was added to samples to give a final concentration of 0.5% w/v 
Coomassie BB G-250. Samples were run on a discontinuous buffered gel system, with a 4-16% 
gradient gel and 4% stacking gel. A PROTEAN-3™ gel electrophoresis system (Bio-Rad, 
Hercules, CA, U.S.A.) was used with specific cathode running buffer and anode running 
buffer to run native gels at 4 °C for 16 hrs at 100 V. The Coomassie-containing cathode 
buffer was changed to a buffer without Coomassie when the samples had run approximately 
1/3 the total length of the gel to avoid the transfer of excess dye, which inhibits antibody 
detection. Transfer onto methanol-activated PVDF membranes (GE Healthcare, 
Buckinghamshire, U.K.) was completed at ≤ 20 V with a current density of 1 mA/cm2 for 2 
hrs on a Hoefer SemiPhor™ semi-dry transfer system. Membranes were stained to visualise 
marker proteins and destained again for protein detection with a two stage destaining 
procedure using destaining solutions A and B. Thyroglobulin (669 kDa), ferritin type 1 from 
horse spleen (440 kDa), and bovine serum albumin (134 and 67 kDa) (all from Sigma-
Aldrich), were used as molecular weight markers. Proteins were detected using western 
blotting (section 2.5.3).   
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2.5.5 Preparation of detergent-resistant membranes 
Detergent-resistant membranes/lipid-rafts were prepared as outlined as previously reported 
[492-494]. 1 μl of BBMVs at a protein concentration of 1-2 mg/ml were treated for 30 min 
with 2 ml 1% (v/v) Triton X-100 buffer at 0 °C to 4 °C. The complete membrane extract was 
then diluted with an equivalent volume of 80% (w/v) sucrose dissolved in the same buffer to 
create a 40% (w/v) sucrose gradient bed. The mixture was overlaid with a 5-30% (w/v) linear 
sucrose gradient and then fractionated by equilibrium density centrifugation at 3 °C and 
212,000 g for 24 hrs in a Beckmann SW41Ti swing-out rotor (Beckmann-Coulter, Palo Alto, 
CA, U.S.A.). Sucrose gradient fractions were collected from the bottom of the centrifugation 
tube in 0.8 ml fractions. All fractions were stored at –80 °C and analysed by SDS-PAGE for 
the presence of specific proteins. 
   
2.5.6 Co-immunoprecipitation of membrane proteins 
For co-immunoprecipitations, 150-300 µg of BBMV were solubilised for 1 hr at 1 µg/µl in  
co-immunoprecipitation buffer containing Complete™ EDTA-free protease inhibitor cocktail 
(Roche Diagnostics, Indianapolis, IN, U.S.A.). The lysate was then cleared by centrifugation 
at 15,000 g and 4 ºC for 20 min and transferred into a new reaction tube. The cleared lysate 
was incubated overnight at 4 °C on rotation with 2 µl of primary antibody against either 
B
0
AT1 (custom generated by Pineda Antibody Service, Berlin, Germany) or APN (Epitomics, 
Burlingame, CA, U.S.A.) and Protein-A-conjugated agarose beads (Pierce Biotechnology 
Inc., Rockford, IL, U.S.A.). Samples were subsequently washed five times with the co-
immunopreciptiation buffer at 4 °C followed by a 30-sec centrifugation at 3000 g each time. 
Samples (20 µl) were run on a 4–12% Bis-Tris pre-cast gel (Life Technologies) in MES or 
MOPS buffer, and transferred using the Invitrogen iBlot™ dry transfer system onto 
nitrocellulose membranes.  
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2.5.7 Tissue homogenate preparation 
Female C57BL/6J mice 12–24 weeks old were euthanized, organs surgically removed and 
homogenised in T-PER
TM
 tissue protein extraction reagent (ThermoFisher Scientific) using 
an Omni mixer homogenizer (Omni) at 4 °C. Total protein concentration was measured at 
multiple dilutions using the Bradford Assay (section 2.5.2). Samples were stored at −80 °C 
for up to 6 months.  
 
2.5.8 Co-localisation of membrane proteins using the Venus fly trap  
The original Venus fly trap vectors encode antiparallel leucine-zipper motifs (zip), with each 
zipper fused to one half of GFP (Venus[1] and [2]) from Aequorea victoria in pcDNA3.1 
Zeo(+) [495]. Two vectors Venus[1]-zip and zip-Venus[1] contain eGFP residues 1 to 157, 
another two, Venus[2]-zip and zip-Venus[2], contain eGFP residues 158 to 238 either in front 
of the leucine-zipper or behind it (Appendix D). When the leucine-zippers dimerise, the two 
halves of eGFP come together reconstituting its fluorescent properties. In the experiment the 
leucine zippers are replaced by the proteins to be investigated. 
 
Murine B
0
AT1 was sub-cloned into Venus[2]-zip/pcDNA3.1Zeo(+) and Venus[1]-zip/ 
pcDNA3.1Zeo(+) from pGHJ to generate Venus[2]-B
0
AT1/pcDNA3.1Zeo(+)  and Venus[1]-
B
0
AT1/pcDNA3.1Zeo(+) with eGFP 158-238 or eGFP 1-157, respectively, at the N-terminus 
of B
0
AT1. Murine B
0
AT1 was also sub-cloned into zip-Venus[2]/pcDNA3.1Zeo(+) to 
generate B
0
AT1-Venus[2]/ pcDNA3.1Zeo(+) with eGFP 158-238 at the C-terminus of 
B
0
AT1. Murine APN was sub-cloned into Venus[1]-zip/pcDNA3.1Zeo(+) from pGHJ to 
generate Venus[1]-APN/pcDNA3.1Zeo(+)  with eGFP 1-157 at the N-terminus of APN. Both 
B
0
AT1 and APN were co-expressed to allow for possible interaction between intracellular 
89 
 
termini, namely the C-terminus (B
0
AT1-Venus[2]) and N-terminus (Venus[2]-B
0
AT1) of 
B
0
AT1 and the N-terminus (Venus[1]-APN)  of APN. The assay was conducted by seeding 
75-80 % confluent HEK293 cells into 0.7 cm
2
 8-well covered Millicell EZ™ microscope 
slides (Millipore, Billerica, MA, U.S.A.). The cells were incubated for 24-48 hrs in 
RPMI1640 (10 % v/v FCS, 2 mM glutamine, 5 % CO2, 37 °C) until they had reached > 90 % 
confluency. Transfection of Venus fly trap constructs was then carried out using 
Lipofectamine™ 2000 reagent (Life Technologies) with 1.6 µg of total DNA per well. 
Transfected cells were incubated for 48 hrs before the media was aspirated. The cells were 
then mounted with ProLong anti-fade Gold™ (Life Technologies) and coverslips, cured for 
24 hrs, and then sealed with epoxy resin (Maybelline, New York, U.S.A.). The eGFP 
fluorescence was visualised at excitation λ of 485 nm from an argon laser, with emission 
recorded at 492-550 nm. All images were captured using the following settings: bright-field 
gain 250 HV; fluorescent light gain 600 HV; scan speed 400 Hz; and 1024 × 1024 × 1024 
pixel resolution. In images where cellular outlines were visualised, the bright-field gain was 
increased to between 280 HV and 330 HV. All digital images were taken under identical 
conditions using the LAS AF software visualised using the Leica SP5 confocal microscope 
system. HEK293 cells were visualised using the ×63 oil objective. 
 
2.6 Radiolabelled Tracer Experiments and Electrophysiology  
2.6.1 Radiolabelled uptake  
As the broad neutral amino acid transporters B
0
AT1 and B
0
AT3 are solute translocating and 
electrogenic (section 1.4.1), direct metabolite flux (uptake) and measurement of any 
associated electrical currents are complementary approaches for studying their physiology. 
Unless stated otherwise all neutral amino acids used are L-enantiomers.  
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Radiolabelled uptake experiments in oocytes were conducted as previously described [39, 
496]. For cRNA titration experiments cRNAs were injected in different ratios as indicated in 
the experiments or figure legends. In general, for all experiments, groups of eight to fifteen 
cRNA-injected oocytes were washed thrice with 4 ml of ND96 (pH 7.4, unless indicated 
otherwise) buffer. Oocytes were then incubated at RT in 100 μl of the same buffer 
supplemented with 
14
C- or 
3
H-labelled amino acids and different amounts of unlabelled 
substrate in a 5 ml polypropylene tube. Transport was stopped at the indicated time by 
washing oocytes thrice with 4 ml of ice-cold ND96 (pH 7.4) buffer. Single oocytes were 
placed into scintillation vials, and lysed by addition of 200 μl of 10% (w/v) SDS. Assay 
buffer conditions, numbers of oocytes and time-course of incubation as well as other 
conditions varied from this basic protocol as indicated in individual experiments. After lysis, 
3 ml of scintillation fluid was added, and the radioactivity was determined by liquid 
scintillation counting on a Beckman-Coulter LS 6500 or PerkinElmer Tri-Carb 2810TR. All 
14
C- or 
3
H-labelled amino acids used are uniformly labelled unless otherwise indicated. 
 
2.6.2 Electrophysiology: the two-voltage clamp configuration 
In order to simulate the membrane potential across the brush border membrane of small 
intestine and kidney (Tables 1.1 and 1.2) Xenopus laevis oocytes are routinely clamped at 
−50 mV. Activation of a transporter by substrate addition will then generate an electrical 
current, which is neutralised by an opposite current generated by the amplifier to keep the 
voltage constant. The movement of positively charged Na
+
 ions into the cell would cause a 
depolarisation, or movement towards 0 mV, if the cell was not voltage-clamped. Under 
voltage-clamp conditions the membrane potential (Vm) is held constant but we can still refer 
to changes in the membrane potential that would occur in the absence of a voltage-clamp. 
Hence, any depolarising current is said to be an inward current, and the outward movement of 
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Cl− is also considered an inward current. Conversely, any current which hyperpolarises the 
membrane potential is considered an outward current. Non-neuronal cells, such as intestinal 
enterocytes, maintain a relatively stable Vm, which provides the driving force for powering 
the movement of Na
+
 ions into the cell (section 1.1.3). The chemical component of the driving 
force is provided by the ion concentration difference across the cell membrane (section 1.1.3).  
 
The main electrophysiological configuration used for recording in oocytes throughout this 
thesis is the two-electrode voltage-clamp configuration (Fig. 2.2). The same configuration 
was first developed and implemented for the recording of ion channel currents in oocytes 
[432, 497] and subsequently for secondary active transporter-associated currents [498, 499]. 
A detailed explanation of the configuration can be found with Figure 2.2 and has been 
described in detail previously [39, 104, 496, 500].  
 
Boron silicate microelectrodes capillaries (World Precision Instruments) with a tip resistance 
of: 1.5 ≥  𝑅𝑒 ≥  0.5 M Ω  were pulled by a P-97 Flaming/Brown micropipette (Sutter 
Instruments) puller and filled with 3 M KCl. Silver microelectrodes are coated using a 5 M 
NaCl single-chamber galvanic cell to form AgCl2 electrodes. The amplifier was placed in set-
up (current clamp) mode and the oocytes impaled under a light microscope with both the 
voltage sensing and current passing microelectrode. Before voltage clamping, the amplifier 
output current is set to zero to normalise currents recorded in voltage clamp mode. Following 
this, a test membrane potential pulse is administered and the current output adjusted using the 
amplifier gain and oscillation control (clamp stability) dials, until the response time is 
sufficiently rapid i.e. replicating the square wave-form. Oocytes were clamped at −50 mV 
unless indicated otherwise. All steady-state recordings were made with an Axon GeneClamp 
500B amplifier (Axon Instruments, Union City, CA, U.S.A.) connected to 1×LU and  
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Figure 2.2 Two-electrode voltage-clamp configuration for electrophysiological 
recording in oocytes 
The classic two-electrode voltage-clamp configuration for whole cell oocyte recording 
utilises 2 intracellular electrodes, mechanically impaled into the oocyte followed by a period 
for the recovery of membrane integrity as measured by the baseline current. The voltage 
recording electrode (E’) connects to a high impedance circuit (x 1) where its output is 
measured as Em and then compared with the command voltage from the Feedback Amplifier 
(FBA). Although traditionally commanded from the FBA, the FBA itself is more commonly 
commanded by computerised driver software, requiring digitisation of analogue electrical 
signals in a closed loop. The E’ output is digitised (A  D), and sent to the command driver 
software. The computer sends digital responses which are converted to analogue (D  A) to 
implement the command at the FBA. The difference between E’ and the command pulse Em 
is applied as a negative feedback through the current delivery electrode (I’) across the 
membrane (dashed line inside oocyte) to the bath grounding electrode (Im). The total 
membrane current (IM) has two components: ionic current (Ii) passing across the membrane, 
and capacitive current (IC), which is the charging current of the membrane when the 
command pulse changes with respect to time (dE/dt). Charging of the membrane to the 
command voltage is usually rapid in oocytes (< 100 msec) such that steady-state recordings 
of the ionic current can be isolated and measured.  
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10×MGU head stages. The current passing microelectrode and head stage should be able to 
pass up to 100 μA, and therefore, of low resistance.  Output signals greater than 1 μA were 
amplified at  × 1 gain, those lower than 1 μA were amplified at × 10 gain. All output signals 
were low-pass filtered at 1 kHz. The analogue signal was converted into digital by a Digidata 
1322A (Axon Instruments), and data were sampled at 3-10 Hz using Clampex v 8.0 software 
(Axon Instruments). For certain experiments the sampling rate was increased, e.g. in 
current/voltage step experiments where holding time at each membrane potential was 200 ms. 
All experiments were performed using 1 ×  ND96 (pH 7.4) oocyte assay buffer, unless 
indicated otherwise in the results.  
 
In all electrophysiology experiments where substrate was applied multiple times, data were 
normalised to a reference superfusion of substrate indicated in the text for both B
0
AT1 and 
B
0
AT3. This was done to compensate for any run-down effect of B
0
AT1 or B
0
AT3 mediated 
transport. 
 
2.6.3 Steady-state Michaelis-Menten kinetics  
Substrate dependence was measured by a step-wise exchange of substrate concentrations 
using a run-up and run-down series of concentrations for each oocyte. For example, if L-
leucine steady-state kinetics were analysed, every concentration of L-leucine would first be 
administered to steady-state (i.e. flat line in current measurements) starting with the highest 
to lowest concentration and then the order reversed and the sequence repeated.  Perfusion of 
oocytes was conducted with substrates dissolved in 1 × ND96 (pH 7.8), or variants thereof as 
indicted. Data for each concentration point was averaged over the run-up and run-down 
points.  
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2.6.4 Recordings of APN induced tetrapeptide currents and inhibitors 
The function of APN and its site-directed mutants was tested using the tetrapeptide NH2-Leu-
Ser-Lys-Leu-COOH (Sigma-Aldrich) or the tripeptide NH2-Leu-Leu-Leu-COOH (Bachem, 
Baubendorf, Switzerland). Peptides and all single amino acid substrates were titrated to pH 
7.4 before use. For experiments where the di-peptide analogue bestatin hydrochloride 
(Sigma-Aldrich) was used, oocytes were pre-incubated for 1 min in 70 μM bestatin (pH 7.4) 
to ensure steady-state conditions before a mixed solution of 100 μM L-[14C(U)]leucine and 
70 μM bestatin (pH 7.4) was added. This concentration represented  ~10 × the inhibition 
constant (Ki) for E. coli APN [501], and was used to ensure maximum competition for 
murine APN hydrolytic activity. 
 
2.6.5 Simultaneous current and radiolabelled uptake recordings  
For simultaneous measurements of L-[
14
C(U)]lactate uptake and L-alanine-induced currents, 
oocytes were superfused with ND96 (pH 7.4) buffer and clamped to −50 mV. The gravity 
flow of ND96 (pH 7.4) was then stopped and the bath outflow pump allowed to run further to 
evacuate the bath to a volume of approximately 100 µl. A 100 µl volume of 10 mM L-alanine 
and 0.5 mM L-[
14
C(U)]lactate was then added to the bath solution to give a final 
concentration of approximately 5 mM L-alanine and 0.25 mM L-[
14
C(U)]lactate. 
Subsequently, recordings were continued for 10 mins to allow for sufficient quantifiable flux 
of charge and radiolabelled L-lactate into the oocytes. Recordings were stopped and oocytes 
washed thrice with 200 µl ice-cold ND96 (pH 7.4), before being transferred individually into 
scintillation vials and prepared for radioactivity quantification.   
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2.7 In Silico Computation Methods 
2.7.1 Genomic and protein sequence databases and tools 
Protein sequence information was routinely sourced from either UniProtKB database 
(http://www.uniprot.org/) or NCBI database (https://www.ncbi.nlm.nih.gov/) except where 
indicated. Nucleic acid sequences were sourced through the NCBI database except where 
indicated. Accession numbers for individual proteins or nucleic acids are also given in the 
text where appropriate.  
 
2.7.2 Protein model construction and verification 
Topology models of membrane proteins were predicted by obtaining a consensus of TM 
domains as predicted by numerous algorithms. The main algorithms used include, but are not 
exhaustive of: TMHMM, TMpred, TopPred, SOUSI, CCTOP, OCTOPUS, Phobius, 
TMMOD and HMMTOP. The programs use various algorithms for the prediction of TM α-
helical domains, including Kyte-Doolittle hydrophobicity scores for individual amino acids 
[502], the inside positive rule [503, 504], more sophisticated domain-based [505], 
experimental [506], statistical [507], free-energy calculations [508], homology [509] or 
machine learning-based techniques (reviewed in [510-512]). In addition, several excellent 
reviews on the physico-chemical determinants and constraints of α-helical membrane 
topology also exist [513-517]. Consensus region(s) for TM domains were then used as input 
for visualisation of topology models using either the TOPO2 
(http://www.sacs.ucsf.edu/TOPO2/) or Protter (http://wlab.ethz.ch/protter/#).  
 
The murine APN homology model was generated using the HHpred comparison tool from 
the Bioinformatics Toolkit website of the Max-Planck Institute for Development Biology 
(http://toolkit.tuebingen.mpg.de/hhpred). After analysing the HHpred search results and 
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manual sequence alignments that contained the same proteins, the E. coli leucine 
aminopeptidase (LAP) enzyme (PDB ID 3B34) was selected as template to model murine 
APN. In silico verification of the murine APN model was conducted as previously outlined 
for homology structures [518]. Primary checking was conducted using WHATIF [519] and 
PROCHECK [520], which verify local factors such as dihedral angle distribution, backbone 
conformation, bond lengths and backbone packing. The backbone RMSD between E. coli 
leucine aminopeptidase (LAP) and murine APN was 0.68 Å. Analysis of the Ramachandran 
plot in Swiss PDB Viewer (http://spdbv.vital-it.ch/) showed > 95% of dihedral angles in the 
allowable regions. Caution in using predictions made by WHATIF and PROCHECK is 
advised as these indicators were originally developed for use with globular proteins, although 
they are now widely used for membrane protein structural predictions as well. 
 
B
0
AT1 and B
0
AT3 homology models in various conformations were generated using the 
Swiss model server (http://swissmodel.expasy.org/) with SLC6 homologue LeuT x-ray 
crystal structure templates: outward open (PDB ID 3TT1), outward occluded (2A65), and 
inward open (3TT3); the D. Melanogaster dopamine transporter DAT (4m48); and the 
inward occluded structure of the Bacillus halodurans tryptophan transporter MhsT (4US3). 
Validation of homology models was taken from the Swiss modeller output or conducted as 
explained for the APN homology model above. The annotated -helical TM domain of 
collectrin (V142 to I166) (TMHMM, v 2.0) was modelled as an ideal -helix using 
SwissPdbViewer [521]. To ensure that sufficient residues were included to extend beyond the 
span of the membrane, the selection was extended from M136 to R171. Helical wheels were 
created with HelixWheel v1.4 using the consensus N-terminal helix start as derived from TM 
domain predictions [522].  
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2.7.3 Hidden Markov analysis and multiple sequence alignment of collectrin  
A Hidden Markov Model (HMM) profile of human collectrin was used to find homologous 
proteins. The phmmer web server was used for the 1
st
 iteration, and the jackhammer 
algorithm, for all subsequent iterations. The HMMER v3.1 stand-alone program or online 
sever was employed [523, 524]. Search parameters were set to search the non-redundant 
protein databases (uniprotrefprot v.02-03-2016) using a probability value (e-value) for 
likelihood of random alignment at a threshold of 0.03. The BLOSUM62 substitution matrix 
was used to evaluate evolutionary distance based on amino acid changes. The initial phmmer 
search identified 134 significant sequences hits (167 in total). These significant hits (e < 0.03) 
were then used as input sequences for the 2
nd
 jackhammer algorithm search, and the 
significant hits from the 2
nd
 iteration used as input for the 3
rd
 and so on through 4 iterations in 
total. All four iterations resulted in identification of 2433 significant database entries (11020 
in total). Alignments were combined and filtered to create a HMM profile alignment of 
collectrin sequences. Sequences were filtered to remove any sequences with < 150 residues, 
which were assumed to represent partial or incomplete collectrin sequences. Non-collectrin 
sequences > 300 residues (i.e. ACE2) were also filtered out, as were sequences where 
alignment coverage of human collectrin was less than 20 % (i.e. mucin-1, integrin V, 
uncharacterised proteins). Finally, the combined HMM profile alignment was edited to 
remove non-relevant gaps (developed from sequence filtering) and to remove redundant 
sequences from the same species that were identical. All filtering and editing of the HMM 
profile alignments was conducted using the BioEdit v7.1.9 (or later) sequence alignment 
editor software (http://www.mbio.ncsu.edu/BioEdit/bioedit.html). Verification of full 
collectrin ortholog coverage and of descent from a single ancestor was conducted using the 
OrthDB and Pfam databases [525]. The large tabulated datasets or raw output from each 
HMM iteration were created and downloaded from the HMMER server and stored as .csv 
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files or in tabulated text format. All HMMER searches for which data is presented were 
conducted between 12-11-2015 and 10-01-2016.  
 
2.7.4 Putative motif and PTM analysis of collectrin 
The annotated human collectrin sequence (UniProtKB Q9HBJ8) was used as the input for 
sequence analysis and motif search algorithms. Many algorithms were accessed through the 
SIB ExPASy Bioinformatic Resource Portal (http://www.expasy.org/tools/#topology), 
Molecular Biology Online Analysis Tool Portal (http://molbiol-
tools.ca/Protein_secondary_structure.htm), Centre for Biological Sequence analysis (CBS) 
(http://www.cbs.dtu.dk/services/), or Softberry (http://www.softberry.com/). Significant 
motifs or PTMs were annotated only if algorithm scores past thresholds set by the software 
authors. All putative protein motifs were filtered based on biological probability of 
occurrence, either by species or if putative motifs have cellular location/orientation matching 
collectrin’s. Because of this filtering many putative kinase, phosphatase and other identified 
post-translational modification binding sites were discarded as they occurred in the non-
cytosolic/extra-cellular domain of collectrin. Likewise, any putative N-linked cytosolic 
carbohydrate post-translational modification sites were also dismissed.  
 
All tabulated putative motifs were cross-referenced to the HMM sequence alignment profile 
(section 2.7.3) and cross-species activation of B
0
AT1 to evaluate evolutionary conservation 
of sequence motif and function. This conservation was then used to design the collectrin 
truncation proteins and mutants for the mouse or human collectrin sequences. In general, 
truncations and mutants were designed to delete a single conserved putative motif or 
sequence feature. Truncations were created using PCR driven sequence deletion (section 
2.4.1).  
100 
 
 
2.7.5 Protein sequence alignments and phylogenetic trees  
All sequence alignments of membrane proteins were conducted using PROMALS3D [208]  
or AlignMe [346] for improved alignment of α-helical membrane proteins.  The MSA of 
APN was generated using COBALT 
(http://www.ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi?CMD=Web), as the TM domain was 
not included in this alignment. PROMALS3D was used to generate a structure-based 
alignment of human and mouse B
0
AT1 and B
0
AT3 transporters to LeuT from Aquifex 
aeolicus strain V5 (UniProt O67854) or D. Melanogaster dopamine transporter DAT 
(Q7K4Y6) [208] . The following settings were used for the B
0
AT1 and B
0
AT3 alignment: 
identity threshold = 1, secondary structure weight = 0.1, and amino acid weight = 0.5. Minor 
adjustments were made to the B
0
AT1 and B
0
AT3 alignments to reflect a lack of consensus or 
hydropathy overlap between them, based on a previously established multiple sequence 
alignment of LeuT to SLC6 neurotransmitter transporters [209]. Alignment of collectrin 
orthologs was conducted using proteins identified by human collectrin (Q9HBJ8) HMM 
profile search (section 2.7.3). The following settings were used: identity threshold = 0.6, 
secondary structure weight = 0.2, and amino acid weight = 0.8. 
 
Phylogenetic trees were built using MEGA7 [526].The evolutionary history was inferred by 
using the Maximum Likelihood method based on the Jones-Taylor-Thornton (JTT) matrix-
based model [527]. Initial trees for the heuristic search were obtained automatically by 
applying Neighbour-Join and BioNJ algorithms to a matrix of pairwise distances estimated 
using a JTT model, and then selecting the topology with superior log10 likelihood value.  
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2.8 Data Analysis and Statistics 
2.8.1 Data analysis, graphical representations, and nomenclature 
All raw data were analysed using the Origin data analysis and graphing software (versions 
7.0 to OriginPro 2015, OriginLab, Northampton, MA, U.S.A.). Electrophysiological data was 
recorded and manipulated using pCLAMP v8.0 (Axon Instruments). Steady-state currents are 
reported and presented in figures as absolute current magnitudes independent of current 
direction, while current tracings are presented in their correct inward or outward direction.  
 
All de novo graphical representation and artwork was designed using Microsoft Office 
Powerpoint 2010, Microsoft Paint, CorelDraw v7.0, and Adobe Photoshop CC 2. Graphics of 
organic chemical structures and other biochemical images were rendered by the author using 
ChemBioDraw Ultra (v 13.0.2.3021). Protein structural images were rendered in PyMol v9.9 
(DeLano Scientific, Palo Alto, CA, U.S.A.).  Nomenclature follows the IUBMB conventions 
for biochemical naming and IUPAC conventions for non-physiological organic compounds. 
 
2.8.2 Equations and curve fitting 
Use of equations is indicated in results chapters where appropriate. In general, steady-state 
kinetics analysis of transporters data was fitted to the Michaelis Menten function (eq. 1.10). 
When substrate-induced, sodium-generated transporter currents (I) replace the usual velocity 
term equation 1.10 becomes: 
                  
𝐼 =
(𝐼𝑚𝑎𝑥[𝑆]) 
(𝐾0.5 + [𝑆])
 
           (eq. 2.3) 
 Data was also fitted to the Hill equation: 
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𝐼 =
(𝐼𝑚𝑎𝑥 [𝑆]
𝑛) 
(𝐾0.5
𝑛  +   [𝑆]𝑛)
 
           (eq. 2.4) 
 
Where substrate-induced currents ( 𝐼 ) (i.e. velocity) is modified to incorporate the 
stoichiometry (𝑛) of substrate molecules per transport cycle and 𝐾0.5 = apparent 𝐾𝑚.  
Steady-state kinetic data also underwent linear regressions, using the Eadie-Hofstee 
transformation: 
                    
𝐼 =  −𝐾0.5  
𝐼
[𝑆]
+  𝐼𝑚𝑎𝑥 
            (eq.2.5) 
 
Mouse syntaxin cRNA titrations were fitted to the single competitive binding site equation: 
 
         𝑦 =  𝐴2 + 𝐴1 −  
𝐴2
1 + 10(𝑥−log 𝑥0)
    
(eq. 2.6) 
 
Where 𝐴1 and 𝐴2  are the maximum and minimum horizontal (ordinate) asymptotes, 
respectively. All curve fitting was conducted using the Origin data analysis software package 
(versions 7.0 to OriginPro 2016, OriginLab). 
 
2.3.8 Statistical analysis 
A Shapiro-Wilk normality test was used to ensure that experimental data sets in oocyte 
experiments were drawn from a normally (i.e. Gaussian) distributed population. Experimental 
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figures are mostly presented as mean ± S.D. from n individual replicates per experimental 
condition and are a representative example of at least 3 experimental repeats (𝑒) except where 
otherwise stated. Otherwise experimental figures are presented as mean ± S.E.M. represent 
the averaged means from multiple repeats (𝑒) indicated.  
 
Significance was evaluated using student’s t-test in the case when only 2 experimental 
conditions were tested. In cases where more than two experimental conditions were tested, 
either one-way (paired) or two-way (unpaired) ANOVA was used to test for overall 
significance. The Bonferroni post-hoc test was used for comparison of means from all 
conditions to each other, while Dunnett’s post-hoc test was used for comparison of means 
from all conditions with a single control condition mean.  P-values for confidence intervals 
are indicated using either * or with lettering a,b,c,d etc., as explained in figure legends.  
 
Pearson’s coefficient of correlation (Pearson’s r) was used to determine the strength of the 
correlation between independent experimental parameters. For all linear and non-linear 
regressions R
2
 values are quoted in figure legends as well as the p-value for determining if 
the slope is significantly different from a 0 gradient. All statistical analysis was conducted 
using the Origin data analysis and graphing software (versions 7.0 to OriginPro 2016, 
OriginLab). 
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Chapter 3: Intestinal Peptidases form Functional Protein Complexes 
with B0AT1 
This results chapter is based on the following publication: 
Fairweather, S.J., Brӧer A., O’Mara M.L., Brӧer S., Intestinal peptidases form functional 
complexes with neutral amino acid transporter B
0
AT1. Biochem J, 2012. 446, 135-148. 
 
The results section remains largely unmodified from the original publication. The 
introduction and discussion have been substantially modified to align them with the rest of 
this thesis. The methods section of the original paper have been removed, modified and added 
to the general methods section. All data from this chapter were generated during the author’s 
PhD thesis with the exception of Figure 3 and Figures 4A, B, C, and D. S.J. Fairweather 
wrote the manuscript of the original paper. The original manuscript was edited by S. Brӧer. 
 
3.1 Introduction 
The brush-border membrane of the small intestine epithelium functions as a highly 
specialised surface for the digestion and absorption of nutrients following the intake of food 
(section 1.1.2). Protein digestion has generally been viewed as being carried out by a number 
of individual enzymes and transporters functioning independently [17]. However, the 
discovery that ACE2 is required for the trafficking of B
0
AT1 in vitro and in vivo in the 
intestine has led us to re-evaluate this view [169, 176, 189] (section 1.5.2). This discovery 
raise the possibility that close associations between brush-border peptidases and neutral 
amino acid transporters may be a widespread phenomenon at the small intestine brush border 
membrane. Evidence for this was provided by an earlier observation that removal of another 
brush-border hydrolase, aminopeptidase N (APN) from bovine renal brush-border-membrane 
vesicles (BBMV) by papain treatment, significantly reduced Na
+
-dependent alanine transport 
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[422]. Moreover, an antibody raised against a partially purified Na
+
-dependent alanine 
transporter from these vesicles also recognised APN, suggesting a close proximity of both 
proteins. Further characterisation demonstrated that both the Vmax and apparent Km for the 
uptake of various neutral amino acids were affected by the removal of APN. However, the 
non-specific cysteine protease papain was employed to remove APN and other extracellular 
membrane protein domains from BBMVs. The identity of the neutral amino acid transporters 
in epithelial vesicles corresponding to system B
0
 was unknown at the time [59].  
 
Protein complexes containing APN have also been biochemically isolated in detergent 
resistant glycolipid rafts from porcine intestine brush border membranes [343]. These rafts 
also containing numerous brush border transporters and are thought to be stabilised by 
galectin-4 binding of N-linked glycans attached to different proteins [344-346]. Additional 
protein complexes containing APN and other brush-border peptide hydrolases have been 
analysed by blue-native electrophoresis but these did not seem to contain membrane 
transporters [528]. All brush-border peptidases are heavily glycosylated and B
0
AT1 also has 
several putative N-linked glycosylation sites. The physiological significance of any of these 
protein complexes at the brush-border is still unknown. 
 
3.2 Results 
3.2.1 Evidence for protein complexes in the intestinal brush-border membrane 
In agreement with earlier findings, B
0
AT1, ACE2 and APN were significantly enriched in 
BBMV compared to homogenised intestinal mucosa (Fig. 3.1A). The renal trafficking 
facilitator of B
0
AT1 collectrin, was not detected in BBMVs, but was detected in the intestinal 
mucosa homogenates, indicating expression outside the apical membrane. APN function was 
demonstrated using the peptidomimetic substrates L-leucine-p-nitroanilide or L-alanine-4-
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nitroanilide (Fig. 3.1B). APN was estimated to comprise about 2.7 ± 0.3 % of total protein in 
BBMV and 0.5 ± 0.1 % of total protein from the intestinal homogenate based on relative 
enzymatic activity using a purified kidney porcine APN as a standard (Sigma-Aldrich).  
 
Solubilisation of BBMV membrane proteins with two different detergents, followed by Blue-
native gel electrophoresis revealed the presence of large protein complexes, containing 
B
0
AT1, APN and/or ACE2 (Fig. 3.2A). An overview of the complexes and their protein 
content is presented in Table 3.1. Solubilisation with digitonin (0.5% or 1% w/v) resulted in 
two large complexes (1 and 2) containing B
0
AT1 and ACE2 at 611 kDa and 558 kDa, 
respectively. A slightly smaller complex (3) at 488 kDa appeared to contain all three proteins 
and a smaller complex containing ACE2 only was detected at 376 kDa (4). The presence of 
the protein monomer for APN and ACE2 was confirmed by solubilisation in the non-ionic 
detergent Triton X-100 (5, 7). The size of B
0
AT1 (121 kDa) solubilised by Triton X-100 (6) 
suggested the presence of a homodimer. The absence of β-actin in every sample confirmed 
that solubilisation isolated lipid-soluble complexes (data not shown). The size of complexes 
suggests that B
0
AT1, ACE2 and APN could interact with additional brush-border membrane 
proteins (section 3.3). 
 
Detection of membrane proteins in complexes of the same molecular weight provides 
evidence for protein-protein interaction, but the similarity of the molecular weight could be 
incidental. To provide further evidence of specific B
0
AT1 and APN complexes co-
immunoprecipitation was used. Following solubilisation of BBMV, pull-down of B
0
AT1 
revealed co-immunoprecipitation of APN and the pull-down of APN revealed the co-
immunoprecipitation of B
0
AT1 (Fig. 3.2B).  
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Figure 3.1 Isolation of intestinal brush-border membrane vesicles and APN activity 
Murine intestinal BBMV were prepared using MgCl2 precipitation and centrifugation (section 
2.2.2). A) Total BBMV or homogenate (homo) protein (20 µg) was separated by SDS-PAGE. 
Following semi-dry transfer onto a nitrocellulose membrane and blocking, individual proteins 
were detected and visualised using immunoblot analysis. B) APN activity in BBMV and 
intestinal homogenate was measured by a colorimetric assay using 6.5 mM L-alanine-4-
nitroanilide. Each data point represents the mean ± S.D. of 8 to 10 individual time-courses for 
each experimental condition.  
  
110 
 
 
 
 
 
 
 
  
111 
 
 
 
 
 
 
 
Figure 3.2 Detection of intestinal brush-border protein complexes 
Murine intestinal BBMV were prepared using MgCl2 precipitation and centrifugation (section 
2.2.2). A) BBMVs (50 µg/sample) at 1 mg/ml were solubilised with percentage v/v or w/v of 
detergent as indicated and mixed with Coomassie Brilliant Blue G-250 loading dye before 
separation. Samples were separated by native PAGE. Following semi-dry transfer onto a 
PVDF membrane, individual proteins were detected by immunoblot analysis. To allow a 
direct comparison of band positions the blot was stripped and  re-probed for the proteins 
indicated. Protein complexes and individual proteins are numbered 1 to 7 (Table 3.1). B) 
Murine BBMV were solubilised in co-immunoprecipitation buffer, followed by incubation 
with primary antibodies against either B
0
AT1 or APN and isolation using protein A. 
Following overnight incubation BBMV samples, cleared lysate, and intestinal homogenate 
were separated by SDS-PAGE. After semi-dry transfer onto nitrocellulose membranes, blots 
were pre-stripped and blocked o/n to reduce background signal. Individual proteins were 
detected as indicated above the blots.  
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Table 3.1: Molecular weight isolated from murine intestinal brush-border. 
Protein complexes were identified using 4-16% non-continuous blue native PAGE (Fig. 
3.2A). The protein standards, thyroglobulin (669 kDa), ferritin (440 kDa), and BSA (134 kDa 
and 69 kDa), were used to create a standard curve for calculating mean M.W. ± S.D. (n = 3). 
Complex Solubilisation Conditions Proteins Detected M.W. (kDa ± S.D.) 
1  digitonin 0.5%/1% w/v B
0
AT1, ACE2 611 ± 11 
2  digitonin 0.5%/1% w/v B
0
AT1, ACE2 558 ± 5 
3  all conditions B
0
AT1, ACE2, APN 488 ± 3 
4  digitonin 0.5%/1% w/v ACE2 376 ± 6 
5  Triton X100 0.5%/1% w/v APN 195 ± 3 
6  Triton X100 0.5%/1% w/v B
0
AT1 126 ± 4 
7  Triton X100 0.5%/1% w/v ACE2 91 ± 54 
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To examine if the isolated complexes were contiguous with detergent-resistant membrane 
micro-domains, BBMV were treated with Triton X-100 at 0 °C to 4 °C and the suspension 
separated by density equilibrium centrifugation on a linear sucrose gradient (section 2.5.2). 
All three proteins co-segregated to the Triton X-100 resistant fractions 7 and 8 (Fig. 3.3A). 
The majority of ACE2 and APN protein, however, remained in the detergent soluble protein 
fractions of the gradient bed (fractions 1-5, 40 % (w/v) sucrose), while a larger proportion of 
B
0
AT1 was retained in the floating lower density fractions. Interestingly, the peptidases, but 
not B
0
AT1, also appeared in the last two sucrose gradient fractions (14-15), corresponding to 
the lowest density area of the sucrose gradient. Caveolin-1, a lipid-raft marker from other 
tissues but not intestinal epithelial cells [493], was not detected in either the soluble or 
detergent-resistant fraction (Fig. 3.3B). Detergent resistant membranes are expected to appear 
in the lower density sucrose gradient fractions, corresponding to fractions 6 to 15, or 30% 
(w/v) to 5 % (w/v) of the linear sucrose gradient [494]. 
 
To further investigate the specificity of the APN/B
0
AT1 interaction we used a protein 
complementation assay in which both APN and B
0
AT1 were fused to halves of the enhanced 
GFP (eGFP) protein (Fig. 3.4A). Venus1 represents eGFP residues 1-157 and was fused to 
the intracellular N-terminus of APN (Venus1-APN), while Venus2 represents eGFP residues 
158-238 fused to either the intracellular N-terminus (Venus2-B
0
AT1) or C-terminus (B
0
AT1-
Venus2) of B
0
AT1. If protein–protein interactions bring the two halves of eGFP closely 
together, fluorescence can be observed [495]. Transfection of B
0
AT1-Venus2 or Venus2-
B
0
AT1 with Venus1-APN constructs in HEK293 cells, resulted in a significant green 
fluorescent signal above background, suggesting that both halves could recombine. When 
HEK 293 cells were co-transfected with Venus1-B
0
AT1 and Venus1-APN vectors, 
containing the same half of the eGFP protein (residues 1 to 157), no fluorescence was  
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Figure 3.3 Isolation of detergent-resistant membranes from BBMV  
A) BBMV (2 ml at 1 to 2 mg/ml) were treated with 1% (v/v) Triton X-100 at 0-4 °C and 
centrifuged with a 5-30% (w/v) linear sucrose gradient for 24 hrs. The gradient was 
fractionated and samples analysed by SDS-PAGE. Following semi-dry transfer onto a 
nitrocellulose membrane, individual proteins were visualised using immunoblot analysis as 
indicated next to each blot. Sucrose gradient fractions (1 ml) are numbered from highest (1) 
to lowest (15) density (e = 4). B) 30 µg of protein from the homogenates of listed organs or 
tissue samples were loaded onto gels and analysed using an anti-human caveolin antibody. 
Homo = intestinal homogenate, BBMV were isolated from mouse small intestine. 
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Figure 3.4 Co-localisation of B
0
AT1 and APN 
HEK293 cells (> 90% confluent) were transfected with plasmid DNA in 8-well microscope 
slide dishes. The eGFP fluorescence was visualised with a Leica SP5 confocal system and 
processed with LAS AF software, the white scale bars = 25 µm. All images were taken with 
the ×63 magnification manual lens, with the right hand panel of each experimental group 
digitally magnified. A) Cartoons (left) represent the various paired B
0
AT1 and APN Venus 
Fly Trap constructs transfected and visualised in the confocal micrographs (right), including 
the non-B
0
AT1 and APN fusion constructs Venus1-zip and zip-Venus2. The + or – above the 
panels indicates whether or not cells were co-transfected with a pcDNA3.1+ expression 
vector encoding collectrin. B) Single B
0
AT1 and APN Venus Fly Trap controls (overleaf), 
including non-Venus Fly Trap eGFP expression at lower (left) and higher (right) digital 
magnification. 
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observed. In the absence of collectrin, the kidney-specific B
0
AT1-trafficking subunit (left 
panel), the fluorescence induced by the Venus2-B
0
AT1/Venus1-APN and B
0
AT1-
Venus2/Venus1-APN vector pairs was observed largely inside the cells and not at the plasma 
membrane. In contrast, when the same vector pairs were co-transfected with collectrin (right 
panel), co-localisation of B
0
AT1/APN predominated at the plasma membrane. The 
transfection of individual eGFP halves showed only background fluorescence (Fig. 3.4B). 
 
3.2.2 Effects of APN on the transport kinetics of B0AT1 
Together, the results suggest a close association of B
0
AT1, ACE2 and APN in the brush-
border membrane. To investigate whether there are functional interactions between these 
proteins, we expressed them in X. laevis oocytes. As previously reported, expression of 
B
0
AT1 in X. laevis oocytes resulted in a significant increase in the uptake of neutral amino 
acids [37, 168], which was strongly stimulated further by co-expression of B
0
AT1 with the 
carboxypeptidase ACE2 [169, 176] (Fig. 3.5A) (p < 0.001). Co-expression of APN with 
B
0
AT1 resulted in a 4-fold increase in 100 μM L-[14C(U)]leucine uptake over oocytes 
expressing only B
0
AT1 (p < 0.05), which was not as high as that observed when B
0
AT1 was 
co-expressed with ACE2. Functional expression of APN in oocytes was demonstrated by 
superfusing X. laevis oocytes with the tetrapeptide NH2-Leu-Ser-Lys-Leu-COOH and 
recording the resulting B
0
AT1-mediated currents created by transport of the liberated N-
terminal L-leucine (Fig. 3.5B). 
 
The increase of B
0
AT1 activity following APN co-expression was confirmed through the 
measurement of L-amino-acid-induced Na
+ 
cotransport currents (Fig. 3.5C). Interestingly, the  
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Figure 3.5 Effect of APN on B
0
AT1 transport activity 
Oocytes were injected with 10 ng of B
0
AT1 cRNA, 15 ng of APN cRNA, or 10 ng of ACE2 
cRNA. A) Uptake of 100 µM L-[
14
C(U)]leucine was measured over 30 minutes on day 5 
post-injection. Oocyte-endogenous L-[
14
C(U)]leucine uptake has been subtracted from all 
conditions. Each bar represents the mean ± S.D. (n = 8-10, e = 3). Experimental groups that 
are statistically different at the p = 0.05 level are labelled by different letters. Groups with the 
same letter are not statistically different. Note, there is a break in the ordinate axis between 50 
and 150 pmol/30 min × oocyte. B) Oocytes were voltage-clamped at -50 mV and 
subsequently superfused with 10 mM L-leucine or Leu-Ser-Lys-Leu tetrapeptide. Substrate-
induced Na
+
 currents were recorded on day 5 post-injection for all oocytes except for those 
co-injected with B
0
AT1 and collectrin, which were recorded on day 3 or 4 post-injection. 
Each tracing is a typical example of currents observed in all oocytes injected with the 
indicated cRNA. C) Transporter currents were recorded as described in B) and superfused 
with 10 mM leucine for the time period indicated. D) Concurrent uptake and 
electrophysiological experiments were conducted under the same conditions as in A) and B), 
with uptake experiments using 100 µM L-[
14
C(U)]leucine and electrophysiology experiments 
using 10 mM unlabelled L-leucine. Uptake and currents were normalised to B
0
AT1 injected 
oocytes (= 1).  Each data point represents the mean ± S.D. (n = 6-10, e = 3, p <0.01 or p 
<0.001, for 10 mM and 100 µM L-leucine, respectively). Data for this figure was originally 
generated during  pre-PhD research.  
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increase in sodium current - measured at a substrate concentration of 10 mM - was only 
double that observed in oocytes expressing B
0
AT1 alone. By contrast, the increase in amino 
acid uptake at 100 µM L-leucine from flux experiments showed a ≥4-fold increase in L-
leucine transport in B
0
AT1/APN co-expressing oocytes (Fig. 3.5D). These results raised the 
possibility that APN may alter the substrate affinity of B
0
AT1 mediated neutral amino acid 
transport.  
 
A kinetic characterisation of B
0
AT1 and APN co-expressing oocytes revealed that APN 
significantly increased the apparent substrate affinity of B
0
AT1-mediated L-leucine transport 
(apparent Km = 0.52 ± 0.02 mM), while oocytes expressing B
0
AT1 alone gave an apparent 
Km value of 1.02 ± 0.06 mM, consistent with previous findings (Fig. 3.6A) [39, 40]. We 
could also confirm previous observations that co-expression of ACE2 does not affect the 
substrate affinity of B
0
AT1 [169] (apparent Km =1.09 ± 0.04 mM). These results were 
confirmed by analysing the transport kinetics of several of the main B
0
AT1 substrates (Table 
3.2). L-leucine, L-glutamine and L-phenylalanine showed a 2- to 3-fold increase in substrate 
affinity in oocytes co-expressing APN. 
 
The APN-mediated increase in B
0
AT1 substrate affinity did not, however, account for the 
total ~4-fold increase in L-leucine transport rate observed in flux experiments at sub-Km 
B
0
AT1 substrate concentration (Fig. 3.5D). This suggested the possibility that APN may also 
act as a moderate facilitator of B
0
AT1 trafficking to the plasma membrane, similar to the role 
of ACE2 with B
0
AT1 [169]. To investigate this possibility, we monitored the temporal 
interaction between B
0
AT1 and APN by measuring their co-expression in oocytes over 6 
days (Fig. 3.6B). A significant increase in B
0
AT1-mediated transport was observed from day 
3 post-injection onwards. This pattern differs to the steady increase in membrane expression  
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observed when B
0
AT1 and ACE2 are co-expressed [169], suggesting APN may not be a 
strong facilitator of B
0
AT1 trafficking. 
 
Quantification of trafficking using surface biotinylation indicated a 2.6 ± 0.9 fold increase of 
surface expression in B
0
AT1 and APN-co-expressing oocytes compared with oocytes 
expressing B
0
AT1, as exemplified in Figure 3.6C. In contrast, ACE2 co-expression resulted 
in a 32 ± 12 fold increase in B
0
AT1 expression, consistent with its role as a trafficking 
facilitator of the transporter. All ancillary proteins co-injected with B
0
AT1 were shown to be 
expressed at the plasma membrane (Fig. 3.6D). Together these results suggest that while 
APN increases the surface expression of B
0
AT1, this function may be subsidiary to its role in 
increasing B
0
AT1 substrate affinity, and that other auxiliary proteins, ACE2 and collectrin, 
play a more significant role in trafficking of the transporter.  
 
The two-fold increase in apparent substrate affinity and the ~2.5-fold increased surface 
expression of B
0
AT1 can account for the ~4-fold increase in neutral amino acid transport 
initially observed at an L-leucine concentration of 100 µM. This conclusion was confirmed 
quantitatively, by inserting the corresponding data into the Michaelis-Menten function (Table 
3.3).  
 
An increase in apparent substrate affinity can also manifest as altered substrate specificity, if 
that increase in substrate affinity is preferential for certain substrates and not others. Co-
expression of APN with B
0
AT1 significantly increased amino-acid-induced currents for L-
glutamine, L-asparagine, L-serine and L-phenylalanine, which, apart from L-glutamine, are 
normally lower-affinity substrates of the transporter (p <0.05) (Fig. 3.6E). All measurements 
were conducted at Vmax-inducing substrate concentrations, indicating that APN either  
124 
 
 
  
  
125 
 
Figure 3.6 Effect on B
0
AT1 transport kinetics by APN and ACE2.  
Oocytes were injected with combinations of the following amounts of cRNA:  B
0
AT1 10 ng, 
APN 15 ng, ACE2 10 ng, collectrin 2 ng. L-leucine-induced Na
+
 currents were recorded on 
day 5 post-injection except when using oocytes co-injected with B
0
AT1 and ACE2, which 
were recorded on day 3 or 4 post-injection. A) Oocytes were voltage-clamped at -50 mV and 
subsequently superfused with serial concentrations of L-leucine (0.1-10 mM) in descending 
and then ascending order. B
0
AT1-expressing oocytes were not superfused with 0.1 mM L-
leucine due to low S/N ratio elicited at this concentration. An Eadie-Hofstee transformation 
of the data points is shown: for all regressions R
2
 > 0.94 and p < 0.001 for the slope of the 
B
0
AT1/APN regression being different to B
0
AT1 injected oocytes. Each data point represents 
the mean ± S.D. (n = 6-8, e = 3). B) Uptake of 100 µM L-[
14
C(U)]leucine was measured over 
15 minutes on days 1-6 post-injection. Oocyte-endogenous L-[
14
C(U)]leucine uptake was 
subtracted,  p < 0.05 for all groups on days 3-6 post-injection of cRNA. Each data point 
represents the mean ± S.D. (n = 8-12, e = 3). C) Fifteen oocytes per sample were incubated 
with 0.5 mg/ml Sulfo-NHS-LC-Biotin on day 5 post-injection before being lysed and treated 
with streptavadin-coated agarose beads. Samples were separated by SDS-PAGE, blotted, 
analysed and visualised for the presence of B
0
AT1 using immunoblot analysis. D) Fifteen 
oocytes per sample were prepared as in C). Following SDS-PAGE, proteins were probed for 
the presence of APN. Membranes were prepared for detection of subsequent proteins by 
stripping, re-blocking and re-probing with antibodies detecting the indicated protein. E) 
Oocytes were voltage-clamped at -50 mV and subsequently superfused with 20 mM of the 
indicated L-amino acid. All substrate-induced currents were normalised to a 20 mM L-
leucine current (ILeu) to account for transporter de-sensitisation. Each bar represents the mean 
± S.D (n = 6-8, e = 3, * indicates p < 0.05). Data for panels A to D were originally generated 
during pre-PhD research.  
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Table 3.2: Kinetic properties of B
0
AT1/APN co-expressing oocytes 
X. laevis oocytes where injected with the transporter and auxiliary protein indicated. The 
sodium-induced currents were recorded as outlined in Fig. 3.6A. Each fitted data point 
represents the mean ± S.D. (n = 6-8, e = 3). 
Transporter Substrate Auxiliary 
Protein 
Imax (nA ± S.D.) Apparent Km 
(mM ± S.D.) 
B
0
AT1 
 
Leucine collectrin 523 ± 57 1.35 ± 0.17 
APN 17 ± 2 0.63 ± 0.07 
B
0
AT1 
 
Glutamine  
 
collectrin 720 ± 111 2.56 ± 0.54 
APN 27 ± 6 1.17 ± 0.18 
B
0
AT1 Phenylalanine 
 
collectrin 577 ± 69 8.66 ± 1.83 
APN 23 ± 4 4.00 ± 0.43 
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Table 3.3: Validation of experimental apparent Km values for B
0
AT1 and APN 
 Kinetic parameters apparent Km and Imax were calculated using electrophysiological 
recordings of the indicated proteins expressed in X. laevis oocytes (Fig. 3.6A). Vmax 
(pmol/min × oocyte) values were calculated from Imax values and Vpredicted was calculated by 
substituting these values into the Michaelis-Menten function at 10 mM or 100µM substrate 
concentrations. Vexp represents the mean ± S.E.M. from 3 experiments using 
electrophysiological and uptake experiments (Fig. 3.5D). All rate (V) values were calculated 
as pmol/min × oocyte and fold-change was calculated relative to B
0
AT1 expressing oocytes. 
Oocytes 
Expressing 
Apparent 
Km (mM ± 
S.D.) 
Imax (nA ± 
S.D.) 
[L-leu] = 10 mM [L-leu] = 100 uM 
Vpredicted  Vexp  Vpredicted  
 
Vexp  
 
B
0
AT1 1.02 ± 0.06 8 ± 2 1 1 1 1 
B
0
AT1/APN 0.52 ± 0.02 19.78 ± 2 2.42 2.16 ± 
0.18 
4.18 4.70 ± 
0.39 
B
0
AT1/ACE2 1.09 ± 0.04 459 ± 85 56.53 49 ± 6 53.40 46 ± 10 
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increased the capacity of the transporter for these particular substrates relative to other 
substrates; or, more likely, that the increase in substrate affinity is greater for these three 
relative to others. 
 
 
3.2.3 Mechanism of increased substrate affinity in B0AT1 
Having established a close physical and functional interaction between B
0
AT1 and APN, we 
hypothesised that APN may act as molecular funnel, channelling hydrolysed N-terminal 
amino acids into the extracellular binding site of the transporter. In this case, L-leucine 
hydrolysed from the peptide substrates of APN may experience reduced competition by free 
L-leucine. To investigate this, we incubated oocytes co-expressing B
0
AT1 and APN 
simultaneously with free L-leucine and peptide substrates Leu-Ser-Lys-Leu or tri-leucine. In 
the absence of ACE2 or collectrin (i.e., small amounts of transporter in the membrane) the 
combined addition of substrates increased transporter currents to a degree which, within the 
error of the measurements, was equivalent to the addition of currents from individually added 
substrates – suggesting channelling of substrate by APN does not occur (Fig. 3.7A). Oocytes 
expressing B
0
AT1 alone exhibited no response to peptide perfusion, nor was there any 
addition of currents when both potential sources of L-leucine were added simultaneously. 
The result was different when large amounts of transporter were in the membrane due to co-
expression of collectrin (Fig. 3.7B). Addition of 500 µM L-leucine or 2 mM peptide resulted 
in similar currents, but the combined superfusion of L-leucine and peptide resulted in currents 
that were similar to those of leucine alone (Fig. 3.7C). Increasing the free L-leucine 
concentration to 2 mM confirmed that the combined addition does not exceed the currents 
induced by free L-leucine. 
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Since APN did not channel substrates into the transporter, we next hypothesised that the 
increase in apparent substrate affinity could be caused by an increase of the local substrate 
concentration as compared to the bulk concentration. An amino acid binding site has been 
observed in APN and many high-resolution structures of the E. coli APN have bound amino 
acids [529-531]. Theoretically, rapid APN-mediated binding of neutral amino acids could 
lead to such a local concentration increase. Incubating B
0
AT1 and APN co-expressing 
oocytes with the peptidase inhibitor bestatin, which competes with substrate for APN’s 
binding site, blunted the APN-mediated increase of B
0
AT1 L-leucine transport (Fig. 3.8). The 
APN-facilitated increase in B
0
AT1 activity was not entirely subdued however, consistent 
with APN’s role in increasing B0AT1 surface expression. 
 
We further mutated critical residues in the amino-acid-binding site of APN as an additional 
way of testing whether binding of amino acids to APN was the cause of an increase in B
0
AT1 
apparent substrate affinity. In order to identify the critical amino acid residues involved in 
substrate and zinc ion stabilisation in murine APN, we generated a homology model based on 
an X-ray crystal structure of the E. coli L-leucine aminopeptidase (LAP) enzyme (PDB ID 
3B34) (Figs. 3.9A and 3.9B). A preliminary sequence alignment of APN with potential 
orthologs from diverse species identified E. coli LAP as belonging to the aminopeptidase 
family of M1 class metalloproteases, with 24 % or greater sequence identity to APN (Figure 
3.10). The aminopeptidase family is characterised by three active-site motifs: The HEXXH 
and BXLXE zinc-binding motifs are located 24 residues apart in all family members, and 
substrate binding is associated with the GXMEN motif  [327]. All three motifs are fully 
conserved between E. coli LAP and APN (Fig. 3.10). The main features of the overall 
structure of E .coli LAP were reproduced in the APN model with a backbone chain R.M.S.D. 
of 0.68 Å, and > 95 % of dihedral angles in the allowable regions. As the N-terminus of APN 
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Figure 3.7 Mechanism of APN-mediated  increase in substrate affinity of B
0
AT1 
Oocytes were injected with 10 ng of B
0
AT1 cRNA, 15 ng of APN cRNA, 2 ng of collectrin 
cRNA. A) Oocytes were voltage clamped at -50 mV and superfused with either 200 µM L-
leucine or 1 mM Leu-Ser-Lys-Leu tetra-peptide or a combination of both. L-leucine-induced 
sodium currents were recorded 4-6 days post-injection for all oocytes. All sodium currents 
were normalised to the sodium currents elicited by 200 µM L-leucine (ILeu) at 100 %, which 
were 3.7 ± 0.8 nA for B
0
AT1 expressing oocytes and 10.1 ± 2.4 nA for B
0
AT1/APN co-
expressing oocytes. Each bar represents the mean ± S.D. (n = 6-8, e = 3). B) Oocytes were 
recorded as indicated in (A) and superfused with either 2 mM L-leucine or 2 mM leucine 
tripeptide or a combination of both. All sodium currents were normalised to the sodium 
currents elicited by 2 mM L-leucine (ILeu) at 100 %, which were 433 ± 40 nA for 
B
0
AT1/collectrin co-expressing oocytes and 363 ± 32 nA for B
0
AT1/APN/collectrin co-
expressing oocytes. Each bar represents the mean ± S.D. (n = 15). C) Oocytes were recorded 
and superfused as indicated in (B), but using an L-leucine concentration of 500 µM. All 
sodium currents were normalised to the sodium currents elicited by 500 µM L-leucine (ILeu) 
at 100 %, which were 203 ± 44 nA for B
0
AT1/collectrin co-expressing oocytes and 195 ± 25 
nA for B
0
AT1/APN/collectrin co-expressing oocytes  Each bar represents the mean ± S.D. (n 
= 14). 
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Figure 3.8 Mechanism of APN-mediated increase in substrate affinity of B
0
AT1 
Oocytes were injected with either 10 ng of B
0
AT1 cRNA and/or 15 ng of APN cRNA. 
Uptake of L-[
14
C(U)]leucine was measured over 30 minutes on day 5 post-injection. Bestatin 
(70 µM) was pre-incubated for 1 minute before L-leucine was added. Oocyte endogenous L-
leucine transport was subtracted in all experimental conditions. Each bar represents the mean 
± S.E.M. of data combined from 4 experiments (n = 33-38, * indicates p < 0.001).  
  
134 
 
 
 
 
  
135 
 
 
 
 
 
Figure 3.9 Homology model of mouse APN 
The homology model of mouse APN was generated using HHpred Homology detection and 
structure prediction tool and visualised using PyMol v9.9. Depicted are E. coli LAP (PDB ID 
3B34) (A) and a murine APN homology model (B) with phenylalanine bound to their active 
site. Top panels: lateral 3D view of the murine and E. coli structures. Subdomains I to III 
from mouse APN have been removed (residues 1 to 89) as no homologous sequence exists in 
E. coli for these. Subdomains are shaded as follows: magenta (subdomain 1 for E. coli, 
subdomain IV for mouse); green (subdomain II for E. coli, subdomain V for mouse); cyan 
(subdomain III for E. coli, subdomain VI for mouse); yellow (subdomain IV for E. coli, 
subdomain VII for mouse). The HEXXH..........BXLXE and GXMEN consensus sequences 
for zinc and amino acid binding are shaded red and orange, respectively. The zinc ion is 
shaded purple. The active sites of E. coli LAP and murine APN are depicted in panels C) and 
D), respectively. The zinc ion is shaded violet, while the bound L-phenylalanine is depicted 
as a space-filled model, with oxygen and nitrogen atoms coloured red and blue, respectively. 
All direct substrate-binding residues are shown as sticks and labelled.  
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Figure 3.10 Partial sequence alignments of aminopeptidase family members 
Potential homologues of mouse APN (UniPROT P97449) were identified by a NCBI blastp 
search. Peptide sequences were aligned using COBALT. Strictly conserved residues are 
shaded red. In the consensus sequence row, X = any amino acid, B = bulky side chain neutral 
amino acids. The full-length aligned sequence from E. coli LAP (not shown) was used as the 
template for homology model of mouse APN. The 3 conserved residues at the active site of 
murine APN selected for site-directed mutagenesis are shaded green, a 4th mutated residue, 
Y476, is not shown. Abbreviations: LTA4, leukotriene A-4 hydrolase; AAP1, 
alanine/arginine aminopeptidase 1.   
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is absent  in E. coli LAP, the cytosolic N-terminus, single-pass membrane helix and linking 
region to the extracellular catalytic domains representing residues 1 to 89 are missing from 
the model (Fig. 3.9B). A phenylalanine residue bound to the E. coli LAP crystal structure 
(PDB ID 3B34) was superimposed into the binding site of the APN model (Fig 3.9C and 
3.9D). No steric interference was observed, suggesting that amino acid substrates are likely to 
bind in a similar manner in both enzymes. This hypothesis is supported by the conservation 
of the binding site residues.   
 
Four single-residue APN mutants were generated and co-expressed with B
0
AT1 in X. laevis 
oocytes to examine their effects on the transporter’s apparent Km. Mutation E354A affects a 
highly conserved substrate-binding residue. Mutations E388A and E410A change conserved 
zinc-coordinating residues. All 3 mutations were designed to abolish all catalytic activity of 
APN. The fourth mutant, Y476F, also highly conserved, was considered to fulfil a less 
critical substrate-binding role and was introduced as a potential partial loss-of-function 
mutation. Surprisingly, all mutants exhibited various levels of catalytic activity as indicated 
by peptide-induced currents (Fig. 3.11A). APN Y476F exhibited wild-type-like activity, at 
the other extreme APN E354A had lost approximately 80 % of its catalytic activity. A kinetic 
analysis of L-leucine uptake into oocytes co-expressing mutant APN and B
0
AT1 showed an 
inverse correlation between the catalytic activity of the APN mutants and their ability to alter 
B
0AT1’s apparent Km (r = −0.84, p = 0.035, n = 74) (Fig. 3.11B). The mutant with the least 
catalytic activity, E354A, also displayed the least alteration in apparent substrate affinity of 
B
0
AT1-mediated transport compared with oocytes expressing B
0
AT1 alone or B
0
AT1 and 
collectrin. Conversely, the mutants E388A and Y476F, retaining most of the wild-type’s 
catalytic activity, increased the apparent substrate affinity of B
0
AT1 to the same extent as 
wild-type APN. B
0
AT1 surface expression was similar across all oocytes co-expressing wild-
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type APN or the mutants, suggesting that APN’s role as a trafficking facilitator is unaffected 
in all mutants tested (Fig. 3.11C).   
 
3.3 Discussion 
We have demonstrated that the major neutral amino acid transporter of the mammalian small 
intestine B
0
AT1 forms protein complexes with the brush-border peptidases APN and ACE2. 
Co-expression of these peptidases affected the kinetic parameters of B
0
AT1-mediated 
transport differentially. APN increases the surface expression (Vmax) and apparent substrate 
affinity (lower apparent Km) of B
0
AT1 transport activity. ACE2 is the primary trafficking 
subunit of B
0
AT1 in the intestine, but did not modify the apparent substrate affinity, 
confirming previous results [169, 176], and suggesting that the formation of functional 
protein complexes between apical neutral amino acid transporters and peptidases may be 
widespread. Our results suggest these complexes are likely to increase the efficiency of 
protein absorption, by increasing the local substrate concentration for B
0
AT1. 
 
We establish a possible mechanism by which APN alters the apparent substrate affinity of 
B
0
AT1, namely, by increasing the local concentration of neutral amino acids at the plasma 
membrane, thereby causing an ‘apparent’ change in the transporter’s Km. Such a mechanism 
is not uncommon in nature, and is reminiscent of periplasmic binding proteins and ATP 
binding cassette of ABC primary transporters in archeal and bacterial species [532-536], 
where the substrate Km is largely determined by the binding protein and not the transporter 
itself. A local concentration variation and change in ‘apparent’ Km, is also observed in the 
‘proton well’ effect of some proton translocating ATPases [537]. Homology modelling and 
structural data of E. coli LAP [529, 531] suggest APN possesses a binding site for neutral  
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Figure 3.11 Mechanism of APN-mediated increase in substrate affinity of B
0
AT1 
Oocytes were injected with either 10 ng of B
0
AT1 cRNA, 15 ng of WT or mutant APN 
cRNA, or 2 ng of collectrin cRNA. A) Oocytes were voltage clamped at –50 mV and 
superfused with either 10 mM L-leucine or 10 mM Leu-Ser-Lys-Leu tetra-peptide. Each 
tracing is a typical example of currents observed in all oocytes injected with the indicated 
cRNA. Leucine-induced sodium currents were recorded on day 4 and 5 post-injection for all 
oocytes. B) Oocytes were recorded as indicated in A). Each data point indicates an APN 
mutant co-expressed with B
0
AT1, or B
0
AT1 co-expressed with collectrin. All peptide-
induced sodium currents were normalised to the corresponding L-leucine-induced sodium 
current (IPep/ILeu). Each data point represents mean ± S.D. for both peptide-induced sodium 
currents and apparent Km values (Pearson’s r = –0.84, p = 0.035, n = 74). The trend line was 
fitted using linear regression (adjusted R
2
 = 0.74). C) Fifteen oocytes/sample were incubated 
with 0.5 mg/ml Sulpho-NHS-LC-Biotin on day 5 post-injection before being lysed and 
treated with streptavadin-coated agarose beads. Samples were separated by SDS-PAGE and 
B
0
AT1 detected by immunoblotting.   
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amino acids. Several large neutral amino acids have been crystallised in the E. coli LAP 
binding pocket, demonstrating the active site of LAP lies in a groove between the two lobes 
of domain II, and covered by domain IV [529-531]. From sequence identity, structural 
homology and biochemical analysis, we demonstrate APN’s active site is homologous to 
LAP. This basic geometry of the E. coli active site and narrowness of the substrate entry site 
are both conserved in mouse APN. Loss of catalytic activity using mutagenesis of APN’s 
substrate binding site abolished the increase in transport affinity observed for B
0
AT1. The 
increase of the local concentration is expected to become more relevant as the peptidase to 
transporter ratio increases. This was confirmed by oocyte experiments, where peptidase-
induced current were additive to the currents induced by bulk leucine at low surface 
concentrations of B
0
AT1 (Fig. 3.7A). When the B
0
AT1 concentration was increased relative 
to a constant amount of APN the currents were no longer additive. This model does not rule 
out the possibility that APN increases the transporter’s substrate affinity by altering the 
thermodynamics of substrate binding, whether through direct (B
0
AT1 binding site) or 
allosteric means. To determine if the maximal functional effect of APN on B
0
AT1 has been 
realised in this paper, we plan to saturate APN binding by titrating cRNA injections into 
oocyte in the presence of constant B
0
AT1. 
 
In this study we have demonstrated the presence of digestive protein complexes in the 
intestinal brush-border containing APN and ACE2 and the neutral amino acid transporter 
B
0
AT1. We propose these complexes to function as a metabolon, which optimises protein 
digestive and absorption processes at the brush-border. We envision a scenario where B
0
AT1 
trafficking and expression in the membrane is largely dependent on ACE2, whereas optimal, 
or adaptive functioning to changing dietary conditions requires association with APN. It 
appears likely that these complexes contain a wider array of proteins than shown here. 
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Chapter 4: Molecular Basis for the Interaction of B0AT1 and B0AT3 
with Collectrin 
This results chapter is based on the following publication: 
Stephen J. Fairweather , Angelika Brӧer, Nandhitha Subramanian, Emrah Tumer, Qi Cheng , 
Dieter Schmoll, Megan L. O’Mara, and Stefan Brӧer. Molecular Basis for the Interaction of 
the Mammalian Amino Acid Transporters B
0
AT1 and B
0
AT3 with Their Ancillary Protein 
Collectrin. Journal of Biological Chemistry, 2015, 290(40), 24308-25. 
 
Minor modifications to the results section have been made from the original publication. The 
introduction and discussion have been substantially modified to align them with the rest of 
this thesis. The methods section of the original paper have been removed, modified and added 
to the general methods section of this thesis. All data from this chapter were generated by the 
S.J. Fairweather with the exception of: Figures 4.1B (Thuvaraka Thavyogarajah), 4.1C 
(Angelika Brӧer), 4.7A and 4.7B (Qi Cheng and Angelika Brӧer). S. J. Fairweather wrote the 
manuscript of the original paper. The original manuscript was edited by S. Brӧer. 
 
4.1 Introduction 
The SLC6 family comprises secondary active amino acid and neurotransmitter transporters, 
which are involved in a broad variety of physiological functions, most notably 
neurotransmitter uptake at the synapse and epithelial amino acid transport in the proximal 
tubules and intestine (section 1.2.2). A feature of SLC6 transporters is their interactions with 
heterologous protein partners. The most essential of these are the interactions between B
0
AT1 
and B
0
AT3 and their ancillary partner’s collectrin, ACE2 and APN (Chapter 3). However, the 
molecular interactions, stoichiometry and basis of stabilisation of B
0
AT1 and B
0
AT3 by 
collectrin/ACE2 have not yet been described in detail. No other transporter in the SLC6 
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family has this absolute requirement for heterodimerisation to reach the cell surface. The 
neurotransmitter transporters, such as DAT (SLC6A3), rather require homodimerisation 
and/or oligomerisation to exit the endoplasmic reticulum [538-540]. While the dependence of 
B
0
AT1 and B
0
AT3 surface expression on collectrin appears unique, protein-protein 
interactions between SLC6 Neurotransmitter Sodium Symporters (NSS) and smaller 
membrane-anchored proteins is widespread [398, 401, 402, 538, 541, 542]. Syntaxins, for 
example, interact and functionally modulate a wide range of neurotransmitter transporter 
members of the SLC6 family (section 1.5.3). 
 
Collectrin and ACE2 have been the focus of research due to their roles in a number of vital 
human physiologies and pathologies (section 1.5.1). In contrast to an abundance of research 
on their roles in blood pressure regulation and glycemic control, information on the 
interaction between collectrin/ACE2 and B
0
AT1 or B
0
AT3 is scarce. It is thought to involve a 
conserved Arg240 residue in B
0
AT1 (Arg225 in B
0
AT3) [169]. Intriguingly, this mutation 
did not affect B
0
AT1 when expressed alone, but reduced transport severely in the presence of 
collectrin/ACE2 [167]. Several other Hartnup disorder mutations, namely A69, D173N and 
P265, have also been implicated in ACE2 and collectrin-mediated B
0
AT1 dysfunction [176]. 
However, the claim by Carmago et al. of differential binding of B
0
AT1 with collectrin and 
ACE2 was highly exaggerated, and close inspection of axis scales shows very little, if any, 
difference between  ancillaries interactions with B
0
AT1 mutants (see Fig. 2B [176]). 
 
The interactions of B
0
-like transporters with collectrin and ACE2 appear to be tissue specific, 
collectrin-deficient mice lack B
0
AT1 and B
0
AT3 in the kidney, while ACE2 deficient mice 
lack B
0
AT1 in the intestine (section 1.5.2) [175, 176, 189]. It is not immediately apparent 
why ACE2 should not also interact with B
0
AT1 and B
0
AT3 in the kidney. ACE2 proximal 
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tubule expression is robust and its brush border localisation overlaps with B
0
AT1 and B
0
AT3 
[169, 347, 352]. Despite this, no significant compensatory renal absorption of neutral amino 
acids or brush border expression of B
0
AT1 is observed in collectrin knockout mice that could 
be expected with ACE2 still present [175, 178]. It may be ACE2 undergoes differential post-
translation processing in the kidney, which prevents its association with B
0
AT1. The large 
extracellular ectopeptidase domain of ACE2 is indeed cleaved in the kidney by ADAM-17 
[369, 543, 544] (section 1.5.1). However, this processing occurs only at the brush border, as it 
leads to the shedding of and excretion ACE2’s ectodomain in urine [369, 543, 544]. 
Therefore, ACE2 is likely to remain intact and functionally able to interact with B
0
AT1 
during their trafficking to the brush border membrane and its inability to interact with B
0
AT1 
being due to proteolytic cleavage at the brush border. This raises the possibility that ancillary 
proteins may be involved in post-translational processing or catalytic activation of B
0
AT1 
and B
0
AT3 function at the plasma membrane and not simply for trafficking. 
 
In this chapter, I demonstrate that collectrin catalytically activates B
0
AT1 and B
0
AT3 as well 
as acting as a chaperone for plasma membrane trafficking. I also demonstrate the presence of 
a binding site between TMs 5 and 7 of the transporters. In addition, it is shown that syntaxin 
1A and 3 can inhibit the B
0
-like transporter-collectrin interaction and raise the possibility that 
the collectrin binding site represents a conserved site of interaction between SLC6 
transporters and single TM domain ancillary proteins.   
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4.2 Results 
4.2.1 Functional interactions between B0-like transporters collectrin and ACE2 
Collectrin and ACE2 are essential to functionally express mouse B
0
AT1 and B
0
AT3 [106, 
132, 169, 175, 178] (Fig. 4.1A). It is important to note that human B
0
AT3 is an inactive 
protein even if co-expressed with ACE2 or collectrin (Fig. 4.1A). Mouse and human B
0
AT1 
display a small transport activity in the absence of the ancillaries, while mouse B
0
AT3 does 
not.  
 
As shown in chapter 3 and elsewhere, neither collectrin nor ACE2 change the substrate 
affinity of B
0
AT1 [169, 175, 496]. Mouse B
0
AT3, by contrast, demonstrated differential 
substrate affinity for its main substrates L-glycine and L-alanine when co-expressed with 
either collectrin or ACE2 (Fig. 4.1B). The apparent affinity (K0.5) for L-alanine was 0.79 ± 
0.14 mM in the presence of collectrin, whereas in the presence of ACE2 a value of 0.14 ± 
0.02 mM was measured. For glycine the K0.5 was 0.99 ± 0.05 mM and 0.27 ± 0.06 mM in the 
presence of collectrin and ACE2, respectively. To see if the substrate specificity was also 
ancillary partner-dependent, we measured uptake of L-[
14
C(U)]alanine in the presence of 10 
mM of a range of amino acids (Fig. 4.1C). Consistent with the increased apparent affinity of 
glycine and alanine in the presence of ACE2, a higher degree of inhibition was observed in 
the presence of unlabelled glycine and alanine. Serine and threonine showed a similar 
behaviour. By contrast, no incremental change of the maximum substrate-induced transport 
current (Imax) induced by alanine and glycine and other substrates was observed, when 
currents were normalised to the methionine-induced current in the presence of either ancillary 
protein (Fig. 4.1D). 
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These results demonstrate that collectrin and ACE2 are not only trafficking subunits, but also 
affect substrate affinity and specificity of the B
0
AT3 transporter. As a result these subunits 
may also be involved in the catalysis of substrate movement by B
0
-like transporters. 
 
4.2.2 Collectrin is necessary for the catalytic function of B0AT3 and B0AT1 
To differentiate between the trafficking function of collectrin and any potential role in the 
catalytic process we created a tandem transporter with the rat monocarboxylate transporter 1 
(MCT1) (Fig. 4.2A). Rat MCT1 is readily expressed at the oocyte surface due to the 
expression of the Xenopus basigin protein (UniProtKB Q4FZV9), which is involved in 
trafficking of MCT1 to the cell surface [310]. Therefore MCT1 in tandem with a B
0
-like 
transporter will carry this transporter to the cell surface without the aid of collectrin. This 
allowed us to distinguish between the chaperone/trafficking roles of collectrin and any other 
catalytic roles it may have, as has been shown for ACE2 (Fig. 4.1).  We first created a 
MCT1-B
0
AT3 construct, as B
0
AT3 has no activity when expressed alone (see Fig 4.1A). 
Surprisingly, we found that MCT1-B
0
AT3 did not transport L-alanine in the absence of 
collectrin (Fig. 4.2B). In contrast, when collectrin was co-expressed with MCT1-B
0
AT3, full 
L-alanine transport activity was restored. MCT1-B
0
AT3 showed active L-lactate transport 
comparable to MCT1 alone, either with or without collectrin co-expression (Fig 4.2C). An 
MCT1-B
0
AT1 construct displayed similar dependence on collectrin co-expression as the 
MCT1-B
0
AT3 construct (Fig. 4.2D). To further investigate whether collectrin-induced 
activity of B
0
AT1 and B
0
AT3 was proportional to the surface expression of the tandem-
construct we used the natural variability of transporter expression in oocytes. Rat MCT1 is 
electro-neutral [448] allowing us to compare B
0
AT3 currents with L-[
14
C(U)]lactate uptake. 
These experiments demonstrated a strong correlation between lactate uptake and alanine-
induced currents (Fig. 4.2E). However,  
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Figure 4.1 Functional interactions of B
0
AT1 and B
0
AT3 with Collectrin and ACE2 
Ancillary proteins modify substrate affinity of B
0
AT1 and B
0
AT3. Xenopus laevis oocytes 
were injected with 10 ng of the indicated transporter, 2 ng of collectrin, and 10 ng of ACE2 
cRNA in the indicated combinations except where otherwise stipulated. All uptake and 
electrophysiological measurements were made 4-6 days post-injection. A) Uptake of 100 µM 
L-[
14
C(U)]leucine or 100 µM L-[
14
C(U)]alanine was measured in oocytes expressing B
0
AT1 
or B
0
AT3 over 30 mins. Each bar represents mean ± S.D. (n = 12, e > 3). All ancillary co-
injected conditions were significantly different (p < 0.05) from their respective transporter-
only injected condition. B) Oocytes were voltage-clamped at -50 mV and perfused with serial 
concentrations of L-alanine or glycine. Eadie-Hofstee linear regression was fitted to the data, 
for all regressions 0.99 > R
2
 > 0.88, and Pearson's r > – 0.94 (n = 7). C) Oocytes were 
injected with 6 ng B0AT3 cRNA, 5 ng of ACE2, and 2 ng of collectrin cRNA. Uptake was 
measured as in A) with the exception that it was challenged by 10 mM of unlabelled L-amino 
acids as indicated. The first pair of bars from the left represents unchallenged 100 µM L-
[
14
C(U)]alanine uptake. Uptake from uninjected oocytes was subtracted. Each bar represents 
mean ± S.D. (n = 8-10, * indicates p < 0.05). D) Oocytes were perfused with 10 mM of the 
indicated amino acid and steady-state substrate-induced currents were recorded. All currents 
were normalised to the maximal current induced by 10 mM L-methionine. Each bar 
represents mean ± S.D. (n = 6, e = 3).  
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Figure 4.2 Collectrin is required for catalytic activation of mouse B
0
AT3 and B
0
AT1 
Xenopus laevis oocytes were injected with 10 ng of the indicated transporter cRNA or 18 ng 
of MCT-B
0
AT3 or MCT-B
0
AT1 fusion cRNA and 2 ng of collectrin cRNA. All 
measurements were made 4-6 days post-injection of cRNA. A) Schematic of B
0
AT3 
expression conditions: B
0
AT3 alone cannot traffick to the plasma membrane (i), as it requires 
collectrin co-expression (ii). It was hypothesised that it would traffick without collectrin 
when fused to MCT1 (iii).  B) Uptake of 100 µM L-[
14
C(U)]alanine or 100 µM L-
[
14
C(U)]lactate was carried out over 30 mins. Each histogram bar represents mean ± S.D. (n = 
10-15, e > 3). Identical lettering a, b, c, above individual bars indicates groupings of 
conditions whose differences of means are not statistically significant from each other at the p 
= 0.05 level. C) Uptake of 100 µM L-[
14
C(U)]lactate was carried out over 24 mins. Each 
histogram bar represents mean ± S.D (n = 10, e = 3). Identical lettering a and b, above 
individual bars indicates groupings of conditions whose differences of means are not 
statistically significant from each other at the p = 0.05 level. D) Uptake of 100 µM L-
[
14
C(U)]leucine or 100 µM L-[
14
C(U)]lactate was carried out over 25 mins. Each bar 
represents mean ± S.D. (n = 12-15, e = 3). The lettering a, b, c, d above the individual bars 
indicates groupings of conditions whose differences of means are not statistically significant 
from each other at the p = 0.05 level. E) Correlation between L-lactate uptake and L-alanine-
induced currents in the MCT-B
0
AT3 tandem construct. The integral of alanine-dependent 
inward charge transfer (Q 
5 mM L-Ala
) was calculated and plotted against L-[
14
C(U)]lactate 
uptake in the same oocyte (n = 10-13). Pearson's  r = 0.82, the R
2
 value is indicated on the 
graph.  
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the magnitude of L-alanine-induced charge flux (Q
5mM L-Ala
) was generally lower in MCT1-
B
0
AT3/collectrin co-expressing oocytes than those co-expressing native B
0
AT3/collectrin. 
To investigate the behaviour of the MCT1-B
0
AT3 tandem construct further, we measured 
basic kinetic parameters. Inspection of the original tracings suggested that alanine-induced 
currents saturated more readily in the tandem construct compared to the conventional 
transporter (Fig. 4.3A). Consistent with Figure 4.2E, the Vmax of alanine-induced currents 
was significantly lower in the tandem construct plus collectrin (26 ± 2 nA) compared to 
B
0
AT3 plus collectrin (98 ± 13 nA) (Fig. 4.3B). The K0.5 of alanine-induced currents was also 
significantly lower in the tandem construct plus collectrin (0.15 ± 0.03 mM) compared to 
B
0
AT3 plus collectrin (0.79 ± 0.18 mM). This combination of a change in both steady-state 
kinetic parameters explains why we observed similar rates of transport in both native B
0
AT3 
and the fusion construct at sub-K0.5 L-alanine concentrations in uptake assays (Fig. 4.2B). No 
L-alanine induced currents were observed in MCT-B
0
AT3 expressing oocytes in the absence 
of collectrin (data not shown), confirming the necessity of collectrin for sodium-driven 
transport activity in MCT-B
0
AT3.  
 
Together these results clearly demonstrate an essential role of collectrin in both trafficking 
and catalytic activation of B
0
AT3 and B
0
AT1.  
 
4.2.3 Identification of a collectrin interaction site in B0AT3 
To identify the potential binding site(s) for collectrin in B
0
AT3 and B
0
AT1 we used 
mutagenesis-based approaches and sequence alignments of the SLC6 family. A summary of 
the results for all mutants is given in Table 4.1. Mutations were selected by a number of 
processes: (i) mutations associated with iminoglycinuria in humans [177], (ii) protein 
sequence differences between mouse B
0
AT3 (active in oocytes) and human B
0
AT3 (inactive 
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in oocytes), (iii) potential sites for electrostatic interactions between collectrin and B
0
AT3, 
and (iv) molecular dynamics simulation of collectrin binding to B
0
AT3 in the vicinity of 
R225 (equivalent to B
0
AT1 R240). We deliberately excluded mutations of residues lining the 
 
translocation pore as these are likely to be involved in substrate and ion binding. The relative 
activity of single mutations was mapped onto the homology model of B
0
AT3 (Fig 4.4A and 
4.4B).  
 
Several mutations causing functional changes of B
0
AT3 activity, D21N, Q25V, L213W, 
R225T, N283D, D287N, S296R, were found on one face of the B
0
AT3 homology model in 
transmembrane (TM) domains 1α, 5, 7 and adjacent cytosolic and extracellular regions. 
Mutants Y72H, K90T, S158D, M297S, I456T, L477P, Q568R, by contrast, had no 
significant effects on B
0
AT3 transport activity and, with the exception of M297S, were facing 
the side of the transporter opposite to TMs 1α, 5 and 7. A space-filled rendering of B0AT3 
shows TM domains 5 and 7 are separated by a groove in the side of the transporter, with the 
mutated residues D21N, Q25V, L213W, R225T, N283D, D287N, and S296R surrounding 
this groove (Fig. 4.4C). TM1α is proposed to move during the transport cycle through this 
gap between TM5 and TM7 [194]. All mutated B
0
AT3 variants with the exception of D502N 
were expressed in oocytes at comparable protein levels to wild-type B
0
AT3 (Table 4.1). With 
the exception of mutants H50Y, G78S, L213W, R225T and N283D, transport activity was 
highly correlated with surface expression (Table 4.1). This is illustrated by the correlation 
coefficient (r), which increased from 0.87 to 0.99 when the five mutants were excluded. 
Mutants H50Y and G78S were not investigated further as they are not localised to the cell 
surface. 
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Figure 4.3 Properties of MCT-B
0
AT3 activation by collectrin 
Xenopus laevis oocytes were injected with 10 ng of B
0
AT3 or 18 ng of MCT-B
0
AT3 fusion 
cRNA and 2 ng of collectrin cRNA. All measurements were made 4-6 days post-injection. 
All oocytes were voltage-clamped at –50 mV. A) Oocytes were superfused with serial alanine 
concentrations in ascending or descending order. L-alanine-induced currents were used to 
determine the steady-state kinetics of MCT-B
0
AT3 compared with B
0
AT3, both in the 
presence of collectrin. B) Oocytes were superfused with serial concentrations of L-alanine as 
in A) and the Michaelis-Menten function fitted to averaged data for each concentration. 
Insert: Eadie-Hofstee transformation of the Michaelis-Menten data: adjusted R
2
 = 0.77 for 
B
0
AT3 + collectrin and adjusted R
2
 = 0.88 for MCT-B
0
AT3 + collectrin (n = 8-10, e = 3).
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Table 4.1: Summary of single residue mutations in murine B
0
AT3, co-expressed with collectrin: selection, position, activity, expression 
mB
0
AT3 
Mutation 
Selection 
Category* 
Mutation 
Position 
L-
[
14
C(U)]Alanine  
Uptake Activity 
(% wild-type 
±S.E.M., e ≥ 3) 
Plasma 
Membrane 
Expression 
(normalised to 
WT expression) 
Relative Protein 
Expression 
(normalised to 
WT expression) 
Orthologous 
Residue in 
human B
0
AT1 
D21N 3 N-terminal 167.5 ±  9.6
‡
 1.86 ± 0.25 0.96 D36 
Q25V 4 TM 1α 32.0 ± 11.0‡ 0.29 ± 0.09 0.86 Q40 
Q25D 4 TM 1α 3.9 ± 5.0‡ 0.05 ± 0.07 0.84 Q40 
H50Y 2 EL 1 141 ± 11.3
‡
 0.80 ± 0.15 1.21 H65 
Y72H 2 TM 2 79.0 ± 10.3 0.89 ± 0.11 1.20 Y87 
G78S 1 IL 1 15.3 ± 1.8
‡
 0.89 ± 0.19 0.88 G93 
K90T 2 IL 1 72.5 ± 13.4 0.86 ± 0.24 0.90 S106 
S158D 3 EL 2 115.2 ± 5.6 1.25 ± 0.12 1.46 D173 
L213W 4 TM 5 30.3 ± 8.5
‡
 1.10 ± 0.18 1.14 T228 
R225T 3 TM 5 10.2 ± 2.7
‡
 0.39 ± 0.15 1.07 R240 
N283D 2 IL 3 4.9 ± 1.5
‡
 0.21 ± 0.03 1.32 N298 
D287K 3 TM 7 3.5 ± 2.4
‡
 0.10 ± 0.12 1.03 D302 
D287N 3 TM 7 21.0 ± 12.6
‡
 0.21 ± 0.06 1.08 D302 
S296R 2 TM 7 2.6 ± 0.6
‡
 0.09 ± 0.07 1.01 G311 
M297S 4 TM 7 104.0 ± 5.6 0.96 ± 0.10 0.77 F312 
M297C 4 TM 7 117.2 ± 4.8 1.39 ± 0.42  0.84 F312 
I456T 2 TM 9 110.7 ± 6.7 1.05 ± 0.23 1.12 F471 
G464N 2 EL 5 90.0 ± 10.8 0.94 ± 0.55  1.08 Q479 
L477P 1 TM 10 120.0 ± 26 1.21 ± 0.38 0.81 I492 
G495R 1 IL 5 3.9 ± 3.3
‡
 0.01 ± 0.02 0.76 G510 
D502N 3 IL 5 9.3 ± 6.8
‡
 0.12 ± 0.11 0.07 D517 
Q568R 2 EL 6 91.4 ± 9 0.92 ± 0.49 0.93 Y583 
* Mutagenesis selection categories: 1 = imminoglycinuria-associated mutants; 2 = evolved between murine and human B
0
AT3; 3 = electro-static mediated 
interactions in cytosolic and extracellular loops; 4 = in silico molecular dynamics-associated,. ‡ p < 0.05 One-way ANOVA, Bonferroni post-hoc test – conducted 
for all repeats that make up the tabulated data.   
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As there seems to be a preponderance of functional and surface expression mutants in B
0
AT3 
TMs 5 and 7, we hypothesised collectrin’s TM domain may occupy an interaction site in the 
groove flanked by these TM domains. To test this notion, a series of six docking simulations 
between collectrin’s TM domain and B0AT3 were performed, using different sets of 
residuesfrom TM5 and TM7 as docking constraints (Table 2.2) (performed by Dr. Megan 
O’Mara and Nanditha Subramanian). The lowest scoring docking conformer was used to 
initiate a 10 ns molecular dynamics simulation. This simulation identified M297 in TM7, 
L213 in TM5 and Q25 in TM1α as key interacting residues with collectrin’s TM domain (Fig. 
4.4D). Figure 4.4C and 4.4D appear different in the loop regions as they are based on 
Drosophila DAT (4m48) and LeuT (2A65) crystal structures, respectively.  The TM5/TM7 
groove is present in both homology models and the experimental structures on which they 
were based. 
 
Next it was necessary to differentiate whether these residues in TM1α, 5 and 7 interact 
directly with collectrin or affect the transporter independently of it. To do so we hypothesized 
the existence of 3 different types of mutations that could cause loss of function in B
0
AT3. 
The first are catalytic mutations that interfere directly with the transport mechanism, 
independent of collectrin. A second type of mutation interferes with the interaction between 
collectrin and B
0
AT3 resulting in a trafficking modification. These should be rescued when 
expressed in the MCT1-B
0
AT3 tandem construct. A third type of mutation affects the 
catalytic role of collectrin and should not be rescued when incorporated into the tandem 
construct. Although it is difficult to discriminate between non-functional type 1 and type 3 
mutants, a true type 3 mutant is likely to be expressed at the cell surface and is likely to be 
located at the surface of the protein. A possible type 3 mutant is L213W (located in TM5) as 
it is neither active in B
0
AT3 nor in the auto-trafficked MCT1-B
0
AT3 when both are co- 
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Figure 4.4 Surface localisation and activity of B
0
AT3 mutants displayed on 
homology models 
Transport activity of all mutants is indicated by colour coding and was determined by flux 
assays in Xenopus laevis oocytes as described in Fig. 4.1. Data was taken from Table 4.1. The 
homology model structure of mouse B
0
AT3 was built using the D. Melanogaster dopamine 
transporter DAT x-ray crystal structure in the outward open confirmation (PDB ID 4m48) (A, 
B, C) or LeuT from Aquifex aeolicus in an outward occluded confirmation (PDB ID 2A65) 
(D) as a template. Mouse B
0
AT3 is viewed parallel to the membrane. Mutated residues are 
shown in van der Waals radii representation. Wildtype activity is 100% (white), lower 
activity is displayed in red, higher activity in blue (scale bar). A) TM helices 1a, 5, and 7 are 
coloured yellow, orange, and green, respectively. B) The homology model is rotated 180º on 
its vertical axis. C) Surface representation of B
0
AT3 in the same orientation as shown in A). 
The pocket flanked by TM domains 5 and 7, and partially occupied by TM 1a. Only mutants 
located in, or peripheral to, TM 1a, TM 5, or TM 7 are labelled. D) Hypothesised interaction 
site between collectrin's TM domain (M136-R171) and B
0
-like transporters. The model is 
based on the end point of a 10 ns MD simulation (section 2.7.3). The same face of mouse 
B
0
AT3 is shown as in A) and C). The transporter is viewed parallel to the membrane with the 
POPC membrane used during MD simulation removed in order to see the proteins clearly. 
Mouse B
0
AT3 is visualised in grey with collectrin M136 to R171 in green. The same residues 
are shown as in C).  
  
160 
 
 
 
  
161 
 
 
 
 
 
 
 
Figure 4.5 Analysis of mutants in a MCT-B
0
AT3 tandem construct supports a bi-
functional role for collectrin 
A), C), D), E) Xenopus laevis oocytes were injected with the indicated constructs and uptake 
of 100 µM L-[
14
C(U)]alanine measured over 30 min. Each bar represents the mean ± S.D. 
activity (n = 10-15, e = 3). Identical lettering a, b, c, d above individual bars indicates 
groupings of conditions whose differences of means were not statistically significant from 
each other at the p = 0.05 level. B) Surface biotinylation and detection of collectrin and 
B
0
AT3 was carried out as indicated (section 2.1.6). Molecular weight markers (in kDa) are 
indicated on the left, detected proteins are indicated on the right. No TP = No Transporter. F) 
Uptake of 100 µM L-[
14
C(U)]lactate by wildtype and mutated MCT-B
0
AT3 tandem 
constructs. Lactate uptake for all conditions was normalised to lactate uptake of wildtype 
MCT-B
0
AT3 expressing oocytes from the same batch (i.e. either with or without collectrin). 
Each bar represents mean ± S.D. (n = 10, e = 3). No difference at the p = 0.05 level was 
detected for lactate uptake between MCT-B
0
AT3 WT and any MCT-B
0
AT3 mutant.  
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expressed with collectrin (Fig. 4.5A). Furthermore, it is localised and fully expressed at the 
plasma membrane (Fig. 4.5B). N283D can be classified as a type 2 mutant: it lacks surface 
expression and activity when co-expressed with collectrin, but is re-activated in MCT-B
0
AT3 
by the presence of collectrin (Fig. 4.5B and 4.5C). The TM1α mutant B0AT3D21N is also 
type 2 but with opposite effect. It consistently shows higher surface expression when co-
expressed with collectrin, but shows WT-like activity when expressed in the tandem 
construct in the presence of collectrin. Thus both D21N and N283D change trafficking, but 
display WT-like activity in the tandem construct. Both of these mutants are likely to interact 
with collectrin.  
 
A mix between type 2 and 3 is represented by R225T; the mutant has an almost complete loss 
of surface expression, but regains limited activity in the auto-trafficking MCT-B
0
AT3 
construct in the presence of collectrin (Fig. 4.5B and 4.5D). Another type 2/3 mutant is 
B
0
AT3Q25V, which is partially active in the presence of collectrin despite having a strong 
trafficking defect, as shown by western blotting after surface biotinylation (Fig. 4.5B and 
4.5E). However, transport activity of MCT-B
0
AT3Q25V was even lower in the presence of 
collectrin, suggesting that Q25 is also important in the catalytic activation by collectrin. In 
most transporters of the SLC6 family Q25 is an acidic residue (D or E). Replication of the 
negative charge [B
0
AT3Q25D] caused a total loss-of-function in both B
0
AT3 and the tandem 
construct when co-expressed with collectrin (Fig. 4.5E). Membrane expression was 
consistent across all mutants in the tandem construct as ascertained by L-[
14
C (U)]Lactate 
uptake (Fig. 4.5F). 
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4.2.4 Interactions with syntaxin-1A and syntaxin 3 
Protein-protein interactions with single-pass trans-membrane helical chaperones or ancillary 
proteins is a common feature in the SLC6 family [398]. Syntaxin 1A, in particular, has been 
shown to interact with a number of neurotransmitter transporters [398]. We therefore 
wondered whether the collectrin binding region identified here represents a common 
interaction site. The γ-amino-hydroxybutyric acid (GABA) transporter GAT1 (SLC6A1) has 
been shown to interact with syntaxin 1A at aspartate residues in the N-terminus of the 
transporter [405, 407, 409], which is part of our identified collectrin binding region in B
0
AT3 
and B
0
AT1. For syntaxin and collectrin interaction experiments we utilised mouse B
0
AT1, as 
it has a larger transport signal than mouse B
0
AT3, and small, but resolvable levels of 
collectrin-independent transport activity and cell surface expression. In confirmation of 
published results, we found that the presence of murine syntaxin 1A significantly reduced rat 
GAT1-mediated GABA transport [407] (Fig. 4.6A). Co-expression of collectrin and syntaxin 
1A with rat GAT1 recovered GABA transport to a similar rate observed with GAT1 
expressed alone. When expressed with GAT1 alone, collectrin slightly, but significantly, 
increased transport activity. Similarly, B
0
AT1 transport activity - measured in the absence of 
collectrin - was virtually abolished when it was co-expressed with syntaxin 1A. Co-
expression with collectrin resulted in reconstitution of ~80% of transport observed in the 
absence of syntaxin 1A. A similar inhibition of L-alanine transport activity was observed 
when syntaxin 1A was co-expressed with B
0
AT3 and collectrin (data not shown). To 
determine the mode of action of syntaxin 1A, we titrated syntaxin 1A cRNA against B
0
AT1 
and collectrin cRNA (Fig. 4.6B). Surface expression of B
0
AT1in the presence of collectrin 
was very sensitive to expression of small amounts of syntaxin 1A. This effect could be 
reversed by increasing collectrin cRNA (Fig. 4.6C). However, this reversal required large 
amounts of collectrin cRNA (10 to 20 ng/oocyte). Notably, increasing titration of collectrin  
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Figure 4.6 Interactions between B
0
AT1, collectrin and syntaxin 1A 
Uptake measurements in Xenopus laevis were performed 4-6 days post-injection of cRNA A) 
cRNA was injected as follows: transporter = 10 ng/oocyte; collectrin = 2 ng/oocyte; syntaxin-
1A = 5 ng/oocyte. Uptake of 100 µM L-[
14
C(U)]alanine was measured over 30 mins. Each 
bar represents the mean ± S.D. (n = 10-15, e = 3). Identical lettering a, b, c (GAT1) or d, e, f 
(B
0
AT1) above individual bars indicates groupings of conditions whose differences of means 
are not statistically significant from each other at the p = 0.05 level. B) In the presence of 
collectrin cRNA at 2 ng/oocyte and of B
0
AT1 cRNA at 10 ng/oocyte, syntaxin-1A cRNA 
was titrated as indicated. Surface biotinylation was carried out with 15 oocytes/condition as 
described (section 2.1.6). Molecular weight markers (in kDa) are added to the left, the 
detected proteins are indicated on the right. C) In the presence of syntaxin-1A cRNA at 5 
ng/oocyte and of B
0
AT1 cRNA at 10 ng/oocyte, collectrin cRNA was titrated as indicated. 
Surface biotinylation was carried out with 15 oocytes/condition as described (section 2.1.6). 
Molecular weight markers (in kDa) are added to the left, the detected proteins are indicated 
on the right. D) Uptake of 100 µM L-[
14
C(U)]leucine was carried out over 30 mins. For each 
condition one ancillary protein cRNA was injected at a constant amount, while the other 
ancillary cRNA was titrated as indicated. Each data point represents mean ± S.D. (n = 10-15, 
e = 3). E) Single site competitive binding curve fitting to the data collected in D). F) cRNA 
was injected as follows: B
0
AT1 = 10 ng/oocyte; collectrin = 2 ng/oocyte; all syntaxins = 5 
ng/oocyte. Uptake of 100 µM L-[14C(U)]leucine was carried out over 30 mins. Each bar 
represents mean ± S.D. (n = 15, e = 3). Identical lettering a, b, c, d, above individual bars 
indicates groupings of conditions whose differences of means are not statistically significant 
from each other at the p = 0.05 level. 
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reduced the apparent molecular weight of B
0
AT1 from about 80 kDa to 65 kDa (Fig. 4.6C). 
L-leucine uptake rates of B
0
AT1 confirmed the suppression of B
0
AT1-mediated activity by 
syntaxin 1A in the presence of collectrin (Fig. 4.6D). Functional recovery was observed when 
the amount of collectrin cRNA was increased, confirming competition between both ancillary 
proteins. The inhibition of B
0
AT1-mediated transport activity fitted well to a single 
competitive binding site equation (Fig. 4.6E). While our data suggest competition for a 
common binding site between collectrin and syntaxin-1A, the cellular expression of both 
proteins does not overlap [391]. Database searches comparing tissue-specific E.S.T. 
expression data (http://www.ncbi.nlm.nih.gov/unigene) and literature searches [545, 546], 
however, identified several syntaxin isoforms (3, 4, 7 and 17) with overlapping expression to 
B
0
AT1 and/or collectrin. Co-expression experiments showed strong inhibition of B
0
AT1 + 
collectrin activity by syntaxin 3, while syntaxin 7 had no effect (Fig. 4.6F). 
 
To confirm syntaxin 1A and 3 inhibition of B
0
AT1-mediated leucine uptake in a different 
expression system, we generated stably transfected CHO cells expressing human B
0
AT1 and 
human collectrin. CHO-SLC6A19-collectrin cells showed a significant increase in the 
sodium-dependent uptake of leucine above CHO parental cells (Fig. 4.7A). Expression of 
both B
0
AT1 and collectrin was confirmed by Western blotting and immuno-detection in 
whole membrane preparation (Fig. 4.7B). CHO parental cells exhibited no B
0
AT1 or 
collectrin expression (Fig. 4.7B). As observed in oocytes, transient expression of either 
syntaxin 1A or syntaxin 3 in CHO-SLC6A19-collectrin cells significantly reduced sodium-
dependent uptake of leucine compared to pcDNA3.1+ vector only controls (Fig. 4.7C, left 
panel). We also discovered that both syntaxin 1A and 3 are endogenously expressed in CHO-
SLC6A19-collectrin cells (Fig. 4.7D). If competition between collectrin and syntaxin occurs, 
we reasoned that silencing of endogenous syntaxin would increase B
0
AT1-mediated leucine 
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uptake. Accordingly, RNAi against both syntaxin 1A and syntaxin 3 led to an increase in 
sodium-dependent leucine uptake (Fig. 4.7C, right panel). Simultaneous RNAi of both 
mRNAs had a small accumulative effect on sodium-dependent uptake. RT-PCR analysis 
confirmed significant reduction of syntaxin 1A and syntaxin 3 mRNA after siRNA 
transfection (Fig. 4.7D).  
4.3 Discussion 
In this chapter it is reported for the first time that collectrin is not only required for trafficking 
of B
0
AT1 and B
0
AT3 to the plasma membrane, but also for catalytic activation. It is also 
confirms experimentally, for the first time, that human B
0
AT3 is an inactive protein. A lack 
of activity of human B
0
AT3 in X.laevis oocytes does not entirely exclude the possibility the 
transporter may be activated by other means: either another ancillary protein or specific 
membrane lipids. However, several mouse to human B
0
AT3 mutations studied here (see 
Table 4.1), were by themselves significantly detrimental to mouse B
0
AT3 activity – further 
suggesting the accumulation of these mutations in human B
0
AT3 would likely result in a non-
functional transporter. Furthermore, the non-functionality of human B
0
AT3 is consistent with 
PAT2 replacing B
0
AT3 as the primary renal glycine/alanine transporter in humans [132]. It 
also explains the absence of glycinuria in humans with homozygous nonsense mutations in 
B
0
AT3 [177] (section 1.3.5).  
 
 Moreover, we report the localisation of a collectrin interaction region in B
0
AT3, positioned 
in a groove between TM 5 and 7 of the transporter, which also contains TM1α in all 
experimentally isolated structural conformations of the SLC6 transporters [192-194, 198, 199, 
547]. Interestingly, the groove suggested here to harbour collectrin, is occupied by a 
cholesterol molecule in the DAT outward open structure [198]. The authors suggest 
cholesterol may stabilise the transporter in the outward open conformation, which is  
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Figure 4.7 Syntaxin 1A and syntaxin 3 inhibit B
0
AT1 activity 
A) Uptake of 100 µM L-[
14
C(U)]isoleucine was measured over 6 mins in CHO parental and 
CHO-SLC6A19-Collectrin cells in either Hank's buffered saline (Na
+
) or with NMDG 
replacing sodium (NMDG). Each bar represents mean transport activity ± S.D. (n = 3, e = 3, 
*** indicates p < 0.0005). P-values were calculated in comparison to Na
+
-independent uptake 
condition (NMDG). B) Immunodetection of B
0
AT1 and collectrin in whole membrane 
preparations of CHO parental and CHO-SLC6A19-Collectrin cells; 20 µg of total protein was 
loaded into each well. Molecular weight markers (in kDa) are indicated on the left, detected 
proteins are indicated on the right. C) CHO-SLC6A19-Collectrin cells were transfected with 
3 µg of pcDNA3.1+ vector DNA encoding the indicated murine syntaxin gene 
(overexpression, left panel), or were treated with 50 pmoles of siRNA against the CHO 
endogenous syntaxins (RNAi, right panel). Uptake of 100 µM L-[
14
C(U)]leucine was 
measured in CHO-SLC6A19-Collectrin cells over 6 mins in either Hank's buffered saline 
(Na
+
) or with NMDG replacing sodium. The ratio of net sodium-dependent/sodium-
independent uptake for each uptake condition was normalised to the pcDNA3.1+ vector-only 
control (overexpression) or scrambled siRNA (RNAi). Each bar represents mean ± S.E.M. (n 
= 3, e = 3, *** indicates p < 0.0005, ** indicates p < 0.01, * p < 0.05). P-values were 
calculated as differences from control conditions, vector only (overexpression) or scrambled 
(RNAi).  D) Levels of syntaxin 1A and syntaxin 3 mRNA transcripts were estimated by RT-
PCR with 25 cycles of amplification. Closed bars represent control samples using scrambled 
RNAi, open bars show the effect of specific RNAi. Samples were run on agarose gel and 
quantification was made relative to clathrin mRNA expression in the same sample. Each bar 
represents mean ± S.E.M. (e = 3, *** indicates p < 0.0005). P-values were calculated in 
comparison to scrambled conditions. 
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consistent with functional studies of the human serotonin transporter [548]. We would thus 
propose that collectrin and syntaxin isoforms can occupy this binding site, increasing or 
inhibiting transport activity, respectively. In the occluded structure of LeuT, TM1α and the 
cytoplasmic end of TM5 are in contact, but become separated during the transition to the 
cytoplasmic-facing conformation [194, 198, 204, 207, 547]. If collectrin would reduce the 
activation energy of the transporter’s rate-limiting step it could speed up the transport cycle at 
this step (see section 6.2.4 for further discussion). Syntaxin isoforms by contrast could 
stabilize transporter conformations other than the rate-limiting transition state, thereby 
slowing transport. Syntaxin 3 could have a physiological role in regulating the transporter by 
displacing collectrin and thus inhibiting B
0
AT1. 
 
Our results demonstrate a dual role of collectrin. It is required for trafficking of the 
transporter to the cell surface and is required for the catalytic activity. Both functions can be 
separated. L213W is involved in the catalytic activation of the transporter although it is 
located > 10 Å from the ionic radii of the second sodium binding site (Cα-Na
+
 distances) in 
the DAT-based outward open homology model; and even further away from all other 
predicted ion/substrate binding sites. Interestingly, L213W lies within the B
0
AT3 TM5 
(G205-X9-P215) motif, proposed to facilitate the outward to inward occluded transition of 
SLC6 transporters during the transport cycle (see section 6.2.4). It must be noted L213W 
could also plausibly affect B
0
AT3 catalytic activity independently of collectrin. However, all 
Type 2 mutants N283D and D21N, on the other hand, selectively affect trafficking to the cell 
surface. The remaining non-functional mouse B
0
AT3 mutants, the previously identified 
R225T (R240Q in B
0
AT1) [169] and Q25V, were classified as type 2/3 and appear to be 
involved in both collectrin-mediated functions. Alternatively, the small but significant 
reduction of the B
0
AT1 molecular weight, when co-expressed with collectrin (see, for 
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example, Fig. 4.6C) may be associated with its activation. The mechanism of this activation 
remains to be elucidated, but may involve recruitment of additional proteins. Indeed, 
collectrin has been shown to indirectly associate with a wide variety of SNARE, cytoskeletal, 
vesicular trafficking and kidney epithelial polarisation proteins in yeast-two hybrid screens 
and co-immunoprecipitation studies [329, 338, 342, 343].  Interpreting functional modulation 
in the protein-protein interaction context requires a fuller knowledge of the composition, 
stoichiometry and, particularly, the structure of such complexes. It cannot be ruled out that 
neither collectrin nor syntaxin directly bind to B
0
-like transporters. They may interact 
indirectly through other proteins, although there is evidence for direct interaction and co-
localisation between B
0
AT1, collectrin, and ACE2 from mouse kidney and intestinal 
epithelial tissue [175, 496]. It might be expected that the  research on other SLC6 ancillary 
proteins such as syntaxin 1A, could give insight into the structure of B
0
-like heteromeric 
interactions (for a review see [398]). However, a lack of structural knowledge extends to all 
SLC6 heteromeric interactions. 
 
In contrast to collectrin, syntaxin 1A mediates an opposing bi-functional effect [398]. It 
enhances trafficking of GAT1 to the surface, but at the same time reduces its activity. 
Syntaxin 1A-dependent decreases in GAT1 (SLC6A1) turnover are thought to be the result of 
an interruption of the interaction between the IL4 loop and TM 1α of GAT1 by the H3-TM 
domains of syntaxin 1A (residues 188-288) [405, 409]. The IL4 loop of GAT1 inhibits 
GABA transport via an arginine-rich domain and competes with syntaxin 1A for binding to 
the transporter’s N-terminal domain [405]. Only Arg420 in human GAT1 (Lys455 in human 
B
0
AT1) is conserved across SLC transporters in the IL 4 region and we did not investigate 
the role of the IL4 region in the B
0
-like transport/collectrin interaction. The H3 and C-
terminal TM domains also represents the interaction region for syntaxin 1A to other SLC6 
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transporters, including serotonin transporter SERT [405, 409, 549], the norepinephrine 
transporter NET [399] and a C. elegans dopamine transporter DAT-1 [397]. The results 
presented here also suggest binding of syntaxin’s TM domain to a grove between helix 5 and 
7 of SLC6 transporters. The transporter interactions and vesicular fusion roles of syntaxin 1A 
seem to be independent molecular events as the C-terminal TM domain is removed from 
numerous crystal structures of syntaxin 1A-containing SNARE complexes (see [392]). 
Furthermore, other brush border transporters shows direct syntaxin 1A binding occurs via the 
H3-TM domains independently of syntaxin-mediated vesicular fusion [550]. Several lines of 
evidence are converging to establish the N-terminal domain of SLC6 transporters as a key 
domain in establishing conformational equilibrium and controlling intra-cellular gating [551-
553]. This raises the possibility that ancillary proteins like collectrin and syntaxins function to 
lower or increase the activation energy of conformational transitions in the SLC6 transport 
cycle (section 6.2.3).  It is unknown if syntaxin 3’s role in the trafficking of membrane 
transporters to epithelial brush border membranes involves the same TM and H3 domains 
[554, 555].  
 
These results also offer an explanation why ACE2 cannot compensate for the loss of 
collectrin in the renal proximal tubule of collectrin knock-out mice (section 4.1). The 
proteolysis of ACE2 by ADAM-17 occurs between Arg708-Ser709 in human ACE2 [385], 
equivalent to removing the N-terminal extracellular domain of collectrin. Confirmation that 
removal of these regions of collectrin and ACE2 would disrupt catalytic activation of B
0
-like 
transporters is still required (Chapter 5). 
  
The interactions between collectrin and the B
0
-like transporters cannot involve canonical 
coiled-coil domains as these are absent in collectrin. It may, however, involve different 
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stoichiometric combinations with collectrin and/or an association between SNARE proteins 
as has been described in pancreatic β-islet cells [338, 343, 556]. One unexplained aspect of 
the effect of catalytic activation by collectrin of B
0
AT3 is the significant increase in substrate 
affinity when the transporter is auto-trafficked to the plasma membrane as part of the MCT-
B
0
AT3 fusion construct. This construct could have an effect on the overall conformation of 
the transporter resulting in a slight change of the on- or off-rates of transporter substrates, 
which in turn would alter the affinity. 
 
In light of its dual role and identified binding region, collectrin should now be viewed as an 
essential subunit of a heteromultimeric secondary active transporter, rather than simply as an 
ancillary protein or chaperone. 
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Chapter 5: Molecular Analysis of Collectrin 
The results of this chapter are unpublished with the exception of Figure 5.5B, which was 
originally published in the article forming the basis of Chapter 4 of this thesis. 
 
5.1 Introduction 
Collectrin is an important protein in multiple physiological processes including insulin 
secretion and the development of hypertension (section 1.5.1). Foremost among these is its 
necessity and sufficient role in the trafficking and catalytic activation of the epithelial amino 
acid B
0
-like transporters (chapter 4, [175, 178]). Despite the identification of a putative 
collectrin binding site in B
0
-like transporters (section 4.2.3), little is known about the domains 
of collectrin itself mediating heteromer formation. It has been reported that the cytosolic C-
terminus of collectrin, adjacent to its TM domain, mediates interaction with B
0
AT1, yet no 
evidence for this has been provided [557]. This hypothesis attributes single amino acid 
changes in the C-terminus of mouse and human collectrin orthologs as the basis for the 
putative inability of mouse collectrin to activate human B
0
AT1. Our discovery of a collectrin 
binding site in the cavity formed between TM5 and TM7 in B
0
AT3 suggests a significant role 
for collectrin’s TM domain in transporter interaction (section 4.2.3).  
 
Structure-function analysis of collectrin has been confined to its pancreatic β-islet cell 
physiology, where it undergoes various post-translation interactions and modifications [342, 
344, 558]. Dimerization of collectrin in β-islets is mediated through disulphide cytosolic 
residue Cys186 [344], even though the cytosolic environment of eukaryotic cells is generally 
a reducing one [559]. In addition, collectrin interacts indirectly with SNARE proteins in the 
pancreas, mediated through binding of the SNARE-associated protein snapin to its C-terminal 
domain [343]. Collectrin is proteolytically processed by the β-amyloid protease Bace2 at 
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residues F116, L118 and F125 in its extracellular N-terminal domain [558]. No other cleaved 
isoforms of collectrin have been detected in the kidney, although collectrin has been detected 
in exosomes secreted from human kidney collecting duct cells into urine [560, 561]. It is 
unknown if any this β-cell post-translational processing is relevant to collectrin’s role as a 
B
0
AT1 or B
0
AT3 subunit. 
 
A full understanding of the B
0
AT1-collectrin complex would require purification, followed 
by biophysical and structural studies. However, the study of membrane proteins is 
significantly hampered by the technical difficulties of membrane protein purification [562-
564], made even more challenging for membrane protein complexes [565]. An alternative 
approach is predicting protein-protein interaction sites using structure-based or sequence-
based in silico techniques, made viable due to the explosion in sequence database size, 
computational power, and accuracy [566-570]. Structure-based in silico approaches use 
information from one protein complex partner, or the protein-protein interaction of known 
homologues, as a template [566, 571-573]. However, these methods are of limited use for 
membrane protein interactions due to the paucity of available experimental structures [574], 
especially when no known homologue structures exist, as is the case for collectrin. On the 
other hand, strictly sequence-based interface prediction methods have lower accuracy than 
structure-based methods due to an absence of relative spatial positioning information: where 
residues making close intramolecular contacts in space may be far apart in a protein sequence 
[566, 570, 575]. Furthermore, most prediction methods are validated using a positive control 
set (i.e. known protein-protein interfaces) few have been used to predict experimentally 
verified interfaces.    
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In principle, these shortcomings can be overcome by combing phylogenetic analysis with 
algorithms optimised to search for functional motifs and then verifying any predictions by 
experimentation. Correlating putative functional motifs to sequence conservation using a 
multiple sequence alignment (MSA) amounts to ‘fingerprinting’ protein regions for specific 
functional conservation [576].  It is an analogous approach to direct statistical coupling 
(DSC), which identifies functional clues from an MSA using statistical correlation and 
conservation scores [570]. The main difference being that statistical correlation analysis is 
replaced by a series of protein motif likelihood algorithms. Assessing the conservation of 
putative motifs across a protein’s phylogeny is increasingly attractive due to the increasing 
reliability and accuracy of functional motif prediction algorithms. A need for updated and 
accurate functional motif prediction is required for collectrin as the only in silico annotation 
of the protein is now over 15 years old [323, 334]. As an example of earlier inaccuracies, 
collectrin was initially and incorrectly predicted to be localised to the cytoplasm [323]. 
 
The interaction between collectrin and B
0
-like transporters is also attractive for a motif-based 
fingerprinting analysis as amino acid residues mediating stable protein-protein interactions 
evolve at slower rates than other protein regions as they are under stronger positive selection 
pressure [577, 578]. Recent evidence showing the ability to traffick B
0
AT1 is conserved in 
distant collectrin fish orthologs demonstrates the B
0
AT1-collectrin interaction is under strong 
positive selective pressure [579, 580]. Therefore, correlating highly conserved regions of 
collectrin with putative motifs identifies residues potentially involved in conserved 
interactions with B
0
-like transporters. This identification can be verified using the deletion 
and mutation of highly conserved motifs and residues for its effect on B
0
-like transporter 
activity and trafficking. It should be pointed out however, if heteromeric proteins possess 
novel interaction motifs or domains which lack database entries, than known putative motifs 
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are not likely to positively correlate with functional assays assessing their role in protein-
protein complex formation.  
In the current study we explored the major sequence determinants of collectrin as an ancillary 
transporter subunit using this combined bioinfomatic and experimental approach. In the 
process we elucidate multiple conserved regions of collectrin which are responsible for 
interactions with the neutral amino acid transporters B
0
AT1 and B
0
AT3. Several of these 
sequence regions appear unique to collectrin and are not present in annotated databases as 
known protein motifs or PTMs.  
 
5.2 Results 
5.2.1 Generating a collectrin phylogeny using hidden Markov profiling 
Like all phylogenetic-based approaches, result quality depends on the initial accuracy of the 
Multiple Sequence Alignment (MSA).  Hidden Markov Model (HMM) based profiles offer 
the most accurate current method for establishing distant homology of a protein and accuracy 
of the resulting MSA [581, 582]. In order to identify collectrin protein motifs involved in 
transporter interactions, a Hidden Markov Model (HMM) profile was first created, followed 
by ‘fingerprinting’ protein putative linear motifs and PTMs onto this HMM-derived MSA. 
Putative hits for conserved collectrin motifs or PTMs were then analysed using experimental 
data from different collectrin orthologs and paralogs. The overall experimental strategy is 
outlined in Figure 5.1. 
 
Using human collectrin (UniProt Q9HBJ8) for the 1
st
 iteration HMM search against Swiss-
Prot and TrEMBL databases, the phmmer algorithm (HMMER v3.1) [523, 524]) identified 
134 significant homologous proteins (e-value < 0.01). Two paralogs were identified: 
collectrin (often annotated as an uncharacterised protein) and ACE2. To trace collectrin’s 
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evolutionary lineage we used total significant hits (p > 0.03) from each proceeding iteration 
as the input sequences for subsequent iterations (jackhammer algorithm). Collectrin 
sequences from a total of 4 combined HMMER iterations were filtered to remove sequence 
fragments (< 150 residues), species redundancies and non-collectrin paralogs (i.e. ACE2). 
Following filtering, the 95 remaining collectrin orthologs were checked against the OrthoDB 
and Pfam collectrin entries to verify their decent from a single ancestor and for the presence 
of any more ortholog sequences (see section 2.7.3). All collectrin orthologs identified by 
OrthoDB and Pfam were present in the filtered HMM set of 95 sequences, with a last 
common ancestor being a tunicate collectrin located in early chordates. Extracellular matrix 
proteins mucin-1 or integrin α-V were also identified in iterations 2 to 4 of the HMM, 
however, e-values for these proteins were high (i.e. low probability of homology) and their 
sequence coverage with collectrin was restricted to the TM domain (i.e. residues ~130-170). 
All HMM search parameters, hit tables, full sequence alignments (profiles), and taxonomic 
data are available on request in electronic format. 
 
All 95 filtered collectrin sequences were aligned using PROMAL3D [208]. A representative 
MSA of selected collectrin sequences, covering all major taxa, is shown in Appendix E. A 
maximum likelihood phylogenetic tree created from the combined HMM profile MSA 
emphasises the lack of traceable ancestry for collectrin before chordates and suggests an 
evolutionary origin, concurrent with the evolution of this phylum (Fig. 5.2). Convergence of 
collectrin sequences, following identical filtering of hits, was demonstrated using the most 
distal identified collectrin ortholog from the tunicate Oikopleura dioica as the initial input 
(data not shown). Through 4 iterations of HMMER searches and filtering no new collectrin 
orthologs were identified – further illustrating the probable chordate origin of collectrin.   
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Figure 5.1 Strategy for identifying putative transporter interaction sequences in 
collectrin 
A dual in silico approach (top) was used to establish collectrin’s phylogeny and to screen for 
putative motifs and post-translation modification (PTM) sites. The input for both approaches 
was human collectrin. Putative collectrin homologs based on HMM profiling were filtered as 
described (section 2.7.3), leaving 95 unique collectrin ortholog sequences. Putative linear 
motifs and PTMs were filtered based on consensus hits across multiple algorithms (section 
2.7.4). Once filtered to a manageable number, the phylogenetic and putative motif predictions 
were combined and tested against experimental data (bottom), such as activity of serial 
truncations of collectrin and ability of collectrin orthologs and paralogs (ACE2) to cross-react 
with B
0
AT1. The aim was to identify (fingerprint) regions of collectrin involved in its 
functional interactions with the epithelial amino acid transporters, B
0
AT1 and B
0
AT3. MSA 
= Multiple Sequence Alignment. 
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Figure 5.2 Phylogenetic tree of collectrin orthologs 
The phylogenetic tree (circle representation) was created using MEGA v7.0.14 [583] using a 
maximum likelihood method (section 2.7.5). The tree with the highest log10 likelihood (-
13644.0997) is shown. The analysis involved 95 amino acid sequences identified by 
comparison to a collectrin HMM profile following filtering for redundancy, fragment 
sequences and non-collectrin paralogs. All positions containing gaps and missing data were 
eliminated. There were a total of 325 positions in the final dataset. Scale bar = 0.2 amino acid 
substitutions per site. The tree is unrooted, however common decent of all collectrin 
orthologs was verified using OrthoDB and Pfam. The tree is subdivided by colour into 
chordate taxa: birds (magenta), reptiles (indigo), mammals (green), amphibians (yellow), 
which are classes, the paraphyletic group fish (orange), and chordate subphylum tunicates 
(red). Selected collectrin orthologs from the Hidden Markov Model profile MSA (Appendix 
E) are named in their respective positions.    
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5.2.2 In silico identification and conservation of linear motifs and PTMs in collectrin 
A topology model for collectrin was generated from a consensus of trans-membrane 
orientation and secondary structure prediction algorithms (Appendix F, Table 5.1). In 
agreement with earlier annotation [323], all TM domain algorithms identified a membrane-
spanning α-helix between residues 140 to 167 except for DAS, an algorithm optimised for 
prokaryotic TM prediction [584]. Collectrin’s extracellular domain was predicted to contain 
long sections of ordered secondary structure, while its C-terminal cytosolic domain was 
predicted to be less ordered.   
 
The conservation scores of the collectrin MSA were represented as a heat-map on this 
topology model of human collectrin (Fig. 5.3A). Overall, sequence coverage and 
conservation are high across collectrin, with slightly more sequence divergence observed in 
the cytosolic C-terminal. To fingerprint the conserved features of collectrin, the human 
sequence was run through multiple functional and structural motif prediction algorithms. As 
the human collectrin and B
0
AT1 interaction is highly conserved [580], it was rationalised that 
strongly scoring and consensual putative linear motifs or PTMs may mediate this heteromeric 
interaction.   
 
Using 83 search algorithms, 49 putative functional motifs in human collectrin were identified 
(Appendix F, Table 5.2). Only 12 putative motifs or PTMs displayed consensus across 
multiple algorithms searching for the same motif. These consensus motifs and PTMs were 
mapped onto the topology model of human collectrin (Fig 5.3B). Consensus was observed for 
N-linked glycosylation sites at Asn76 and Asn93, in addition to cytosolic phosphorylation 
sites at Thr214, Ser177, and, less frequently, at Thr220. Several databases have also manually 
annotated Thr214 and 220 as phosphorylated: inferred from sequence similarity to mouse  
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collectrin (UniPROT Q9ESG4) and based on phospho-proteomic evidence [585, 586].  Other 
PTMs displaying consensus, or near consensus, predictions include a ε-amino (lysine-linked) 
glycation residue at Lys38, and a N-acetylgalactosamine (O-linked) site at Thr78. A potential 
PDZ binding domain at collectrin’s C-terminus (217-222 or 218-222) was also identified. 
This is notable as several SLC6 transporters also contain C-terminal PDZ-binding domains 
[587-589], which is absent in B
0
AT1 and B
0
AT3. Putative dibasic convertase (170-172) (E.C. 
3.4.24.61) and PCSK family (32-36) (E.C. 3.4.21) protease cleavage sites were predicted in 
addition to the already confirmed Bace2 cleavage sites [558]. As confirmed by our manual 
observation (section 4.3), we found little evidence for canonical SNARE-forming coiled-coil 
domains, which require a ~60 residue long linear sequence of heptad repeating α-helical 
coiled-coils. 
 
Sequence conservation of >80% from the HMM-derived MSA (Fig. 5.3A) and putative motif 
search of human collectrin (Fig.5.3B) were combined to identify putative functional motifs or 
PTMs as potential mediators of collectrin’s interactions with B0-like transporters (Fig. 5.3C). 
Three of the 12 consensus putative motifs or PTMs were not conserved at >80% in collectrin 
orthologs: phosphorylation sites at Ser177, Thr214, and the ε-amino glycation site at Lys38.  
These PTMs were removed from subsequent analysis. Several residues in the putative PDZ-
binding domain site (L218 and P220) and R32 in the putative PCSK cleavage site were 
not >80% conserved. However, both of these motifs have allowable redundancies in positions 
where conservation was not >80% [590-592]. 
 
5.2.3 Collectrin motifs involved in interactions with B0-like transporters 
To narrow down which of the remaining 9 conserved putative sequence features of collectrin 
could potentially be involved in transporter interactions, functional cross-referencing 
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Figure 5.3  Conservation of collectrin putative motifs and PTMs 
A topology model of human collectrin was created using consensus TM domain predictions 
(Appendix F, Table 5.1) and visualised using TOPO2 (section 2.7.2). A) Conservation was 
calculated from the 95 remaining HMM collectrin orthologous sequences, filtered for 
redundancy, fragment sequences, and non-collectrin paralogs (i.e. ACE2). The final 
alignment was verified using OrthoDB and Pfam (section 2.7.3).  Sequences were aligned 
using PROMAL3D (section 2.7.5). The percentage of conservation from human collectrin 
was calculated using BioEdit and coloured using a 300 RGB red shaded scale. B)  All 
sequence features represent consensus identifications from in silico analysis of human 
collectrin (UniPROT Q9HBJ8). A full list of algorithms used to identify features can be 
found in Appendix F (Table 5.2).  Putative consensual motifs and PTM sites are colour coded 
according to the figure legend. C) Conservation at >80% across collectrin orthologs (A) and 
putative sequence features (B) were combined. Colour coding of conserved putative motifs 
and PTMs is the same as those in B.  
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experiments were used (see Fig. 5.1). The effects on B
0
-like transporter activity of truncated 
and mutated collectrin were combined with ortholog-specific experimental evidence on 
collectrin and cross-referenced against the collectrin HMM profile MSA.  
 
To examine if any of the 9 conserved putative features could be eliminated as mediating B
0
-
like transporter interaction low resolution deletions of collectrin’s extracellular and cytosolic 
domains were created (Fig. 5.4A). A total N-terminal domain truncation (collΔ15-135) 
reduced mouse B
0
AT3-mediated L-alanine uptake to basal levels, when uptake by collΔ15-
135 expressing controls was subtracted. A truncation of collectrin’s C-terminal domain 
(collΔ175-221) retained ~40% of L-alanine uptake compared to wild-type collectrin co-
expressed with B
0
AT3. B
0
AT3 was not detected at the plasma membrane when co-expressed 
with collΔ15-135, while surface expression of B0AT3 with collΔ175-221 is reduced, 
consistent with B
0
AT3 transport activity (Fig. 5.4B). Total B
0
AT3 expression was almost 
unchanged between oocytes co-expressing either collΔ175-221 or WT collectrin. In contrast, 
B
0
AT3 was almost entirely absent from total membranes when co-expressed with collΔ15-
135. Together, these results suggest a lack of collectrin’s N-terminal may facilitate B0AT3 
degradation, while the C-terminal domain of B
0
AT3 impairs trafficking to the plasma 
membrane. 
 
Next, collectrin truncations were created to systematically isolate the role of the 9 conserved 
motifs and PTMs in B
0
-like transporter interactions. Increasing the molecular resolution of 
collectrin-specific interactions using these truncations demonstrated a positive correlation 
between B
0
AT3-mediated L-alanine uptake and plasma membrane expression of B
0
AT3 (Fig. 
5.4C). B
0
AT3 co-expressed with the collectrin truncations Δ41-65, Δ66-90,  
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Δ179-195, Δ196-212, and Δ213-221 (Fig. 5.4D) showed no significant reduction in either L-
alanine uptake or plasma membrane expression. These truncations contain the putative N-
glycosylation PTM at N76, O-glycosylation site T78, ubiquitination site K204, 
phosphorylation site T220, and the C-terminal PDZ-binding domain – thereby eliminating 
them as mediating the formation of B
0
AT3-collectrin complexes. In contrast, B
0
AT3 co-
expressed with the N-terminal domain truncations collΔ2-14, collΔ15-40, and collΔ116-135, 
showed significantly reduced L-alanine transport and surface expression. A small reduction 
was also observed for co-expression with collΔ91-115 in both transport activity and 
membrane expression. A truncation deleting the α-helix domain and adjacent regions, 
collΔ136-174, displayed no B0AT3-mediated activity or plasma membrane expression. One 
collectrin truncation which could not be studied was collΔ163-178. Oocytes co-injected with 
this cRNA died after 3-4 days of expression. Necrosis was sudden with oocytes relatively 
healthy until 3 days post-injection.   
 
To examine if the decreased B
0
AT3 activity was due to direct collectrin-transporter 
interaction or just the stability of collectrin truncations, total membrane expression of each 
truncation was tested in the presence of B
0
AT3 (Fig. 5.4E). B
0
AT3-mediated L-alanine 
uptake with collΔ2-14 and collΔ116-135 is consistent with the reduced expression of these 
two proteins. It is unlikely this reduced expression results from a lack of anti-collectrin 
antibody recognition as both truncations represent only a small region of the collectrin 15-
144 residues used as the immunogen for antibody rearing (Table 2.2). The absence of collΔ2-
14 protein is consistent with the N-terminal’s role as an ER translocation signal peptide (see 
Appendix F, Table 5.2). In contrast, collΔ15-40 and, Δcoll91-115 are stable but have  
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Figure 5.4 The effect of collectrin truncations on transporter activity and expression 
Xenopus laevis oocytes were injected with 10 ng of the indicated transporter and 2 ng of full-
length collectrin or truncated collectrin cRNAs. All measurements were made 4-6 days post-
injection of cRNA. A) Uptake of 100 µM L-[
14
C(U)]alanine was carried out over 30 mins. 
Each histogram bar represents mean ± S.D. (n = 10, e = 3). Identical lettering a, b, c, above 
individual bars indicates groupings of conditions whose differences of means are not 
statistically significant from each other at the p = 0.05 level. B) Plasma membrane or total 
membrane detection of collectrin, its deletion variants and B
0
AT3 was carried out as 
described (sections 2.1.6 and 2.1.7). Molecular weight markers (in kDa) are indicated on the 
left, detected proteins are indicated on the right. C) Uptake measurements were conducted as 
in A) with each data point representing mean ± S.E.M. (n = 10-12, e = 3). Plasma membrane 
expression of B
0
AT3 was determined by western blotting. Plasma membrane blots were 
quantified by surface area integration using Image J v1.43, with each data point representing 
mean ± S.E.M. (n = 15, e = 3). Data on both axes was normalised to B
0
AT3 + collectrin WT 
expressing oocytes (Pearson’s r = 0.98). The trend line was fitted using linear regression (R2 
= 0.92). D) A topology diagram of mouse collectrin is shown outlining the position of 
truncations made to the protein sequence. E) Total membrane and F) plasma membrane 
detection of collectrin truncations in the presence of B
0
AT3, ladders and detected proteins are 
labelled as indicated. B
0
AT3 is also detected in F) for several collectrin truncations.  
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impaired plasma membrane expression (Fig. 5.4F), indicating these regions of collectrin are 
directly or indirectly involved in transporter trafficking to the plasma membrane. For 
collectrin N-terminal truncations where B
0
AT3 expression was examined, no corresponding 
decrease in B
0
AT3 stability was observed that mimicked the same effect observed when 
B
0
AT3 was co-expressed with the whole N-terminal truncation of collectrin (see Fig 4.B). 
 
Unexpectedly, the truncation of collectrin’s TM domain (collΔ136-174) was stably expressed 
and detected at 38 kDa, presumably as a soluble protein (see Fig. 4C). No B
0
AT3-mediated 
L-alanine transport or plasma membrane expression was detected in the presence of this 
truncation. There was little correlation between the expected and observed M.W. reduction of 
the collectrin truncations Δ66-90 and Δ91-115, suggesting the presence of large PTMs, 
possibly carbohydrate chains, which are not involved in transporter interactions. Together 
these collectrin truncations indicate residues 15-40 and 116-178 as potentially important for 
stability, trafficking and/or catalytic activation of B
0
AT3. These regions contain the 
conserved putative PCSK and dibasic convertase proteolytic cleavage sites in addition to the 
TM domain and long stretches of unannotated conserved sequence. The remaining 7 of 9 
conserved motifs and PTMs identified following fingerprinting can be eliminated as they lie 
in regions of collectrin whose deletion had no effect on B
0
AT3 activity and surface 
expression.  
 
The regions 15-40 and 116-178 of collectrin containing putative PCSK and dibasic 
convertase proteolytic cleavage sites were further interrogated by using collectrin ortholog 
and paralog cross-reactivity with B
0
-like transporters. Margheritis and colleagues [579, 580] 
have demonstrated human B
0
AT1 can be chaperoned to the plasma membrane by collectrin 
orthologs as phylogenetically distant as salmon and sea bass. Surprisingly they also reported 
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that mouse collectrin cannot perform the same function [557, 580]. In contrast, I found that 
mouse collectrin effectively trafficks human B
0
AT1 and vice versa human collectrin trafficks 
mouse B
0
AT1 (Fig. 5.5A). In addition, the activation of mouse B
0
AT1 L-leucine transport by 
a ACE2 truncation (Δ18-580) retaining only its collectrin homologous region was unchanged 
compared to full-length ACE2 (Fig. 5.5B). These results confirm the homologous regions of 
collectrin orthologs and ACE2 are responsible for interactions with B
0
-like transporters. Of 
the two remaining putative motifs within collectrin’s 15-40 and 116-179 regions, both the 
PCSK and dibasic convertase protease cleavage sites are conserved in cross-reactive 
collectrin orthologs and the homologous region of ACE2 (Fig. 5.5C). In addition, 25 amino 
acid residues are conserved in the HMM profile of cross-reactive collectrin orthologs and 
homologous region of ACE2. Another 15 residues were identified as conserved by chemical 
identity e.g. S/T, R/K, I/L/V, mostly within the TM domain. These results suggest the 
transporter interface region of collectrin may be large, involve multiple interactions, and 
possibly involve motifs previously unidentified in annotation databases. 
 
5.2.4 Screening for conserved transporter interacting residues in collectrin 
The putative dibasic convertase protease recognition site, adjacent to collectrin’s TM domain 
and represented within 169-RRR-17, motif is conserved across all cross-reactive collectrins 
and lies within the collΔ163-178 truncation, which had a necrotic effect on oocytes. Single 
and double dibasic mutations of collectrin at R169, R170, and R171, however, displayed no 
effect on B
0
AT1-mediated transport, substrate-induced sodium currents, or surface 
expression (Figs. 5.6A and 5.6B). Similarly, no effect was observed when collectrin dibasic 
mutants R169T or R170-171T were co-expressed with B
0
AT3 (data not shown).  
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Figure 5.5 Filtering collectrin interacting sequences using ortholog and paralog 
cross-reactivity 
All measurements were made 4-6 days post-injection of cRNA. A) Xenopus laevis oocytes 
were injected with 10 ng cRNA/oocyte of the indicated B
0
AT1 ortholog and 2 ng of 
collectrin ortholog cRNA/oocyte. Uptake of 100 µM L-[
14
C(U)]leucine was carried out over 
30 mins. Each histogram bar represents mean ± S.D. (n = 10). Identical lettering a, b, c, 
above individual bars indicates groupings of conditions whose differences of means are not 
statistically significant from each other at the p = 0.05 level. B) B
0
AT1 was co-expressed 
with truncated (Δ18-500 or Δ18-580) or wildtype ACE2. ACE2 was injected at 10 ng/oocyte 
for WT protein, with ACE2 deletions injected at 3.8 ng/oocyte (Δ18-500) or 2.8 ng/oocyte 
(Δ18-580) to maintain 1:1 stoichiometric equivalence with B0AT1. Uptake was measured as 
in A) (n = 10-12, e = 3). Identical lettering a, b above individual bars indicates groupings of 
conditions whose differences of means are not statistically significant from each other at the p 
= 0.05 level. C) Collectrin ortholog and ACE2 sequences were aligned using PROMAL3D 
(section 2.7.5) and edited using BioEdit v7.1.9.  
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Figure 5.6 Screening conserved transporter interacting residues in collectrin 
Xenopus laevis oocytes were injected with 10 ng/oocyte of transporter or transporter mutant 
cRNA. All collectrin variants were injected at 2 ng of cRNA/oocyte. All measurements were 
made 4-6 days post-injection of cRNA. A) Uptake of 100 µM L-[
14
C(U)]leucine was carried 
out over 30 mins. Each histogram bar represents mean ± S.D. (n = 10, e = 3). Identical 
lettering a, b, c, above individual bars indicates groupings of conditions whose differences of 
means are not statistically significant from each other at the p = 0.05 level. L-leucine induced 
steady-state currents (insert) were recorded in oocytes voltage-clamped at −50 mV and 
superfused with 100 µM L-leucine as indicated. B) Plasma membrane protein isolation was 
carried out by surface biotinylation. Collectrin and B
0
AT1 were detected by immunoblotting. 
Molecular weight markers (in kDa) are indicated on the left, detected proteins are indicated 
on the right. C) and D) Uptake was measured as in A). Each histogram bar represents mean ± 
S.D. (n = 10, e = 2). Identical lettering a, b, c, d above individual bars indicates groupings of 
conditions whose differences of means are not statistically significant from each other at the p 
= 0.05 level. 
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The high number of conserved residues within the identified transporter-interaction regions 
of collectrin 15-40 and 116-179, suggests other, potentially novel, motifs are involved in the 
transporter-collectrin heteromer formation and function.  Salt bridges, for example, often play 
a significant role at protein-protein interfaces by stabilising the loss of solvation energy from  
water displacement with electrostatic interactions. Numerous acidic residues are conserved 
with the collectrin 15-40 and 116-179 regions which could form electrostatic pairings with 
R240 in B
0
AT1 and R225 in B
0
AT3 – previously shown to be a key residue for transporter- 
collectrin interaction independent of intrinsic transporter activity [169, 500]. Located at the 
bilayer-solvent interface on the extracellular side of the transporters, R240 would be 
accessible to the N-terminal domain of collectrin. As a result we mutated D120 and E124, 
two acidic residues from our conserved set of 25, and attempted salt bridge complementation 
with R240 in B
0
AT1 (Fig. 5.6C). Although mutating both collectrin acidic residues to 
arginine moderately decreased B
0
AT1-mediated L-leucine uptake, neither mutant recovered 
transport activity when paired with a complementary R240D or R240E transporter mutant. 
Two other strongly conserved acidic residues from collectrin region 15-40, E22 and D37, 
also significantly decreased B
0
AT1 L-leucine uptake when mutated to arginine (Fig. 5.6D). 
As with D120 and E124, however, these residues were unable to complement the activity of 
B
0
AT1R240E or R240D. Mutation of non-conserved N-terminal collectrin acidic residues 
E137 and D100 to arginine had no effect on B
0
AT1 leucine uptake (data not shown). 
Moreover, no acidic residue mutation in collectrin completely ablated transport activity in 
B
0
AT1, indicating they are not absolutely necessary for this interaction.  
 
A highly conserved but unannotated WBIBFGVB TM domain motif (where B = L, I, or V) 
also lies within the functionally important B
0
AT1 interaction modules of collectrin. 
Tryptophan 143 is predicted to sit at the bilayer-extracellular interface and could be involved 
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in cation-𝜋 interactions with cationic phospholipids and the topologically adjacent R225 in 
B
0
AT3. Mutation of collectrin Trp143 to arginine (W143R) or the more hydrophobic alanine 
(W143A) caused a significant reduction in B
0
AT3-mediated transport activity, similar to that 
observed for the B
0
AT3R225W mutant (Fig. 5.7A). However, when both the 
collectrinW143R and B
0
AT3R225W mutants were co-expressed to attempt complementation  
of function, no increase above single mutant activity was observed. Co-expression of 
collectrinW143R also had a significant, if smaller, effect on substrate uptake via B
0
AT1 (Fig. 
5.7B). As with B
0
AT3 however, complementation of collectrinW143R with B
0
AT1R240W 
had no effect on reversing the decreased activity of single mutants. Interestingly, plasma 
membrane expression of B
0
AT3 was not decreased when co-expressed with collectrinW143R 
(Fig 5.7C). This suggests W143 plays a role in the catalytic activation of the transporter. The 
W143R mutation does not affect the stability of collectrin as assessed by total membrane 
analysis.  
 
5.3 Discussion 
A combined bioinformatic and experimental approach demonstrates that the interaction of 
collectrin with the amino acid transporters B
0
AT1 and B
0
AT3 is dependent on multiple 
regions, much of which represents no currently known linear sequence motifs. Large regions 
of collectrin’s extracellular N-terminal and TM domains are involved in collectrin stability, 
transporter trafficking and function. Effects on transporter interaction are observed when 
regions 15-40 and 116-179 are deleted or residues within them mutated. The putative 
signalling peptide residues 2-14 control protein stability, most likely due to their role as a 
signal sequence. The N-terminal region 116-135 appears to affect collectrin stability, rather 
than directly interacting with B
0
AT3. However, as the epitope used to raise the sheep anti-  
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Figure 5.7 Collectrin tryptophan 143 is involved in catalytic activation of B0AT1 and 
B
0
AT3 
Xenopus laevis oocytes were injected with 10 ng/oocyte of transporter or transporter mutant 
cRNA. All collectrin variants were injected at 2 ng of cRNA/oocyte. All measurements were 
made 4-6 days post-injection of cRNA. A) Uptake of 100 µM L-[
14
C(U)]alanine was carried 
out over 30 mins. Each histogram bar represents mean ± S.D. (n = 10, e > 3). Identical 
lettering a, b, c, d above individual bars indicates groupings of conditions whose differences 
of means are not statistically significant from each other at the p = 0.05 level. B) Uptake of 
100 µM L-[
14
C(U)]leucine was measured as in A). Each histogram bar represents mean ± S.D. 
(n = 10, e = 3). Identical lettering a, b, c, d, e above individual bars indicates groupings of 
conditions whose differences of means are not statistically significant from each other at the p 
= 0.05 level. C) Plasma membrane protein isolation was carried out by surface biotinylation, 
isolation of total membranes by centrifugation. Collectrin and B
0
AT1 were detected by 
immunoblotting. Molecular weight markers (in kDa) are indicated on the left, detected 
proteins are indicated on the right.  
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mouse collectrin antibody used in this study is against collectrin residues 15-144, decreases in 
collectrin detection could also be due to reduction in primary antibody affinity. Therefore, 
any conclusions derived from western blots concerning collectrin stability are made with 
caution.  
 
Despite the comprehensive use of available computational algorithms and correlation with 
functional assays, few putative linear motifs and PTMs were identified that are conserved 
across collectrin cross-reactive orthologs. The one exception was the putative subtilisin-like 
proprotein convertase (PCSK) cleavage site at R(32)TALG in the collectrin 15-40 region, the  
only conserved putative motif not eliminated by functional analysis. PCSK proteases are 
responsible for the proteolytic processing of many neuro- and endocrinal peptide hormones, 
including insulin [590, 591]. Intriguingly, the putative PCSK site is only one of our putative 
motifs which is still annotated when the program ELM is used with more stringent filters 
specifying sub-cellular location and membrane orientation [593] (recent data available upon 
request). The PCSK cleavage site is currently being investigated at higher resolution in 
several B
0
AT1 cross-reactive collectrin orthologs and ACE2. 
 
A lack of known, annotated collectrin motifs involved in B
0
-like transporter interactions 
could represent variability in the accuracy of different algorithms. Alternatively, it could also 
suggest collectrin, as a recently evolved protein, contains novel motifs or variants of existing 
motifs not yet represented in annotated databases. Of interest in this respect is the C-terminal 
region of collectrin immediately adjacent to the TM domain. Mutations to disrupt a putative 
dibasic convertase protease recognition site had no effect, while, in contrast, deletion of a 
wider flanking region, collΔ163-179, killed all oocytes. Other residues in the collΔ163-179 
region, besides the conserved dibasic convertase site, display little sequence conservation 
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across collectrin orthologs. For example, collectrin residues 175-178 displays significant 
sequence divergence when checked against the collectrin orthologs known to interact with 
B
0
AT1 (see Fig. 5.5C). This suggests possibly a more general biophysical role for the C-
terminal TM-adjacent region in collectrin, relying on chemical profile and physico-chemical 
properties. For example, the non-uniform distribution of charged residues across membrane 
protein aqueous domains helps determine their orientation [516]. As this region contains 5-6 
basic residues in cross-reactive collectrin orthologs, it could be a more cumulative disruption 
of electrostatic interactions is required to elucidate any underlying role. Alternatively, these 
regions may represent more general ER retention and export motifs, although no established 
ER exit motifs, e.g. dileucine, YxxxNPF or LxxxE sequences [594, 595] are found in 
collectrin, ACE2 or B
0
AT1/B
0
AT3 cytosolic domains. 
 
Also of interest are the N-terminal region and TM domain of collectrin, both of which contain 
many highly conserved residues not identified as part of existing linear motifs or PTMs. The 
N-tryptophan in the novel TM domain motif W(143)BIBFGVB (where B = L, I, or V), is also 
conserved in the unrelated ancillary Ost β subunit of the heteromeric SLC51 bile acid 
transporter [322]. The periodicity of this motif is also conserved in the B
0
AT1 cross-reactive 
collectrin orthologs and ACE2, perhaps determining the B
0
AT1-facing and bilayer-facing 
sides of the TM domain (see section 6.2.1). 
 
The C-terminus of collectrin, excepting the TM-adjacent region 163-178, appears to be 
unnecessary for B
0
-like transporter trafficking and function. This suggests tissue-specific 
functions of collectrin in the pancreas or kidney are mediated by different domains of the 
protein. For example, collectrin’s C-terminal intracellular domain is responsible for binding 
to snapin, a SNAP-25 binding protein in pancreatic β-cells, and is proposed to play a role in 
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insulin secretion [343]. Furthermore, collectrin dimerization in pancreatic β-cells is mediated 
by a C-terminal Cys186 residue [344], suggesting collectrin dimerization may play no 
significant role in collectrin-transporter interactions.   
 
Notably, several putative sequence motifs in collectrin appear to have no role in complex 
formation with B
0
-like transporters: the putative C-terminal PDZ-binding domain, and 
serine/threonine C-terminal phosphorylation sites. The putative PDZ-binding domain, 
strongly annotated in human collectrin residues 217 to 222, is not conserved across collectrin 
chordate phylogeny, nor does its deletion (collΔ213-221) have any effect on collectrin-
dependent B
0
-like activity in oocytes. The N-linked glycosylation site at human/mouse 
collectrin N76 and N93, are also highly conserved across species. However, their deletion 
(collΔ65-90) shows no effect of transporter activity or surface expression. 
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Chapter 6: Conclusions and General Discussion 
6.1 Aims Revisited and Conclusions 
Our knowledge of neutral amino acid transporter complexes at the small intestine and 
proximal tubule brush border membranes has been considerably advanced by this thesis. For 
the 3 specific aims (section 1.6) the following conclusions are stated: 
 
1. B0AT1 does not only interact with collectrin and ACE2. Aminopeptidase N forms a 
stable ternary membrane complex with B
0
AT1 and ACE2. Mechanistically, APN and 
ACE2 enhance the substrate affinity of B
0
AT1 and B
0
AT3, respectively. The 
trafficking of B
0
AT1 is inhibited by syntaxin 1A and 3, most likely by displacing 
collectrin/ACE2.  
2. Collectrin is necessary for catalytic activation of B0AT3 and B0AT1 in addition to 
membrane expression. Activation and trafficking are dependent on a binding site for 
collectrin, mapped in B
0
AT3, to a hydrophobic pocket between TM helices 5 and 7. 
Syntaxins appear to compete competitively with collectrin for access to B
0
AT1.  
3. Collectrin is a chordate-specific protein and interactions with B0AT1 and B0AT3 are 
highly conserved among collectrin and ACE2 homologues. The N-terminus, TM 
domain and membrane proximal C-terminal regions of collectrin are involved in 
interactions with B
0
AT1 and B
0
AT3 and contribute to collectrin stability.  
 
Collectively, these results show that B
0
AT1 and B
0
AT3 are heteromultimeric transporters, 
formed by an essential transporter subunit and ancillary subunit of unknown stoichiometry. 
The results suggest that heteromultimeric transporters form part of larger protein digestion 
and absorption metabolons in the brush border membrane of the small intestine and proximal 
tubules of the kidney.  
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6.2  Discussion of Conclusions 
6.2.1 Molecular determinants of trafficking  
The endoplasmic reticulum is the major point of quality control for trans-membrane proteins. 
Trafficking determinants of secretory proteins in the ER lie predominately on the intracellular 
domains/loops or TM domains, due to dependence on COPII vesicle recognition for ER exit, 
or, alternatively, COPI vesicle recognition for retrieval to the ER [596-598]. These 
determinants link the trafficked proteins or cargo to the Sec24 subunit of COPII or coat 
subunit of COPI, the permissive vesicular proteins essential for bidirectional ER to Golgi 
transit [595, 599]. In this context, collectrin, ACE2, and APN may be viewed as cargo 
receptors or, in the case of syntaxins, as receptor inhibitors, which provide both the 
specificity and quality control for B
0
AT1/B
0
AT3 ER exit. We know ancillary proteins act as 
receptors for permissible B
0
AT1/B
0
AT3 trafficking as they traffic to the plasma membrane 
independent of transporters (see, for example, Figs.3.6D, 4.6C).   
 
A lack of topological similarity among collectrin, ACE2, APN and syntaxins means the TM 
domain emerges as the common regulatory domain controlling trafficking by B
0
AT1 and 
B
0
AT3 ancillaries.  For example, APN has no cytosolic domains accessible to act as a cargo 
receptor during trafficking (Fig. 6.1). Syntaxin 1A or 3 lack extracellular domains, which 
could serve as competitive binding sites with collectrin extracellular domains for transporter 
interactions. In contrast, collectrin’s extracellular domain mediating transporter trafficking is 
confirmed by truncation of residues 15-40, which shows reduced surface expression in 
conjunction with B
0
AT3 (Fig. 5.4C, E, F). However, a lack of homology within the TM 
domains, and an opposite membrane orientation of collectrin and syntaxin, also suggests 
competitive interactions based on chemical analogy rather than sequence conservation. In  
207 
 
many instances the exposure of hydrophobic, trans-membrane domains of proteins is an 
intrinsic property of incompletely folded proteins or proteins requiring oligomeric formation 
to exit the ER or prevent ER retrieval [595]. Many TM domains are known to harbour 
signalling sequences to mediate ER retrieval, such as in the yeast iron transporter heteromer 
Ftr1/Fet3 [600] and NMDA receptors [601, 602]. In other cases, ER exit can be controlled by 
both the TM and cytosolic C-terminal domains of ancillary proteins, which, like collectrin 
and ACE2, are responsible for the secretory trafficking of membrane proteins [603, 604].  
 
The major entropic cost of α-helical packing in lipid bilayers is compensated by intra-helical 
hydrogen-bonding and lipid-helical interactions [516, 605]. Therefore, major TM-TM 
interactions in lipid bilayers are expected to be delocalised induced-dipole (London 
dispersion) forces [606, 607]. However, many TM α-helices contain single residues and short 
motifs with specific roles in TM-TM binding and protein function [206, 608-610]. Multiple 
residues with specific trafficking or catalytic functions were identified within the proposed 
collectrin binding pocket of B
0
AT1 (sections 4.2.3). Residue-specific functionality is 
observed with W143 in the TM domain of collectrin (section 5.2.4), which is conserved 
across all collectrin and ACE2 homologues. This residue is part of a TM domain 
WBIBFGVB linear motif (where B = L or I) at the N-terminus of the putative collectrin and 
ACE2 helix. This motif is conserved in collectrin orthologs and ACE2 cross-reacting with 
B
0
AT1 orthologs. Helical wheel renderings [611] of collectrin homologues shows W143 and 
other large hydrophobic residues from the WBIBFGVB motif and TM domain form one side 
of the consensus helix (Fig 6.2).  Aromatic residues play vital roles in both π-cation 
interactions with cationic phospho-lipid head-groups and lipid-carbonyl interactions [612, 
613]. In addition, membrane helix translocation into the ER membrane and stability in 
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bilayers is directly proportional to the hydrophobic surface area exposed to the surrounding 
lipid 
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Figure 6.1 Topology, orientation and chemical analogy in B
0
AT1 and B
0
AT3 
heteromer partners 
Tertiary structure of B
0
AT1 and B
0
AT3 ancillaries are presented as a mixture of x-ray crystal 
structures and TM domain cartoons (green). Positive (+, red) and negative (−, blue) charged 
regions are displayed on the cytoplasmic side of the TM domains, adjacent to the membrane-
spanning helices. Human ACE2 (PDB ID 1R42) and APN peptidase domains have been 
crystallised and are shown coloured according to their four subdomains. ACE2 domains:  
subdomains I (cyan) II (yellow) III (green) IV (purple) and the linker-TM domain (cartoon). 
Zinc (pink) and chloride (red) ions show the approximate location of the ACE2 catalytic site. 
APN: linker-TM domain (subdomains I to III, cartoon), subdomain IV (magenta),  
subdomain V (green), subdomain VI (cyan); subdomain VII (yellow). The consensus 
sequences for zinc metalloprotease and amino acid binding are shaded red and orange, 
respectively, in APN. The zinc ion is shaded purple. Rat Syntaxin 1A (PDB ID 3C98, chain 
A) cytosolic domains have also been crystallised. Domains include a 3 anti-parallel helix N-
terminal regulatory domain (green and grey), a coiled-coil T-SNARE H3 domain (cyan), and 
a short intracellular and TM domain (green).   
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Figure 6.2 Transmembrane a-helix consensus and periodicity in collectrin and ACE2 
homologues 
Helical wheel of TM domains from collectrin and ACE2 homologues (left) were created 
using the HelixWheel program (section 2.7.2). The relative hydrophobicity of individual 
amino acid residues and the length of side-chains are represented by a colour scale and 
different shapes in the helical wheels, respectively (Figure legend). The start of helices was 
the consensus predicted TM domain for human collectrin (section 5.2.2). Helices were 
shortened to contain the first 18 residues following the N-terminal start residue, which 
reflects one full period looking down the helical axis of a 3.1613 helix. The consensus helical 
wheel (right) was drawn using the PROMAL3D structural alignments of collectrin and 
ACE2 homologues.  
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hydrocarbon chains [614-616]. As there is a bias of W143 and large hydrophobic residues to 
one side of the consensus helix it is probable that this side forms the lipid-helical interface of 
collectrin and ACE2. The opposing helix interface contains more compact hydrophobic 
residues and increased numbers of glycine, alanine and cysteine. Glycine is disproportionally 
represented at the TM-TM interfaces of α-helical transmembrane proteins [617-619]. One of 
these glycines, Gly148 in human collectrin, also represents one of the key conserved residues 
in the WBIBFGVB motif. Taken together, this analysis suggests that the lipid and B
0
AT1 
interfaces of collectrin and ACE2 are defined by the position of the conserved tryptophan 143 
and glycine 148 (human collectrin numbering), respectively. Interestingly, a tryptophan 
residue at the bilayer-aqueous interface of the steroid-derivative transporter ancillary subunit 
Ost-β (SLC51B) also displayed a role in transporter subunit (Ost-α, SLC51A) activation 
[322].  
 
APN was not included in the helical wheel analysis as it has the opposite membrane 
orientation to collectrin and ACE2, being a type II single-pass membrane protein, and has no 
homology to the other two proteins. Therefore, unlike ACE2 and collectin (which could be 
pre-aligned using sequence homology) an accurate pairing of helical residues from APN with 
those of ACE2 and collectrin is very difficult and highly speculative. Comparison made 
between ACE2/collectrin and APN with miss-paired APN helical residues would lead to 
highly inaccurate predictions of APN-transporter possible interactions. This is because a 
turning of a 3.6 α-helix by a single residue moves the right-handed movement of residues by 
~100°, and would cause large disruptions to the pattern of protein-protein and protein-lipid 
interactions, and, ultimately, helical bundles formed [620]. 
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Chemical similarity is also observed in basic residue-rich regions immediately adjacent to 
collectrin’s TM domain and an acidic residue-rich region just downstream of this (see Fig. 
6.1). Both regions are conserved across collectrin orthologs by chemical identity rather than 
sequence conservation. The TM-adjacent basic-rich region is conserved topologically in 
ACE2, a collectrin homologue, and in syntaxin 1A and 3, which are not homologues. The 
syntaxin 1A basic-rich sequence lies within the cytosolic membrane-adjacent coiled coil H3 
region which interacts with GAT1 and is hypothesised to interact with N-terminal of other 
SLC6 transporters [397, 400, 405, 409, 411, 412, 538, 549, 621]. Both basic and acidic linear 
motifs are implicated in retrograde [622-624] and anterograde [622, 625-629] membrane 
protein trafficking to and from the ER, respectively. Cytosolic dibasic motifs can control 
heteromeric membrane proteins complex composition by retrieval from or retention in the ER 
depending on the exposure to COPI complexes [595, 630]. Kir6, GABA and kainate 
receptors are all retrieved from Golgi back to ER unless their arginine-based retrieval motifs 
are masked by oligomerisation [599, 631-633]. B
0
AT1 and B
0
AT3 are unique among SLC6 
transporters interacting with ancillary proteins in having a highly conserved RXRR/K 
potential retrieval/retention motif on IL1. A second arginine-rich region in IL4 represents the 
loop competing with syntaxin 1A for GAT1 N-terminal binding and is present in all SLC6 
transporters. However, IL4 displays significantly less positive charge density in B
0
AT1 and 
B
0
AT3 (see Fig 1.5, IL4). Furthermore, all SLC transporters contain acidic residue-rich linear 
sequences in their cytosolic N-terminals – acidic residues which mediate syntaxin 1A 
interactions with several SLC6 transporters [399, 409, 411, 412]. Mutation of D25 in 
B
0AT1’s N-terminal also increased transporter expression, the reverse effect of what is 
observed for syntaxin 1A interactions [409]. That both collectrin and syntaxin 1A interact 
with the N-terminal of SLC6 transporters, yet mediate an opposite trafficking effect, suggests 
further molecular complexity underlying these interactions.  
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A significant bottleneck in determining the trafficking determinants of transporter complexes 
is separating coincident observations of ancillary or transporter dysfunction from actual 
disruption of trafficking dependent heteromer formation. One recent development is the 
improvement in supra-molecular resolution microscopy beyond diffraction limits, which is 
promising to greatly improve our understanding of membrane protein complex composition, 
formation and trafficking in real time [634, 635].  
 
6.2.2 B0AT1 transport metabolon identity, oligomeric state, and sub-cellular formation 
Little is known about the initiation of B
0
AT1 or B
0
AT3 complex formation, its spatial 
location, its full composition or stoichiometry in larger brush border metabolons? Are they 
independent or form complexes with other post-translational processing and trafficking 
proteins known to associate with collectrin, ACE, APN, and syntaxins in the kidney or 
intestine?  
 
Investigating the stoichiometry and physiological identity of membrane complexes is limited 
by their membrane solubilisation or reconstitution in heterologous systems [565]. 
Solubilisation is the critical step in biochemical processing and isolation of membrane 
proteins, but is hampered by the arbitrary nature of the complexes isolated. On one hand 
solubilisation must be extensive enough to isolate the proteins from the lipid bilayer, on the 
other it potentially disrupts biologically relevant protein-protein interfaces, especially 
between TM domains.  These problems of isolation are exemplified by the isolation of 
different B
0
AT1 intestinal complexes (section 3.2.1). Size and composition are a function of 
solubilisation conditions – detergent, temperature, time, and the lipid composition of the sub-
cellular tissue isolated. Thus, the complex between B
0
AT1, APN and ACE2 should be 
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viewed as a core complex of yet unknown stoichiometry and, perhaps, larger composition. 
Likewise, a single large complex (> 500 kDa) isolated from kidney BBMVs using digitonin 
0.5 % (w/v) (data not shown) is much larger than a single B
0
AT1-collectrin hetero-dimer 
[175, 178]. In agreement with this notion, APN-associated complexes of different sizes have 
been isolated previously [528, 636-638]. Using 10% (w/v) dodecylmaltoside at 4 °C, 
Babusiak et al. [528] isolated several APN-containing complexes, which included maltase-
glucoamylase, sucrose-isomaltase, and endopeptidase-2. B
0
AT1 was found to be complexed 
with villin, microsomal triglyceride transfer protein, alpha-actinin-4 and protein disulphide 
isomerase, but not with APN, ACE2, or any syntaxins. This may be due to the different 
solubilisation conditions used, or because mice were starved for 24 hrs before being 
euthanized, a treatment known to effect the composition and structural integrity of the 
intestinal brush-border [639]. Likewise, isolation of brush border complexes from lipid rafts 
has been performed under various solubilisation conditions, initially using Triton X-100 at 
different temperatures [492, 640-642], later with different detergents from primary tissue and 
cultured epithelial cell lines [643-645]. Current advances in cryo-electron tomography and 
scanning electron tomography suggests problems associated with detergent-based  protein 
chemistry may be overcome by in situ visualisation of membrane protein complexes, 
allowing for the accurate elucidation of complex composition and stoichiometry [646-648] 
 
Evidence exists for glycolipid-rich/cholesterol poor micro-domains stabilised by galectin-4. 
Galectins bind the extracellular carbohydrate motifs of many membrane peptidases [637, 640, 
645]. APN, ACE2 and collectrin are glycosylated [344, 417, 649], and both APN and 
syntaxin 3 are components of brush-border and kidney cell lipid rafts [492, 636, 637, 650]. 
B
0
AT1 has also been shown to contain N-glycosylation sites in its extracellular loops [107]. 
If, however, brush border metabolons are formed by the combined action of lipid micro-
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domain formation and galectin stabilisation, the mechanism is specific to the small intestinal 
or ACE2-dependent. The deletion of N-glycosylation sites N76 and N93 in collectrin had 
little effect of B
0
AT1 trafficking (section 5.2.3), while syntaxin has no ER-
resident/extracellular domains which could be glycosylated.  
 
The TM domain sequence and periodicity conservation between ACE2 and collectrin 
homologues (section 6.2.1) makes a common binding mode with B
0
AT1 and B
0
AT3 
plausible. However, some aspects in the biochemistry of these obligatory heteromers remain 
puzzling and unexplained. For example, B
0
AT1-collectrin complexes demonstrated reliable 
functionality in Xenopus laevis oocytes, whereas transient transfection into multiple cell 
cultures has produced surface expression without transport activity (S. Fairweather and A. 
Brӧer, unpublished). B0AT1 isolated from mouse proximal tubule or intestinal brush border 
membranes also display different molecular weights [50]. Furthermore, B
0
AT1 and B
0
AT3 
both demonstrate small reductions in molecular weight (~5 kDa) when expressed with 
collectrin, which is not apparent when co-expressed with ACE2 (compare, for example, Figs. 
4.6C and 3.6C). And, although exaggerated by the authors, slight differences between ACE2 
and collectrin interactions with Hartnup mutations in B
0
AT1 are observed [176]. 
Cumulatively, this data suggests cell-specific expression of metabolons requires 
additional/different proteins or post-translational modifications to reach a fully functional 
transport state and location. Efforts are currently underway to determine the ancillary- and 
tissue-specific molecular constitution of B
0
AT1 using stably-expressed cells lines, 
purification and identification by mass spectrometry. 
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6.2.3 Mechanism of collectrin catalytic activation and the B0AT1 transport cycle 
The catalytic activation of B
0
AT1 and B
0
AT3 by collectrin necessitates intervention in the 
transport mechanism (section 4.2.2). The alternate access model [97] combined with 
structural evidence has been used to develop a more comprehensive, but theoretical, SLC6 
family transport cycle [95, 191]. A revision of the original 4-state kinetic mechanism 
proposed for B
0
AT1 [39], incorporating possible steps of collectrin activation can be 
proposed (Fig. 6.3, inner ring). The basic conformational steps are: outward open (apo) state 
(C
’
apo); Na
+
/L-leucine binding transition (C
’
Na-L); outward occluded state (C
o’
Na-L); outward to 
inward transition (C
o
Na-L); inward occluded state (C
o’’
Na-L); Na
+
/L-leucine dissociation (C
’’
Na-
L); inward open (C
’’
apo); and isomerisation step (Ciso), returning the inward facing transporter 
to the C
’
apo conformation. 
 
For energetic reasons the substrate binding/dissociation (C
’
Na-L and C
’’
Na-L), occluded 
transition (C
o
Na-L) and isomerisation (Ciso) steps are thought to represent transition states [95, 
191]. Supporting this hypothesis is the crystallisation of the four other predicted 
conformations (C
’
apo, C
o’
Na-L, C
o’’
Na-L, C
’’
apo) as stable intermediates of SLC6 transporters 
[192-194, 651-654]. These structures provide homology templates for B
0
AT1 models in these 
states (Fig. 6.3, outer ring). However, sodium bound conformations have been isolated in the 
outward open conformation (C
’
apo) rather than a true apo state, suggesting this as the more 
stable C
’
apo conformation [193, 194, 198, 199]. SLC6 ancestors LeuT and the Drosophila 
dopamine transporter DAT have been isolated in outward open substrate bound state (C
’
Na-L) 
using competitive inhibitors [196, 198, 655]. Competitive inhibitors are predicted to ‘lock’ 
the transporter in this transition state due to optimal substrate binding energy stabilisation 
consistent with the induced-fit model of transition state theory [3, 656].  
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Figure 6.3 The B
0
AT1 transport cycle with hypothesised collectrin-mediated 
transitions 
Inner ring: All 8 hypothesised transport cycle intermediates are shown as cartoons with the 
extracellular (top) and cytosolic (bottom) salt-bridge gates represented as + and − pairs at the 
top and bottom of each transporter conformation. The gates are either closed (close) or open 
(distant) in each B
0
AT1 conformation. Outer ring: Structural models of human B
0
AT1 were 
based on template PDB IDs (from top left moving clockwise): 3TT1 (C’apo), 2A65 (Co'Na-L), 
4US3 (Co’’Na-L), 3TT3 (C’'apo) - bacterial ancestors of B
0
AT1, LeuT (3TT1, 2A65, 3TT3) 
from Aquifex aeolicus and MhsT (4US3) from Bacillus halodurans. Helices 1, 6, 2, 7, 
forming the bundle subdomain (cyan), and helices 3, 8, 4, 9, forming the scaffolding hash 
subdomain (pink), are shown in conformations of the transport cycle for which homology 
models could be made. TM5 (yellow) and IL4 (blue) are also shown. Sodium ions (purple) 
are represented as non-bonded radii. L-leucine, extracellular and cytosolic gating residues 
(green) are shown as stick figures. ΔΨ reflects the transition at which net positive charge 
transfer (from Na
+
) is most likely to be affected by the membrane potential.  Sections of TM7 
and IL3 have been removed from all models for ease of viewing.  
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In the proposed transport cycle, the outward to inward occluded transition (C
o
Na-L) is a key 
step, analogous to the alternate access movement of the original model [95, 191]. It is 
accompanied by large-scale conformational movements in the transporter, characterised by 
the ‘rocking’ or hinge bending movement of TM1α outward in the membrane plane to release 
substrate to the cytosol. This transition is accompanied by hypothesised simultaneous or co-
ordinated breaking/formation of the extracellular and cytosolic salt-bridge gates, R57-D486 
in human B
0
AT1 (R43-D472 in B
0
AT3) and R32-D445 (R18-D431 in B
0
AT3), respectively. 
Considerable evidence suggests they are indispensable for the alternating water accessibility 
required for substrate binding and release [657-659]. Outward to inward-facing movement 
seems to be controlled by substrate binding in SLC6 prokaryotic ancestors [194, 658, 660-
662]. Sodium binding shifts inward/outward facing conformational equilibrium in favour of 
the outward open (C
’
apo) conformation, priming the transporter for substrate binding and 
coupled transport [194, 549, 660, 661, 663, 664]. Sodium release at the Na2 site is coupled to  
hinge bending of TM1α and its separation from TM8. As Na2 co-ordinating residues are 
formed exclusively from these TM domains, this helical separation facilitates cytoplasmic 
release of the Na2 sodium [194]. In contrast to many other SLC6 transporters, including 
B
0
AT3, B
0
AT1 does not translocate 2 sodium ions or a chloride ion, although whether it 
binds a second sodium at Na2 has not been resolved. 
 
It is tempting to speculate that collectrin’s role in activating B0AT1 is compensation for the 
absence of chloride or Na2 sodium binding. However, lowering transition state activation 
energy is an intrinsic function of substrate binding energy and appears divorced from 
subsequent conformational transitions [95]. Instead, ion binding enables subsequent substrate, 
or additional ion binding, by determining the conformational equilibrium of transporters, or 
‘permissiveness’ for subsequent binding events. This conformational equilibrium hypothesis 
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has been demonstrated recently in unrelated transporter families [663, 665]. Under the rapid 
equilibrium of binding assumption for transporters, Km will be primarily determined by 
substrate dissociation (𝑘−1 𝑘1)⁄  (see section 1.3.3). Substantial evidence from LeuT and DAT 
confirms ion binding proceeds substrate binding and controls the conformational equilibrium 
of the transporter prior to substrate binding [658, 660, 662, 663, 666]. Evidence of binding 
order from B
0
AT1 is also consistent with sodium binding occurring before substrate [39]. In 
addition, little correlation exists between SLC6 ion stoichiometry and changes in observed 
Km or Kcat values for different SLC6 transporters under conditions where saturation 
concentrations of co-substrates are present (see [100]).  For example, B
0
AT3 has a many fold 
higher apparent Km than the monoamine transporters, yet it retains a 2Na
+
:1Cl−stoichiometry. 
Similarly, B
0
AT1 and B
0
AT3 apparent Km values are both in the hundreds of μM to low mM 
range, yet B
0
AT1 only translocates one sodium and both B
0
-like transporters are equally 
dependent on collectrin for catalysis despite these ion coupling differences. Direct contact 
between collectrin and substrate binding sites is also unlikely as only B
0
AT3N295 
(B
0
AT1N310) in TM7 of our hypothesised ancillary binding site is involved in direct binding 
site co-ordination (see section 1.3.4). Sodium is co-ordinated by the asparagine amide oxygen 
of N295, which is turned away from the putative collectrin binding site in our homology 
models of B
0
AT1 and B
0
AT3 (see Fig 1.7B).  
 
The identification of a putative binding site in B
0
AT3 helix 5/7 groove makes this site a 
plausible starting point to examine collectrin-specific kinetic effects. Collectrin directly 
contacts TM1α in this proposed binding site. A static collectrin would sterically impede the 
hinge-bend movement of TM1α during the outward to inward transition of the transporter. 
However, it may be that a dynamic collectrin actually facilitates this step, compensating for a 
rate-limiting hindrance (chemical or steric) somewhere else in B
0
AT1, which is not present in 
222 
 
other SLC transporters. Collectrin would directly compensate for structural or chemical 
changes that radically slow collectrin-unsupported transport in B
0
AT1 and B
0
AT3: analogous 
to the actions of an allosterically activating coenzyme, or co-operative binding. The outward 
occluded to inward transition state might therefore be a rate-limiting step in the B
0
AT1 
transporter cycle, accelerated only in the presence of collectrin. In agreement with this 
possibility, Q25 mutations in B
0
AT1 play a role in modulating catalytic activation of B
0
AT3 
and B
0
AT1 in the presence of collectrin.  
 
The largest structural difference to other SLC6 transporters, which may be related to 
ancillary-dependence, is an extended EL4 loop, which at 52 residues is longer in B
0
AT1 and 
B
0
AT3 (see Fig 1.6). Another transporter region involved in collectrin-dependent catalytic 
activation of B
0
AT3 is TM5, as evidenced by the L213W and R225 mutations. Both TM5 
and EL4 undergo significant movements, which are heavily co-ordinated with TM1α hinge-
bending, during the outward to inward transition of the SLC6 transport cycle [194]. The 
intracellular half of TM5 blocks TM1α’s outward swing into the bilayer and is proposed to 
partially unwind, flex (extend) or tilt in the membrane plane, causing a cascade of movements 
ending in extracellular gate closure [194, 654]. Gate closure is concurrent with large 
movements of EL4 blocking the extracellular access pathway (vestibule) route to the 
substrate binding site [194, 198, 654, 655]. 
 
The partial unwinding of TM5 is hypothesised to depend on a GlyX9Pro motif, which is 
conserved in TM5 of both B
0
AT1 (G220-X9-P230) and B
0
AT3 (G205-X9-P215) [654]. This 
unwinding at the conserved proline allows for TM5 tilting in the membrane. The intracellular 
half of TM5 then extends into the cytoplasm and allows Na2 site water access, whose release 
drives the full outward to inward transition [654]. The inward open B
0
AT1 homology 
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structure also shows a smaller unwound TM5 region not present in the template structure 
[194]. Most interesting is the presence of the GlyX9Pro motif in collectrin itself. It is strictly 
conserved in all collectrin and ACE2 homologues known to functionally interact with B
0
AT1 
orthologs (see Fig. 5.6D). In this case GlyX9Pro is reversed in the sequence but remains in 
the same orientation as the transporter GlyX9Pro motif: glycine on the cytosolic side and 
proline on the extracellular i.e. G148-X9-P138. Collectrin also contains the highly conserved 
WBIBFGVB motif within the GlyX9Pro motif (section 6.2.2).  
 
Based on the proposed TM5-TM7 binding pocket, a model for collectrin’s role in the 
transport cycle of B
0
AT1 and B
0
AT3 is shown in Figure 6.3. Collectrin binding represents a 
kinetic pathway through the outward occluded to inward occluded transition state (C
o
Na-L). 
Bound between TM5 and 7, collectrin is hypothesised to lower activation energy for the C
o
Na-
L transition, which is higher in B
0
-like transporters, possibly due to the steric clashes with the 
much larger EL4 domain.  The unwinding and tilting of TM5, which controls the co-
ordinated opening/closing of the cytosolic/extracellular gates in other SLC6 transporters, is 
unable to do so in B
0
-like transporters without the presence of collectrin. Under the 
assumption that the return transition (Ciso) travels the same reaction co-ordinate as the C
o
Na-L 
transition in reverse, collectrin would also be required to catalyse the return of the empty 
transporter.   
 
6.2.4 Speculations on the positive selection and evolution of collectrin  
The evolution of the primitive kidney (pronephric kidney) and collectrin in chordates are 
concurrent events according to our phylogenetic analysis (Chapter 5). Furthermore, 
collectrin’s interactions with B0AT1 are also conserved to the beginning of this lineage with 
jawed fish [579, 580]. This evidence suggests an intrinsic role for collectrin in kidney 
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development and function. It has been speculated that the kidney evolved to stabilise the 
internal milieu of chordates, which arose with fish, as a replicated internal sea-water 
environment [667]. A major component of this evolution was the development of a blood-
filtering (mesonephric) kidney for salt and water retention. 
 
 The need to maintain a stable internal milieu perhaps also represents the prime positive 
selective pressure for collectrin’s evolution as a transporter subunit. On one hand, blood 
amino acid levels are remarkable consistent across chordate species [17]. On the other, the 
requirement for amino acid retention from blood filtrate is also commensurate with the 
evolution of the stable internal environment from fish onwards [667]. The specific evolution 
of an ancillary protein to maximise surface expression and activation of existing amino acid 
transporters could have been a requirement of chordate evolution.  The author believes these 
requirements to be primary drivers in the evolution of large brush border complexes, the 
understanding of which research has only begun to uncover. 
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APPENDICIES 
 
Appendix A: Physical Equations and Explanations  
1. Biophysical equations relevant to membrane transport 
Fick’s 1st law of diffusion, when applied to solute diffusion across a lipid bilayer states: 
 
        𝐽 = (
−𝐷𝛽
∆𝑥
) (𝐶𝑖 − 𝐶𝑜) = −𝑃(𝐶𝑖 − 𝐶𝑜) = −𝑃∆𝐶    (eq. 1.1) 
 
Where 𝐽 is flux, 𝐷 is the diffusion constant for any solute, 𝛽 is the partition coefficient for 
solvation into the bilayer, 𝐶𝑖 and 𝐶𝑜 are inside and outside concentrations of solute, and ∆𝑥 is 
the membrane thickness. The potential energy built up by a concentration gradient of solute 
(𝑠) across a lipid bilayer is given by 
: 
              𝜇𝑠 =  𝜇𝑠
′° + 𝑅𝑇 ln[𝑠]      (eq. 1.2) 
 
Where 𝜇𝑠
′° is the standard potential energy of solute 𝑠 (i.e. for [𝑠] = 1M, at pH 7, [H2O] = 
55.5 M, and all other standard physical conditions). R (universal gas constant) and T 
(temperature in Kelvins) have their usual meaning. The amount of free energy available from 
this build-up of a potential chemical energy gradient is given by: 
 
     𝐺𝑠 = 𝐺𝑠
′° + ln[𝑠]     (eq. 1.3) 
 
Where 𝐺𝑠 is Gibb’s free energy resulting from the concentration gradient of solute, 𝑠. In most 
eukaryotic cells the most important solute gradients are of inorganic ions, the stored potential 
energy gradients of which are then used to drive the thermodynamically unfavourable 
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transport of other organic solutes, such as neutral amino acids. The chemical gradients of 
sodium and potassium are created and maintained by the Na
+
/K
+
 ATPase, according to the 
reaction: 
 
           (eq. 1.4) 
 
Where the thermodynamically unfavourable translocation of ions between the cytosol and 
extracellular (EC) compartments is driven by bond energy released from ATP hydrolysis. 
The Na
+
/K
+
 ATPase, which catalyses the ATP hydrolysis, creates a large . However, as 
inorganic ions are charged species, there also exist an electrical potential or voltage that 
arises due to the asymmetric distribution of sodium and potassium across the plasma 
membrane. For each asymmetrical distributed ion the resultant electrical potential energy can 
be calculated by: 
 
𝐸𝑠𝑧 =
𝑅𝑇
𝑧𝐹
ln (
[𝑠]𝑜𝑢𝑡
[𝑠]𝑖𝑛
)     (eq. 1.5) 
  
In this equation 𝐹 is Faraday’s constant (96485.3328959 C mol-1)5, and 𝑧 is the elemental 
charge per atom for the ion. The Nernst’s potential (𝐸𝑠𝑧 or 𝐸𝑖𝑜𝑛) for an ion is defined as the 
electrical potential of the inside relative to the outside of the cell.  
 
                                                          
5
 Faraday’s constant  𝐹 =  𝑒𝑁𝐴 or the product of Avogadro’s number and the value of an elemental charge in 
coulombs.  
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The combination of Nernst potentials for the major permeable ions across a biological 
membrane is given by the GHK equation: 
 
𝑉𝑚 =
𝑅𝑇
𝐹
ln
𝑃𝑁𝑎[𝑁𝑎
+]𝑜𝑢𝑡+ 𝑃𝐾[𝐾
+]𝑜𝑢𝑡+𝑃𝐶𝑙[𝐶𝑙
−]𝑖𝑛
𝑃𝑁𝑎[𝑁𝑎+]𝑖𝑛+ 𝑃𝐾[𝐾
+]𝑖𝑛+ 𝑃𝐶𝑙[𝐶𝑙
−]𝑜𝑢𝑡
     (eq. 1.6) 
 
Where permeability (𝑃) is the relative permeability of the contributing ions to each other.  
The size and direction of ion transport/current (𝐼𝑖𝑜𝑛) is a direct function of the membrane (𝑉𝑚) 
and Nernst (𝐸𝑖𝑜𝑛) potentials for the ion in question: 
 
𝐼𝑖𝑜𝑛 = 𝛾𝑖𝑜𝑛(𝑉𝑚 − 𝐸𝑖𝑜𝑛)     (eq. 1.7) 
 
The ion velocity or current (𝐼𝑖𝑜𝑛) is limited by the conductance 𝛾𝑖𝑜𝑛 across the membrane, 
which is determined by the number of ion channels and their biophysical properties. The ion 
conductance for any transporter will be directly proportional to the stoichiometry of the 
transporter. For a 1:1 Na
+
: AA
0
 transporter the neutral amino acid transport rate equals the 
electrical conductance of sodium permeation through the transporter. 
 
Total electro-chemical free energy for any solute with a charge z (𝑠𝑧) is given by combining 
equations 1.2 and 1.5: 
 
       𝐺𝑠𝑧 = 𝑅𝑇 ln[ 𝑠
𝑧]𝑜𝑢𝑡 − 𝑅𝑇 ln[ 𝑠
𝑧]𝑖𝑛 + 𝑧𝐹𝐸𝑠𝑧   (eq. 1.8) 
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2. Concentrative capacity of B0AT1 and B0AT3 
The membrane equilibrium equation (eq. 1.8) is first corrected for the total electrical potential 
(𝑉𝑚) as defined by the GHK equation (eq. 1.6) to become: 
 
𝐺𝑠𝑧 = 𝑅𝑇 ln[ 𝑠
𝑧]𝑜𝑢𝑡 − 𝑅𝑇 ln[ 𝑠
𝑧]𝑖𝑛 + 𝑧𝐹𝑉𝑚 
 
For every transport cycle of B
0
AT1, potential energies must balance the translocation of a 
single sodium and L-leucine in and out: 
 
𝜇𝑙𝑒𝑢
𝑖𝑛 +  𝜇𝑁𝑎+
𝑖𝑛 =  𝜇𝑙𝑒𝑢
𝑜𝑢𝑡 +  𝜇𝑁𝑎+
𝑜𝑢𝑡  
 
A membrane equilibrium expression for each solute moving in each direction can be formed 
following re-arrangement and simplification of equation 1.8. Combining the expressions for 
L-leucine and sodium, the concentrative capacity of the downhill fluxing solute (Na
+
) for the 
uphill fluxing solute (L-leucine) calculated from: 
 
[𝑙𝑒𝑢]𝑖𝑛
  [𝑙𝑒𝑢]𝑜𝑢𝑡
=
[𝑁𝑎+]𝑖𝑛
  [𝑁𝑎+]𝑜𝑢𝑡
 𝑒
𝑧𝐹−𝑉𝑚
𝑅𝑇      
        (eq. 1.9) 
 
Under physiological conditions [Na+]out = 150, [Na
+]in = 15 mM, T = 310 K (37°C), z =
 +1, −Vm =  −62 mV, and RT F⁄  reduces to 26.7 mV, the concentrative capacity ratio for L-
leucine is: 
 
[𝑙𝑒𝑢]𝑖𝑛
  [𝑙𝑒𝑢]𝑜𝑢𝑡
=
150
15
𝑒2.32 = 10 × 10 = 100 
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That is, under physiological conditions B
0
AT1 can concentrate L-leucine approx. 100 times 
the concentration inside the brush border cells to the lumen. 
For B
0
AT3 the addition of a 2nd sodium to the transport stoichiometry increases this 
concentrative capacity even further for L-alanine as a squared function of the outside to 
inside sodium concentration gradient: 
 
[𝑎𝑙𝑎]𝑖𝑛
  [𝑎𝑙𝑎]𝑜𝑢𝑡
= (
[𝑁𝑎+]𝑖𝑛
  [𝑁𝑎+]𝑜𝑢𝑡
)2 𝑒
𝑧𝐹−𝑉𝑚
𝑅𝑇      
 
Under the same physiological conditions as for B
0
AT1 mediated transport above: 
 
[𝑎𝑙𝑎]𝑖𝑛
  [𝑎𝑙𝑎]𝑜𝑢𝑡
= (
150
15
)2 𝑒2.32 = 102  × 10 = 1000 
 
Addition of a single sodium ion in the transport cycle increases the concentrative capacity of 
B
0
AT3 for L-alanine by 1000 times for the brush border cytosol to lumen ratio. The value of 
𝑧, the net coulombic charge transfer across the membrane per transport cycle remains as +1 
due to cotransport of a chloride ion by B
0
AT3. The chloride chemical gradient is discounted 
at it is close to equilibrium in resting cells.  
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Appendix B: Table of Solutions 
Solution/Buffer Composition 
Oocyte Ringer (OR2−) 82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 1 mM Na2HPO4, 5 mM Hepes, 
pH 7.8 
Oocyte Ringer (OR2+) 82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 1 mM Na2HPO4, 5 mM Hepes, 
1 mM CaCl2, pH 7.8 
Oocyte Ringer (OR2+) + 
gentamycin 
82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 1 mM Na2HPO4, 5 mM Hepes, 
1 mM CaCl2, 50 μg/ml gentamycin, pH 7.8 
ND96  96 mM NaCl, 2m M KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM Hepes, 
titrated with NaOH to pH 7.4 
Phosphate Buffer Saline 
(PBS) pH 8.0 
137 mM NaCl, 2.7 mM KCl, 5 mM Na2HPO4, titrated with NaOH to pH 8.0 
Oocyte Lysis Buffer 150 mM NaCl, 20 mM Tris-HCl, 1 % v/v Triton X-100, pH 7.6 
Oocyte homogenization buffer 100 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA,  Protease inhibitor tablet (1 
tablet/50 ml) (Roche), pH 7.6 
Oocyte homogenization buffer 
+ SDS 
100 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA,  4% (w/v) SDS 
BBMV preparation buffer A 300 mM mannitol, 5 mM EGTA, 12 mM Tris-HCl, pH 7.1 
BBMV preparation buffer B 150 mM mannitol, 2.5 mM EGTA, 12 mM Tris-HCl, pH 7.1 
BBMV preparation buffer C 80 mM mannitol, 100 mM NaCl, 10 mM Tris-HCl, 10 mM MES, pH 7.4 
Hank’s Buffered Saline 
Solution (HBSS) 
136.6 mM NaCl, 5.4 mM KCl, 2.7 mM NaH2PO4•2H2O, 1% (w/v) or 5 mM 
D-glucose, 1.3 mM CaCl2, 0.5 mM MgCl2, 0.44 mM KH2PO4, 0.41 mM 
MgSO4, 5 mM HEPES, titrated to pH 7.4 using NaOH 
Hank’s Buffered Saline 
Solution (sodium replacement) 
136.6 mM NMDG-Cl (meglumine), 5.4 mM KCl, 2.7 mM NaH2PO4•2H2O, 
1% (w/v) or 5 mM D-glucose, 1.3 mM CaCl2, 0.5 mM MgCl2, 0.44 mM 
KH2PO4, 0.41 mM MgSO4, 5 mM HEPES, titrated to pH 7.4 using HCl 
SOC media SOB media (0.5% w/v yeast extract, 2% w/v Tryptone, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 10 mM MgSO4) + 20 mM D-glucose  
Colony cracking Buffer 300 mM sucrose, 0.25% (w/v) SDS, 200 mM NaOH 
(Colony cracking) 
resuspension buffer 
10 mM EDTA (pH 8.0), 4 M KCl, 0.4% (w/v) bromophenol blue 
APN assay buffer 262 mM Tris-HCl, 262 mM NaCl, pH 7.8 
Alkaline phosphatase buffer 1 M diethanolamine, 0.5 mM MgCl2; titrates to pH 9.8 with HCl 
MES 50 mM MES, 50 mM Tris, 0.1% (w/v) SDS, 1 mM EDTA, pH 7.3 
MOPS 50 mM MOPS, 50 mM Tris, 0.1% (w/v) SDS, 1 mM EDTA, pH 7.7 
SDS-PAGE Tris-glycine 
running buffer 
25 mM Tris, 1.92 M glycine, 1% (w/v) SDS,  
SDS-PAGE transfer buffer 25 mM Tris, 1.92 M glycine, 20% (v/v) methanol (chill until cold before 
use) 
Colloid coomassie BB G-250 
stain  
10% (v/v) > 96% EtOH, 2% > 85% orthophosphoric acid (H3O4P),  5% 
(w/v) Aluminum sulfate-(14-18)-hydrate (Al2(SO4)3∙16H2O) , 0.02% (w/v) 
Coomassie brilliant blue G-250  
PBS-Tween 20 137 mM NaCl, 2.7 mM KCl, 5 mM Na2HPO4, 0.1% (v/v) Tween 20, titrated 
with NaOH to pH 7.4  
Nitrocellulose membrane 
stripping buffer 
100 mM β-mercaptoethanol, 2 % (w/v) SDS, 62.5 mM Tris-HCl (pH 6.7) 
Blue-native detergent buffer 20 mM Bis-Tris pH 7, 50 mM NaCl, 10% (v/v) glycerol, 1 mM DTT (+ 
selected detergent) 
Blue-native loading dye 50 mM ε-amino n-caproic acid, 10 mM Bis-Tris (pH 7.0), 0.5% (w/v) 
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coomassie BB G-250,  
Blue-native gel buffer 66 mM ε-amino n-caproic acid, 50 mM Bis-Tris (pH 7.0) 
Blue-native cathode running 
buffer 
50 mM tricine, 15 mM Bis-Tris (untitrated), 0.2% (w/v) Coomassie BB G-
250 
Blue-native anode running 
buffer 
50 mM Bis-Tris (pH 7.0) 
Blue-native gel staining 
solution 
50% (v/v) methanol, 7% (v/v) glacial acetic acid, 0.1% (v/w) Coomassie BB 
G-250 (made up with MilliQ H2O) 
Blue-native gel destaining 
solution A 
50% (v/v) methanol, 7% (v/v) glacial acetic acid, 47% (v/v) MilliQ H2O 
Blue-native gel destaining 
solution B 
90% (v/v) methanol, 10% (v/v) glacial acetic acid 
Triton X-100 buffer 150 mM NaCl, 25 mM Hepes, pH 6.5, 1% (v/v) Triton X-100 (added 
following titration) 
Co-immunoprecipitation 
buffer 
20 mM Tris (pH 7.4), 150 mM NaCl, 5 mM MgCl, 1% (v/v) Triton X-100 
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Appendix C: Table of Primers and Created Plasmids 
Primer Name Origin Sense/anti
-sense 
Sequence (5’ 3’) 
pGem-He-Juel Cloning Primers 
APN cloning primer mouse sense CGCCACCATGGCCAAGGGGTTCTACAT 
anti-sense CAGGAACTAACTGCTGTTCTCTGTGAA 
Syntaxin 1A mouse sense TTGAAGCTTCCACCATGAAGGACCGA ACC 
anti-sense TTCAAGCTTCTATCCAAAGATGCC 
MCT1XbaI rat sense GCTCTAGACCACCATGCCACCTGCGATT 
B
0
AT1XbaI mouse sense TATCTAGACTAGGCCCATTCAGTTC 
B
0
AT3EcoRI mouse anti-sense TGAATTCTCCGCCTCAGCAGCCTCTG 
MCT1-B
0
AT1 Fusion rat  sense GCGGAGGAGGAGAGCCCAGTCGTGAGGCTTGTGCT
GCCCAAC 
anti-sense GTTGGGCAGCACAAGCCTCACGACTGGGCTCTCCT
CCTCCGC 
MCT1-B
0
AT3 Fusion rat sense GCGGAGGAGGAGAGCCCAGTCGCACAGGCCTCAG
GGATGGAC 
anti-sense GTCCATCCCTGAGGCCTGTGCGACTGGGCTCTCCTC
CTCCGC 
∆18-500ACE2 human sense GCATCTCTGTTCCATGTTTCTAATG 
anti-sense AGCAGCAGTTACAGCAA CAAG GCTG 
∆18-580ACE2 human sense GTAAGGCCACTGC TCAACTACTTTG 
anti-sense AGCA GCAG TTACAGCAACAAGGCTG 
Syntaxin 3 mouse sense TTGGAATTCGCCAGGATGAAGGACCG GCTG 
anti-sense TTCGAATTCTTATTTCAGCCCAACGGACAG  
Syntaxin 7 mouse sense TTGAAGCTTCCAGCCATGTCTTACACTCCG 
anti-sense TTCAAGCTT TCAGCCTTTCAGTCCCCATAC 
Syntaxin 1A mouse sense TTGAAGCTTCCACCATGAAGGACCGA ACC 
anti-sense TTCAAGCTTCTATCCAAAGATGCC 
Syntaxin 3 mouse sense TTGGAATTCGCCAGGATGAAGGACCG GCTG 
anti-sense TTCGAATTCTTATTTCAGCCCAACGGACAG  
pcDNA3.1+ Cloning Primers 
Venus[1]-
zip/pcDNA3.1Zeo(+) 
B
0
AT1  
mouse sense ATATCCGGAATGGTGAGGCTTGTGCTGCC 
anti-sense CCCTCTAGATCAGTTCTTAAGGTCCCCAT 
Venus[2]-
zip/pcDNA3.1Zeo(+) 
B
0
AT1  
mouse sense ATATCCGGAATGGTGAGGCTTGTGCTGCC 
anti-sense CCCTCTAGATCAGTTCTTAAGGTCCCCAT 
zip-
Venus[2]/pcDNA3.1Z
eo(+)B
0
AT1 
mouse sense TTAAGCGGCCGCATGGTGAGGCTTGTGCTGCC 
anti-sense GCCACCATCGATGTTCTTAAGGTCCCCATT 
Venus[1]-
zip/pcDNA3.1Zeo(+) 
APN  
mouse sense AGCGATATCAATGGCCAAGGGGTTCTAC 
anti-sense CCCTCTAGACTAACTGCTGTTCTCTGT 
Mutagenesis and Protein Engineering Primers 
APNE354A mouse sense ACGCTGGAGCCATGGCGAACTGGGGTCTGGT 
anti-sense ACCAGACCCCAGTTCGCCATGGCTCCAGCGT 
APNE388A mouse sense CTGTGATTGCTCACGCGCTGGCCCATCAGTG 
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anti-sense CACTGATGGGCCAGCGCGTGAGCAATCACAG 
APNE410A mouse sense ATCTGTGGCTGAACGCGGGCTTTGCCTCCTA 
anti-sense TAGGAGGCAAAGCCCGCGTTCAGCCACAGAT 
APNY476F mouse sense TTGACAGCATCACCTTCAGCAAGGGAGCCTC 
anti-sense GAGGCTCCCTTGCTGAAGGTGATGCTGTCAA 
B
0
AT3D21N + MCT-
B
0
AT3D21N 
mouse sense GGATGAAAGACCCAAGTGGAACAACAAACTCC 
anti-sense GGAGTTTGTTGTTCCACTTGGGTCTTTCATCC 
B
0
AT3Q25V + MCT-
B
0
AT3Q25V 
mouse sense GGGA CAACAAACTCGTG TACCTCCTGAGC 
anti-sense GCTCAGGAGGTACACGA GTTTGTTGTCCC 
B
0
AT3Q25D + MCT-
B
0
AT3Q25D 
mouse sense GGGA CAACAAACTCGAT TACCTCCTGAGC 
anti-sense GCTCAGGAGGTAATCGA GTTTGTTGTCCC 
B
0
AT3H50Y + MCT-
B
0
AT3H50Y 
mouse sense CCTGTGCCAGACCTACGGAGGAGGGGCC 
anti-sense GGCCCCTCCTCCGTAGGTCTGGCACAGG 
B
0
AT3Y72H + MCT-
B
0
AT3Y72H 
mouse sense GGTATCCCGCTTTTCCACATCGAGCTTGCC 
 anti-sense GGCAAGCTCGATGTGGAAAAGCGGGATACC 
B
0
AT3G78S + MCT-
B
0
AT3G78S 
mouse sense ATCGAGCTTGCCATTAGCCAGCGCCTACGGAGG 
anti-sense CCTCCGTAGGCGCTGGCTAATGGCAAGCTCGAT 
B
0
AT3K90T + MCT-
B
0
AT3K90T 
mouse sense GCATTGGAGTGTGGACGACCATCTCCCCTTACC 
anti-sense GGTAAGGGGAGATGGTCGTCCACACTCCAATGC 
B
0
AT3S158D + MCT-
B
0
AT3S158D 
mouse sense CAGTGGCACCGTGGACTACTTCTGGTACCG 
anti-sense CGGTACCADAAGTAGTCCACGGTGCCACTGC 
B
0
AT3L213W + 
MCT-B
0
AT3L213W 
mouse sense GGTGATCTACTTTACAGCCTGGTTCCCTTACCTGG 
anti-sense CCAGGTAAGGGAACCAGGCTGTAAAGTAGATCACC 
B
0
AT3R225T + MCT-
B
0
AT3R225T 
mouse sense CCATCTTCCTCATCACAGGTCTTACCCTGCC 
anti-sense GGCAGGGTAAGACCTGTGATGAGGAAGATGG 
B
0
AT3R225W mouse sense CCATCTTCCTCATCTGGGGTCTTACCCTGCC 
anti-sense GGCAGGGTAAGACCCCAGATGAGGAAGATGG 
B
0
AT3R225E mouse sense CCATCTTCCTCATCGAAGGTCTTACCCTGC 
anti-sense GCAGGGTAAGACCTTCGATGAGGAAGATGG 
B
0
AT3R225D mouse sense CCATCTTCCTCATCGACGGTCTTACCCTGC 
anti-sense GCAGGGTAAGACCGTCGATGAGGAAGATGG 
B
0
AT3N283D + 
MCT-B
0
AT3N283D 
mouse sense CCCACCCAGGAACGATTGTGAGAAGGACG 
anti-sense CGTCCTTCTCACAATCGTTCCTGGGTGGG 
B
0
AT3D287K + 
MCT-B
0
AT3D287K 
mouse sense GGAACAATTGTGAGAAGAAGGCCGTGATTATTGCC 
anti-sense GGCAATAATCACGGCCTTCTTCTCACAATTGTTCC 
B
0
AT3D287N + 
MCT-B
0
AT3D287N 
mouse sense GGAACAATTGTGAGAAGAACGCCGTGATTATTGCC 
anti-sense GGCAATAATCACGGCGTTCTTCTCACAATTGTTCC 
B
0
AT3S296R + MCT-
B
0
AT3S296R 
mouse sense ATCGCCCTGGTCACCAGCATGACCTCCCTGTAC 
anti-sense GTACAGGGAGGTCATGCTGGTGACCAGGGCGAT 
B
0
AT3M297S + 
MCT-B
0
AT3M297S 
mouse sense CCCTGGTCAACAG CTCGACCTCCCTGTATGC 
anti-sense GCATACAGGGAGGTCGA GCTGTTGACCAGG G 
B
0
AT3M297C + 
MCT-B
0
AT3M297C 
mouse sense CCCTGGTCAACAG CTGCACCTCCCTGTATGC 
anti-sense GCATACAGGGAGGTGCA GCTGTTGACCAGG G 
B
0
AT3I456T + MCT-
B
0
AT3I456T 
mouse sense TTCCTCTCAGCCACTTGCTTCACACTGCAG 
anti-sense CTGCAGTGTGAAGCAAGTGGCTGAGAGGAA 
B
0
AT3G464N + 
MCT-B
0
AT3G464N 
mouse sense GCAGTCTGGAAACTACTGGTTGGAGATC 
anti-sense GATCTCCAACCAGTAGTTTCCAGACTGC 
B
0
AT3L477P + MCT- mouse sense AGTTTTGCAGCTTCTCCGAATTTAATCATCTCC 
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B
0
AT3L477P anti-sense GGAGATGATTAAATTCGGAGAAGCTGCAAAACT 
B
0
AT3G495R + 
MCT-B
0
AT3G495R 
mouse sense GTCATTCACATTTATCGGATGAAACGGTTCTGT 
anti-sense ACAGAACCGTTTCATCCGATAAATGTGAATGAC 
B
0
AT3D502N + 
MCT-B
0
AT3D502N 
mouse sense CGGTTCTGTGATAACATTGAATGGATGACTGG 
anti-sense CCAGTCATCCATTCAATGTTATCACAGAACCG 
B
0
AT3Q568R + 
MCT-B
0
AT3Q568R 
mouse sense CCAGGCTGGGTGAGGGTCACCTGTGTGC 
anti-sense GCACACAGGTGACCCTCACCCAGCCTGG 
B
0
AT1R240Q mouse sense CCATCTTTCTCATCCAGGGCTTGACTCTGAAGG 
anti-sense CCTTCAGAGTCAAGCCCTGGATGAGAAAGATGG 
B
0
AT1R240W mouse sense CCATCTTTCTCATCTGGGGCTTGACTCTGAAGG 
anti-sense CCTTCAGAGTCAAGCCCCAGATGAGAAAGATGG 
B
0
AT1R240E mouse sense CCATCTTCCTCATCGAAGGCCTGACGCTGAAGG 
anti-sense CCTTCAGCGTCAGGCCTTCGATGAGGAAGATGG 
B
0
AT1R240D mouse sense CCATCTTCCTCATCGACGGCCTGACGCTGAAGG 
anti-sense CCTTCAGCGTCAGGCCGTCGATGAGGAAGATGG 
collectrin∆15-135 mouse sense ATGGAGCCATCTGTGCCCGT 
anti-sense AGCGTGAATAGTAGTCACCA 
collectrin∆175-221 mouse sense TGAGAGTGACAGTCTTGTAA 
anti-sense TTTGTTGTTCCTTCTGCGTT 
collectrin∆2-14 mouse sense GAACTCTGCCATCCAGATGC 
anti-sense CATGGTGGAATTCGGATCCC 
collectrin∆15-40 mouse sense GTCTGGGACACGGATCAAGA 
anti-sense AGCGTGAATAGTAGTCACCA 
collectrin∆41-65 mouse sense GCAACAGAAATTTCCCATGT 
anti-sense ATATGCTTTATCTCCAAGAG 
collectrin∆66-90 mouse sense TCCAACAATTATACTCTTCC 
anti-sense TTCTCTGTTGGGAACTTTTC 
collectrin∆91-115 mouse sense TTTTTTCTGGATGACCATAC 
anti-sense AGGGTCCGTGACCACAAACC 
collectrin∆116-135 mouse sense ATGGAGCCATCTGTGCCCGT 
anti-sense TGCACTGGTGATCCGGTTCC 
collectrin∆136-174 mouse sense GGACCACCTGGAGTGGAAGA 
anti-sense CGGGGGAGCAAGAGTAGAAG 
collectrin∆163-178 mouse sense GTGGAAGATGCAGAAGACAA 
anti-sense AACCAGTAGTGCAATTGCAA 
collectrin∆179-195 mouse sense ATCCCTTGTGATCCCTTGGA 
anti-sense TCCAGGTGGTCCTTTGTTGT 
collectrin∆196-212 mouse sense TTGACAGAGGATGAGCCGCCT 
anti-sense GCCATTTTCTATTGTGATGA 
collectrin∆213-221 
 
mouse sense 
anti-sense 
TGAGAGTGACAGTCTTGTAA 
GAAGCCATCATTAATGTGCC 
collectrinE22R human sense CCAGGTGCACGAAATGCTTTTAAAGTG 
anti-sense CACTTTAAAAGCATTTCGTGCACCTGG 
collectrinD37R human sense GCTCTGGGACGTAAAGCATATGCCTGG 
anti-sense CCAGGCATATGCTTTACGTCCCAGAGC 
collectrinD100R human sense CCCTTCCTGCTGTTCGGGTGCAATCAGCC 
anti-sense GGCTGATTGCACCCGAACAGCAGGAAGGG 
collectrinD120R human sense CCTTCTTTCTAAATCGCCAAACTCGG 
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anti-sense CCAGAGTTTGGCGATTTAGAAAGAAGG 
collectrinE124R human sense CCAAACTCTGCGATTTTTAAAAATCC 
anti-sense GGATTTTTAAAAATCGCAGAGTTTGG 
collectrinD137R human sense GCACCACCCATGCGCCCATCTGTGCCC 
anti-sense GGGCACAGATGGGCGCATGGGTGGTGC 
collectrinE137R mouse sense GCTCCCCCGATGAGGCCATCTGTGCCCG 
anti-sense CGGGCACAGATGGCCTCATCGGGGGAGC 
collectrinW143R mouse sense CCATCTGTGCCCGTCAGGATTATTGTATTCGG 
anti-sense CCAATACAATAATCCTGACGGGCACAGATGG 
collectrinW143A mouse sense CCATCTGTGCCCGTCGCGATTATTGTATTCG 
anti-sense CGAATACAATAATCGCGACGGGCACAGATGG 
collectrinR169T mouse sense GGAATCCGGCAAACCAGAAGGAACAACAAAGG 
anti-sense CCTTTGTTGTTCCTTCTGGTTTGCCGGATTCG 
collectrinR170-171T mouse sense GGAATCCGGCAACGCACAACGAACAACAAAGGAC
C 
anti-sense GGTCCTTTGTTGTTCGTTGTGCGTTGCCGGATTCC 
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Appendix E: HMM Profile Sequence Alignment of selected Collectrin Orthologs 
31 collectrin ortholog sequences were selected from the 95 remaining unique HMM collectrin ortholog sequences following filtering and 
verification (section 2.7.3). The species origin and UniPROT identifier (in brackets) of collectrin orthologs are located to the left. Sequences 
were aligned using PROMAL3D (section 2.7.5). Sequences were selected to represent the full range of major taxa. 
Human (Q9HBJ8)                  1   MWLLFF---LVTAIHAELCQP-GAENAFKVRLSIRTALGDKAYAWDTNEEY-LFKAMVAFSMRKVPNREATEISHVLLCNVTQRVSFWFV  
Orangutan (H2PUZ6)              1   MLWLLFF--LVTAIHAELCQP-GAENAFKVRLSIRTALGDKAYAWDTNEEY-LFKAMVAFSMRKVPNREATEISHVLLCNVTQRVSFWFV  
Olive baboon (A0A096NAI7)       1   MLWLLFF--LVTAIHAELCQP-GAANAFKVRLSIRTALGNKAYAWDTSEEY-LFKAMVAFSMRKVPNREATEISHVLLCNVTQRVSFWFV  
Mouse (Q9ESG4)                  1   MLWALFF--LVTTIHAELCHP-DAENAFKVRLSIRAALGDKAYVWDTDQEY-LFRAMVAFSMRKVPNREATEISHVLLCNITQRVSFWFV  
Bovine (Q0VCT4)                 1   MLWLLFF--LVTAIHADLCRP-DAENAFKVRLSIRTALGDKAYAWDANEEY-LFKAMVAFSMRKVPNRETTEISHVLLCNVTQRVSFWFV  
Rat (Q9ESG3)                    1   MLWALFF--LVTTIHAELCRP-DAENAFKVRLSIKAALGDKAYVWDTDEEY-LFRAMVAFSMRKVPNREGTEISHVLLCNVTQRVSFWFV  
Cat (M3WB82)                    1   MLCLLFF--LVTAIHAELCQPADGENAFKVRLSIRTALGDNAYAWDTNEEY-LFKAMVAFSMRKVPNRETTEISHVLVCNVTQRVSFWFV  
Horse (F7DYY2)                  1   MLWLLFF--LVTAIHAELCQP-GAENAFKVRLSIRTALGDKAYAWDTNEEY-LFKAMVAFSMRKVANREKTEISHVLLCNVTQRVSFWFV  
African elephant (G3TXT9)       1   MLWPLFF--LVTAIHAELCQPADAENAFKVRLSIKTALGDKAYAWDTNEEY-LFKAMVAFSMRKVPNRETTEISHVLLCNVTQRVSFWFV  
Rabbit (G1T4N6)                 1   MLWLFFF--LVTAIHAELCQP-DAENAFKVRLSIRTALGDKAYAWDTNEEY-LFRAMVAFSMRKVPNRETTEISHVLLCNVTQRVSFWFV  
Chinese Hamster (A0A061HUM1)    1   MLWLLLF--LVTAIHAELCHP-DAENAFKVRLSIRTALGDKAYVWDTDEEY-LFRAMVAFSMRKVPNRETTEISHVLLCNVTQRVSFWFV  
Little brown bat (G1PY19)       1   MWWLLFF--LVTAIRAELCQP-DAENAFKVRLSIRTALGDKAVSGEPAKEYRINKVVFLWSVKISPNRRTRKISHVLLCNITQRVSFWFV  
Opossum (F6XES0)                1   ALLPALS--LVTVIHAQLCQP-GAKDAFKVRLSLKTALGDKAYTWNENEEY-LFKAMVAFSIRTFSSREKIEISNVLLCNVTKRVSFWFV  
Tasmanian devil (G3WLD7)        1   ALFSTLS--LVTIIHAQLCEP-DAKNAFKVRLSLKTALGDKAYVWDENEEY-LFKAMMAFSLRTFSNRETIEISNILLCNVTKRVSFWFV  
Naked mole rat (A0A0P6K1I7)     1   MLWLFFF--LVTAIHAELCQP-DAENAFKVRLSIRTALGDKAYIWDKNEEY-LFRAMVAFSMRKVPNREATEISHVLLCNVTQRVSFWFV  
Chicken (R4GKR4)                1   VLLLAFS--VVSVASAELCKP-DAQNAFKVRLSIKTALGDNAYAWDANEEY-LFKAMIAFTMRRYSSKSTTQISNVLLCNVTDRVSFWFV  
Dalmatian pelican (A0A091SP85)  1   VLLLTLS--VVAVAHAELCKP-DAQNAFKVRLSIKTALGDNAYVWDANEEY-LFKAMVAFAMRRYSSKTTTQISNVLLCNVTDRVSFWFV  
Zebra finch (H0ZCB6)            1   ALLLLVS--VVAIAHAELCKP-DAQNAFKVRISIKTALGDNAYAWDANEEY-LFRAMVAFAMRRYSSKSTTQISNVLLCNVTDRVSFWFV  
Flycatcher (U3JP51)             1   ALLLTLS--VVAIAHAELCKP-DAQNAFKVRISIKTALGDNAYAWDANEEY-LFKAMVAFAMRRYSSKSTTQISNVLLCNVTDRVSFWFV  
King cobra (V8NIT5)             1   PFGLTFS--SSGVIR-------DAQNAFKVRLSIKTALKENAYSWDATEEY-LFKAVLAYAMRRYLIQETTQISNVLLCNVTSRVSFWFV  
Green anole (G1KTF4)            1   ELLLASV--WVTVACTELCRP-DAENAFKVRLSIKTALGDNAYSWDATEEY-LFKAVVAFAMRRSFSQEATQVSNVLLCNVTERVSFWFV  
Softshell turtle (K7FP24)       1   VLLLVFS--LVALAHAELCRP-DAQNAFKVRLSIKTALGDNAYAWDASEEY-LFKAMVAFAMRRYSNKETTQISNVLLCNMTERVSFWFV  
Xenopus laevis (Q6PE94)         1   ILLFLLS--LPTFVHGDLCEP-GSRGALKVRLNIKAALGDNAYTWNSDEEY-LFKAVMAFVMRSYTKNDTFQISNIVLCNSTERVSFWFV  
Atlantic salmon (B5X131)        1   RILVLLYLAGAPALAQTLCQP-NASNGYRVRISIKTALGNQAYEWNENEMF-LFRATMAFTMRRYYKTETYNVDNIIVCNQTLRVSFWFV  
European seabass (W8FKQ5)       1   KILILLC--LSSALAEQPCKP-DASDGYKVRLSIKTALGDEAYVWNENEMF-LFRATLAFAMRSHLNGQEFDVSNIIVCDETPRVTFWFV  
Zebrafish (F1QQZ6)              1   FLLTIIL--LSPVVAQDLCK--ESKDGFKVRISLKTALGNDAYEWNESEKF-LFRSTLAYAMRKKTGEDTYNIENILVCNDTKRVSFIFV  
Spotted gar (W5MLR7)            1   GLLVLLI--LMPALAVAACEP-NGQDAYKVRLSIKTALGKNAYEWNESELF-LFRATLAFAMRRYLNKENFNVSSVIVCKETPRVSFWFV  
Nile tilapia (I3J503)           1   KILLLLS--LSFSVAEELCKP-GAAEGYKVRFSIKTALGDQAYPWSKNEMF-LFRAALAFAMRDYTNGEEFGVSDIHPCDETKRVSFWFV  
Rainbow trout (A0A060Y6C2)      1   WILFLLCQVGAPALAQDLCQR-DAPNGYKVRISLKTALGEDAYEWNQSEMF-FFQATMAFAMRRHFQMETYNVDNIILCVQTSRVSFWFV  
Coelacanth_(H3B1K1)             1   ALLFALC--LVSVAQAQICHP-HEPNAYKVRLSIKTALGDKAYNWNENEQY-LFRATIAFAMRQYLKNEIFRASNVLTCNETQRVSFWFV  
Tunicate (E4Y0K1)               1   VLLTILA-----AANGLTCE------DGQVKTFFKMTKSEQTSNWDNIAKD-LLQNTLTSAYRKHNSETN-AVVQWNRADETERVSFCLE  
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Human (Q9HBJ8)                  87  VTDPSKN-HTLP--AVEVQSAIRMNKNRINNAFFLNDQTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIIIVAIALLILSGIWQRRRKN  
Orangutan (H2PUZ6)              87  VTDPSKN-HTLP--AVEVQSAIRTNKNRINNAFFLNDQTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIVIVAITLLILSGIWQRRRKN  
Olive baboon (A0A096NAI7)       87  VTDPSKN-HTLP--AVEVQTAIRMNKNRINGAFFLNDQTLEFLKIPSTLAPPMDPSVPIWIIIFGVIFCIVIVAITLLILSGIRQRRRKN  
Mouse (Q9ESG4)                  87  VTDPSNN-YTLP--AAEVQSAIRKNRNRINSAFFLDDHTLEFLKIPSTLAPPMEPSVPVWIIVFGVIFCIVTVAIALLVLSGIRQRRRNN  
Bovine (Q0VCT4)                 87  VTDPSRN-HTLP--AVEVQSAIRMNRNRINNAFFLNDQTLEFLRIPSTLAPPTDPSVPIWIIIFGVIFCIVLVATMLLIISGIRQHRRKN  
Rat (Q9ESG3)                    87  VTDPLKN-HTLP--AAEVQSAIRMNRNRINSAFFLDDHTLEFLKIPSTLAPPMDPSVPVWIIVFGVIFCIVTVAIALLVLSGIRQRRRNK  
Cat (M3WB82)                    88  VTDPLKN-HTLP--AVEVQTAIRMNRNRINGAFFLNDQTLEFLKIPSTLAPPTDPSVPIWIIIFGVIFCIVIVAVMLLILSGIRQRRRMS  
Horse (F7DYY2)                  87  VTDPSEK-HTLP--AVEVQEAIRMNRNRINNAFFLNDQTLEFLKIPSTLIPPTDPPVPIWIIIFGVIFCIVIVAIILLILSGIRQRRRKD  
African elephant (G3TXT9)       88  VTDPSKK-YTLP--AMEVQSAIRMSRNRINNAFFLNDQTLEFLKIPSTLAPPSDPAVPIWIIVFGVIFCIVIVAITVLILSGIRQHRRNN  
Rabbit (G1T4N6)                 87  VTDPSKN-HTIP--AVEVQSAIRMNRDRINNAFFLNDQTLEFLKIPSTLAPPTDPSVPVWIIIFGVIFCIVVVAIALLILSGIQQRRRKN  
Chinese Hamster (A0A061HUM1)    87  VTDPSKN-HTLP--AAEVQSAIRMNRNRINSAFFLDDHTLEFLKIPSTLAPPPDASVPVWIIVFGVIFCIVVVAIALLVLSGIRQRRRNN  
Little brown bat (G1PY19)       88  VTDPTKN-YTLP--ADEIQSAIRMNRNRINSAFSLNDQTLEFLKIPSTLAPPTDPSVPIWIIIFGVVFCIVIVAITLLVLSGIRQRRRKN  
Opossum (F6XES0)                87  VTDPSEN-QTVP--AGEVQGAIRMNRNRINNAFILNDQTLEFLEIPATLGPPTEPSTPIWVIIFSVVFCLVIVGIVLLIVSGIRQRRRKS  
Tasmanian devil (G3WLD7)        87  VTDPSTN-QTLP--ADEVQRAIRMNRNRINHAFFLNDQTLEFLEIPATLGPPTEPSTPVWIITFGVVFCLVIIGIVLLVMSGIRQRRRKS  
Naked mole rat (A0A0P6K1I7)     87  VTDPLKN-HTLPADEVQW--AIRMNRNRINNVFFLNDQTLEFLKIPSTLAPPTDPSVPIWIIIFGVIFGIIIVATTLLVLSGIRQRRRKN  
Chicken (R4GKR4)                87  VTDSSKNTTTVP--GSEVEAAIRMNRNRINSAFLLSDKTLQFLKISTTLSPPVEPSTPVWLIVFGVVLSLIVAGIVFLVVSGIQQRKKKN  
Dalmatian pelican (A0A091SP85)  87  VTDSSKNVTTVP--GSEVEEAIRMNRNRINSAFLLSDKTLQFLKITSTLSPPVEPSTPVWLIIFGVVLCLIVAGIVFLIVSGIQQHKKKN  
Zebra finch (H0ZCB6)            87  VTDSSKNVTTVP--GSEVEAAIRMNRNRINNAFLLSDKTLQFLKITSTLSPPVEPSTPVWIIVFGVVLCLIVAGIVFLIVSGIQKHKKKN  
Flycatcher (U3JP51)             87  VTDSSKNVTTVP--GSEVEAAIRMNRNRINNAFLLSDKTLQFLKITSTLSPPVEPSTPVWLIVFGVVLCLIVAGIVFLIISGIRKHKKKN  
King cobra (V8NIT5)             81  VTNSFTNITTIP--RNDVEAAIRMNRNRINNAFLLTDDTLQFLGISSTLAPPAEQLLPIWLIVFGVILCIIVIGIVLVVSFGIYHRKR-R  
Green anole (G1KTF4)            87  VTDSSTNKTTVP--KSVVEAAIRLNRNRINSAFLLDDSTLQFLQISATLAPRVEPPVPTWLIVFGVSFCLVAVGIVLLIISGIHKNRRRN  
Softshell turtle (K7FP24)       87  VTDSSKNVTTVP--GSEVEAAIRMNRNRINSAFLLTDNTLQFLKISSTLSPPIEPTVPVWLIVFSVVLCLVGAGILFLVLSGIRQRRKNN  
Xenopus laevis (Q6PE94)_        87  VTSPSNESHPVS--YSVVEAAVRNERNRINSAFLLNDKTLEFVQIPPTLAPASQSSSSSWLIVFGVVVFVVSVAIAYLVVSGVIRHRKRL  
Atlantic salmon (B5X131)_       89  VTSPDNSTMLIP--KADVEKAVSMSRHRINNAFLLTDRTLEFLGIPPTLAGPVNPDTPPWLIVFGVVIGAVCAGIIVLLVSSLLQKRRKD  
European seabass (W8FKQ5)_      87  VTSPLNTSGLVD--KGVVEEAIRMSRNRINSAFLLTDKTLEFIGITPTLTAPVNPDTPPWLIVFGVVMGAVGAGIIVVLVSPLVLKKRKK  
Zebrafish (F1QQZ6)_             86  VTLPADPTQLIP--KEEVERAVRQSKHRINNAFLLSDMTLEFVGVPPTLAVPIQYNTPPWLIVFGVVIGIVAVGIVALLMSTVSKRRRAK  
Spotted gar (W5MLR7)            87  ITDPGNTSKLIP--RTDVEHAVRMSRNRINSAFLLTDKTLQFIGIPPTMAVPLEPATQPWLIVFGVIISLVMVAILALIIHGAIQKRRRG  
Nile tilapia (I3J503)_          87  VTRPNT-TDLVD--KGTVEMAIKKSRNRINGAFLLTDQTLEFDGIYPTLAAPVSPDTPPWLIVFGVVMGAVSVGIIALLAYPLVQRKLKK  
Rainbow trout (A0A060Y6C2)_     89  VTSPDNTTMLIP--KADVEKAVRMSRHRINNAFLLSDRTLEFLGIYPTLAAPVNPDTPPWLIVFGVVIGAVCAGIIALLVSSLLQKRRKE  
Coelacanth_(H3B1K1)             87  VTSPENPSVTIP--ENDVAEAIRLNRHRINNAFLLSDKTLQFIGIPPTLSPPVESSLPVWLILFGVVLGLVVIGIIFMIVTGIRQRKSKR  
Tunicate (E4Y0K1)               78  VKDNVS---DDT--AKKLRQAIYYLKPNVYGAMQTNETVLVFDGVPKTYVIE--EESRQWLYPYYAFMGLGLIGIAASLYASVKENKVEE  
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Human (Q9HBJ8)                 174 KEPSE--------VDDAEDK--CENMITIENGIPSDPLDMKGGHINDAFMT-EDERLTPL   
Orangutan (H2PUZ6)             174 KEPSE--------VDDAEDK--CENMITIENGIPSDPLDMKGGHINDAFMT-EDERLTPL  
Olive baboon (A0A096NAI7)      174 KEPSE--------VDDAEDK--CENMNTIENGIPCDPLDMKGGHINDAFMT-EDERLTPL  
Mouse (Q9ESG4)                 174 KGPPG--------VEDAEDK--CENIITIENGIPCDPLDMKGGHINDGFLT-EDERLTPL  
Bovine (Q0VCT4)                174 KGPSE--------MEDSEDK--CENVITIENGIPCDPLDMKGGHINDAFVT-EDERLTPL  
Rat (Q9ESG3)                   174 KGPPG--------VEDAEDK--CENIITIENGIPCDPLDMKGGHINDGFLT-EDERLTPL  
Cat (M3WB82)                   175 KGPTE--------VDDSEDK--CENTITIENGIPCDPLDTKGGHINDAFMT-EDERLTPL  
Horse (F7DYY2)                 174 KGPSE--------VDDTEDK--CENTITIENGIPCDPLDTKGGHVNDAFMT-EDERLTPL  
African elephant (G3TXT9)      175 DGPSE--------VEDAEDK--CETTITVENGIPCDPLDTKDGCLNDAFVT-EGERLTPL  
Rabbit (G1T4N6)                174 EGPSE--------VGDAEDK--CENTITIENGIRCDPLDTKGGCVNDAFMT-EEERLTPL  
Chinese Hamster (A0A061HUM1)   174 KGPLG--------VEDAEDK--CENIITIENGIPCDPLDTKGGLINDGFLT-EDERLTPL  
Little brown bat (G1PY19)      175 KEPSE--------VDDTEDK--SENTITIENGIPCDPLDTKGWHINDTFMT-EDERLTPL  
Opossum (F6XES0)               174 KASTE--------MTDVEDK--CETMVTIENGIPCDTLDSKEGRTNRAFAA-GDEKLTPL  
Tasmanian devil (G3WLD7)       174 KESRE--------TGDVEDK--NETMVTIENGIPCDTLDFKEGCVNRALVA-DDEKLTPL  
Naked mole rat (A0A0P6K1I7)    174 KESSE--------VDDTEDK--FENMATIANSILCDSLDMKGGLVNDVFMT-EDERLTPL  
Chicken (R4GKR4)               175 KESTE--------RENLEEK--GEVTITIENGIPCETLDLKAGHVNGVFAA-DDERFTSL  
Dalmatian pelican (A0A091SP85) 175 KESTE--------RENLEEK--GEVTVTVENGIPCETLDLKAGHINGVFVA-DDERFTSL  
Zebra finch (H0ZCB6)           175 KESTE--------RENLEEK----VEVTLENGIPCEALDLKAGHINGVFAA-EDERFTSL  
Flycatcher (U3JP51)            175 KESTE--------RENLEEK----VEVTLENGIPCEALDIKAGHVNGVFAA-DDERFTSL  
King cobra (V8NIT5)            168 KNVEE--------TEDLDDK--YEAAITMENRIPCHTLDLKAGQINGVYAAADDDRFTPL  
Green anole (G1KTF4)           175 KEPEE--------TEDLEEK--CETTITVENGIPCDTLDLKAGQINGVYAAGDDERLTPF  
Softshell turtle (K7FP24)      175 NESAE--------NGDLEDK--CDTPVTTENGIPCDILDLKTGRINGVYTA-DDERFTPL  
Xenopus laevis (Q6PE94)        175 KSSEE-------ESQNSEAR--MKSLDAIKNGGLHDKTILTDSLVNDSYDY-TGDAYTAF  
Atlantic salmon (B5X131)       177 KGMME--------DGQDEED---RQMKGVDNGNVL------DGIYNKGFT--DDNRFTTL  
European seabass (W8FKQ5)      175 NE--E--------TDEDEEE---TGVKAVENGSTR------EGVYNMSFS--DDERLTQM  
Zebrafish (F1QQZ6)             174 AKDAG--------FDQDGDD----EGIVKENGTALSGLNKKDGVYNQAFS--NDERFTKL  
Spotted gar (W5MLR7)           175 KAISDE------EEEKEEEE---KQGQITENGIHCEVTDGKEGVHNRGFHQ-EDERLTQL  
Nile tilapia (I3J503)          174 NKDAD--------DEDSDE----------ETGVKTAEIGANDGIYNSTFS--DDERFTQM  
Rainbow trout (A0A060Y6C2)     177 KGMTE--------DGQDEED---MQVKGVENGINL------DGTYNRGFT--DDDRFTKL  
Coelacanth_(H3B1K1)            175 LKKPV--------HEEDPEE--KLERGVIENGIACQTIEEAEGIKNGAYEH-DDDKLTQL  
Tunicate (E4Y0K1)              161 AEEEESTRMSKKTSISATDVETKPAYESIEKGD--------------GFS--ESADF---  
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Appendix F: Summary of in silico Algorithms for Collectrin Sequence Analysis 
 
Table 5.1: Human collectrin TM topology, secondary structure and orientation prediction
‡
 
Program/Algorithm Secondary 
Structure 
Elements 
(No of TMs) 
Predicted α-
helical 
Domain(s) 
Predicted 
TM 
Domain(s) 
Other 
Secondary 
Structure 
Element(s) 
Protein 
Orientation 
Internal 
confidence 
Interval  
Reference 
SOSUI/Kyte-Doolittle⃰ 2 (1) 1-14, 142-164 142-164 − − − [323, 668] 
DAS/dense alignment 
surface method 
2 (2) 47-59, 188-212 47-59, 188-
212 
− − Strict cut-off = 2.2 [584] 
HMMTOP 1 (1) 140-164 140-164 − N-terminal out 
(type 1) 
Entropy of the best 
path:  17.0129 
 
[669, 670] 
CCTOP 1 (1) 142-163 142-163 −  Reliability: 98.538 [511, 671] 
PredictProtein/RePROF 
& PROFsec 
8 (1) 2-15, 46-61, 98-
107, 145-171 
142-161 4 × β-
sheets 
− − [672, 673] 
SOUSI v1.1 2 (2) 1-23, 142-164 1-23, 142-
164 
− − Average of 
hydrophobicity : 
0.077477 
[668] 
TMHMM v2.0 1 (1) 142-164 142-164 − N-terminal out 
(type 1) 
Expected residues 
in TM domain: 
23.19681 
 
[674] 
TMPred
†
 2 (2) 1-17, 142-167 1-17, 142-
167 
− N-terminal in  
(type IV-A) 
Helix 1-17 I/O 
score = 1314 
Helix 2 142-167 O/I  
score = 3734 
 
 
TopPred v1.10/ GES-
scale hydrophobicity 
2 (2) 1-21, 142-162 1-21, 142-
162 
− N-terminal 
transmembrane 
Helix 1 (1 – 21) 
score =    1.124 
[675, 676] 
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 (certain) 
Helix 2 (142 – 162) 
score = 2.716 
(certain) 
Phobius 2(1) 2-12, 142-167 142-167 − N-terminal out 
(type 1) 
− [677] 
SPOCTOPUS  2 (2) 1-17, 141-164 1-17, 141-
164 
− N-terminal 
transmembrane 
Hydrophobic 
membrane region 
(0-13 Å from 
membrane centre) > 
0.2 
[678] 
TOPCONS 1 (1) 143-164 143-164 − Not specified ∆G (kcal/mol) 
prediction of 
membrane stability 
[506, 679] 
MINNOU/SABLE 7 (1) 4-15, 46-60, 97-
115, 142-172 
142-172 3 × β-
sheets 
− Sequence and 
hydrophobicity 
index of TM 
domains score > 0.3 
[509] 
SCAMPI 3 (3) 2-23, 67-88, 
142-163 
2-23, 67-88, 
142-163 
− − − [508] 
PHILIUS 1 (1) 142-165 142-165 − − − [507] 
PSIPRED 9 (0) 2-15, 49-60, 98-
107, 148-172, 
181-185 
Not 
specificed 
4 × β-
sheets 
− > 0.5 confidence 
interval 
[680] 
MEMSAT-SVM 1 (1) 143-163 143-163 − N-terminal out 
(type 1) 
summed pore-lining 
and posterior 
probability score = 
3.351542 
 
[681, 682] 
conSSert 9 (0) 2-16, 44-60, 98-
113, 148-173, 
180-187 
Not 
specificed 
4 × β-
sheets 
− > 0.75 probability 
(calculated from 4 
composite 
[683] 
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algorithms) 
ProtComp v9.0 2 (2) 14-47, 138-169 14-47, 138-
169 
− − Neural network 
algorithm 
[684] 
‡ Based on UniProtKB reference sequence Q9HBJ8. 
⃰ Prediction from original collectrin publication [323]. 
† 
TMPred gives TM domain predictions for both directions, the orientation and scores quoted here is based on the highest scores for each 
predicted TM domain. 
 
 
Table 5.2: In silico sequence analysis of human collectrin 
Program/Algor
ithm 
Predicted 
motif(s)/sequence element 
Human Collectrin 
Sequence Location 
Internal confidence Score Reference(s) 
SPOCTOPUS Transmembrane signal 
peptide 
3-14 signal peptide score > 0.3 [678] 
RHYTHM v3.0 Lipid membrane and α-
helical contact residues  
143-159 (membrane 
contact) Ile153 (helical 
contact) 
Internal sensitivity/specificity matrix threshold 
using Pfam database 
[512, 607] 
TOPCONS Signal peptide 1-22 − [679] 
TargetP  v1.1 Signal peptide and secretory 
pathway localisation 
Not given Signal peptide score = 0.892/1 
Reliability class localisation = 2 
[685] 
TermiNator Mature protein N-terminal 
residue 
1 Likelihood % = 100 [686, 687] 
SignalP 4.1 Signal peptide and signal 
peptide cleavage site 
Signal peptide = 1-14 
cleavage site = 14-15 
Signal peptide mean S score = 0.944/1, signal 
peptide cleavage site, Y-score = 0.658/1 
[685] 
MEMSAT-
SVM 
Signal peptide None signal score 7.46 [681, 682] 
ProtComp v9.0 Signal peptide anchor  14-47 Normalised neural network score = 2.1/3  [684] 
Predator  v1.03 ER/secretory pathway signal Yes Probability = 0.97/1  
ProP v1.0b Proprotein cleavage sites Between 14-15 (furin-
specific) 
Proprotein cleavage potential ≥ 0.5 threshold [688] 
NetNES 1.1 Leucine-rich nuclear None − [689] 
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localisation signal 
COILS 2.2 2 heptad repeat coiled coil 177-190 14 frame window residue scores = 0.798/1 [690, 691] 
Paircoil2  Coiled coil heptads None Threshold score < 0.025 [692] 
RADAR 1.1.5 20 residue sequence repeat   107-126, 203-222 Total score = 73.26 [693] 
2ZIP Leucine zipper coiled coil 
domain 
None − [694] 
Spiricoils Coiled coils  None − [695] 
GlobPlot 2.3 
(Russell/Lindin
g) 
Globular and disordered 
domains 
1-129 (globular) 
130-138, 193-220 
(disordered) 
142-164 (TM) 
1st derivative of Disorder propensity sum  [696] 
IUPred Globular and disordered 
domains 
high disordered: 187-212 
Low disorder: 1-141 
Ordered: 142-161 
Disordered threshold probability > 0.5 [697] 
ANCHOR Disordered domains − Disordered threshold probability > 0.5 [698] 
MobiDB v2.1 Ordered/disordered domains 170-184, 216-222 
(disordered) 
1-161, 185-215 (ordered) 
Total % disordered = 9.91 [699] 
GPS 3.0 Disordered domains 173-192 Disordered threshold ≥ 0.46 [700] 
fMoRFPred Ordered/disordered domains 178-184, 214-222 Disordered threshold probability ≥ 0.499 [701] 
DISOPRED3.1 Disordered domains 1-10, 171-186, 219-222 Disordered threshold ≥ 0.5 [702] 
DISOPRED3.1 Disordered protein binding 
regions 
1-10, 171-186 Probability threshold ≥ 0.85 [702] 
ELM N-arginine dibasic 
convertase (nardilysin)  
cleavage site 
58-60, 170-172 
 
Probability 7.465 × 10-3/ conservation score = 
1.0 
[593] 
ELM The subtilisin-like 
proprotein convertase 
(PCSK) cleavage site 
32-36 Probability 6.821 × 10-3/ conservation score = 
1.0 
[593] 
ELM N-degron site for n-end rule 
ubiquitin-dependent 
1-3 Probability 2.302 × 10-4/ conservation score = 
1.0 
[593] 
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proteasome degradation  
BDM-PUB Ubiquitination prediction 
site 
26, 38, 60, 204 Bayesian discrimination scores ≥ 0.5 [703] 
UbPRED Ubiquitination prediction 
site 
185, 204 Combined sensitivity/specificity score ≥ 0.8 [704] 
CKSAAP_UBS
ITE 
Ubiquitination prediction 
site 
38 High confidence residue score = 0.88 [705] 
iUbiq-Lys Ubiquitination prediction 
site 
None SVM analysis extracted from grey-model 
system (Grey-PSSM) 
[706] 
UbiProber Ubiquitination prediction 
site 
38, 174 SVM probability score > 0.7 [707] 
ELM Calcineurin (PP2B)-docking 
motif LxVP 
132-135 Probability 2.296 × 10-3/ conservation score = 
1.0 
[593] 
ELM Atg8 autophagy-related 
protein family ligands 
122-128 Probability 5.2 × 10-3/ conservation score = 1.0 [593] 
ELM PDZ binding domain ligand 217-222 Probability 7.25 × 10-5/ conservation score = 
1.0 
[593] 
PDZPeplnt v1.0 PDZ binding domain ligand 218-222 Positive interaction with multiple potential 
PDZ-domains 
[708] 
POW  PDZ binding domain at C-
terminal sequence 
218-222 SVM highest decision scores on human 
collectrin C-terminal sequence RLTPL = 0.258  
[709] 
Prosite N-glycosylation 76, 93 − [710, 711] 
ELM N-glycosylation site 75-80 Probability 5.018 × 10-3/ conservation score = 
1.0 
[593] 
GlycoEP N-glycosylation site 76, 93 Residue scores, 76 = 0.87 
93 = 0.827 
[712] 
NetNGlyc 1.0  N-glycosylation site 76 Probability threshold ≥ 0.5 [713] 
UniPROT N-glycosylation site 76, 93 Manual assertion by database analyser [714] 
 PTS1  Peroxisomal targeting signal  None Score = −53.751 [715] 
NetCGlyc 1.0   C-mannosylation sites None Probability threshold ≥ 0.5 [716] 
NetOGlyc 4.0  O-GalNAc (mucin type) None Probability threshold ≥ 0.5 [717] 
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glycosylation sites 
GlycoEP O-glycosylation (N-
acetylgalactosamine) sites 
None All residue scores ≤ 0.2 [712] 
 (ISOGlyP) O-glycosylation (N-
acetylgalactosamine) sites 
78, 131, 139 Enhanced value product (EVP) score ≥ 1 for 
multiple O-glycosylated isoforms 
[718] 
YinOYang 1.2 O-linked (N-
acetylgalactosamine) sites 
78 High probability threshold > 0.5545 [719] 
GlycoEP Tryptophan glycosylation 
site 
None All residue scores ≤ 0 [712] 
NetGlycate 1.0 Glycation of ε-amino 
(lysine) groups 
38, 60 Probability threshold ≥ 0.5 [720] 
Phogly-
PseAAC 
Glycation or hydroxylation 
of ε-amino (lysine) groups  
38 Positive score = 3.835 
Negative score = 4.392 
[721] 
PredHydroxy hydroxylation of ε-amino 
(lysine) groups 
None N/A [722] 
big-PI Predictor  C-terminal GPI-anchor site None N/A [723] 
GPI-SOM  N- and C-terminal GPI-
anchor site 
None Neural network analysis [724] 
ProtComp v9.0 GPI-anchor site 190 Neural network analysis [684] 
Prosite N-terminal Myristoylation 
site 
148-153, 205-210 − [710, 711] 
Myristoylator N-terminal glycine N-
Myristoylation 
None No N-terminal glycines [725] 
NMT  N-terminal glycine N-
Myristoylation  
None No N-terminal glycines [726] 
CSS-Palm v4.0 Palmitylation sites 17, 75 High filter cut-off = 4.222 [727] 
PalmPred  Palmitylation sites None No palmitylation motifs [728] 
WAP-Palm Palmitylation sites None Threshold = 0.5 [729] 
PrePS Prenylation sites None No prenylation enzyme conserved sequence [730] 
GPS 3.0 Lipid modifications None Medium threshold level [731] 
NetAcet 1.0 N-acetylation sites by N- None No required residue in position 1-3 [732] 
248 
 
acetyltransferase A 
PAIL N-acetylation sites 38, 60, 92, 204 Bayesian discrimination scores ≥ 0.5 [733] 
Prosite Casein kinase II 
phosphorylation site 
177, 214 − [710, 711] 
NetPhos 2.0 Ser, Thr, Tyr, 
phosphorylation sites 
177, 214, 220  Probability threshold ≥ 0.5 [734] 
GPS 3.0 Phosphorylation sites 177, 214, 220 ≥ high threshold for specific kinases e.g. > 
8.646 for AKT 
[735] 
NetPhorest Phosphorylation sites (CK2) 177, 214 > 0.3 minimal score, < 0.2 maximal difference 
score 
[736] 
Scansite v3.0 Casein Kinase 2 (CK2) 
phosphorylation site 
177 Score = 0.526 [737] 
Scansite v3.0 Casein Kinase 2 (CK2) 
phosphorylation site 
214 Score = 0.547 [737] 
Scansite v3.0 Erk1 Kinase 
phosphorylation site 
220 Score = 0.640 [737] 
UniPROT phosphorylation sites 214, 220 Similarity assertion by database  [585, 586, 738] 
sulfinator Tyrosine sulfation sites None E-cut-off value ≥ 55 [739] 
SUMOplot SUMOylation sites 185, 204  High probability score threshold ≥ 0.5 [740] 
GPS-SUMO SUMOylation (SUMO) 
Interaction sites 
None Cut-off score > 35.23 [741] 
JASSA SUMOylation sites None Position frequency matrix  [742] 
seeSUMO SUMOylation sites None SVM score all below threshold  [743] 
SUMOhydro SUMOylation sites None SVM score threshold  > 0 for all lysine residues [744] 
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